
<html lang="en"     class="pb-page"  data-request-id="4c5300af-6803-4afd-a459-3f02590c0bff"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b00930;website:website:acspubs;issue:issue:10.1021/jmcmar.2017.60.issue-17;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology" /></meta><meta name="dc.Creator" content="Florent  Beaufils" /></meta><meta name="dc.Creator" content="Natasa  Cmiljanovic" /></meta><meta name="dc.Creator" content="Vladimir  Cmiljanovic" /></meta><meta name="dc.Creator" content="Thomas  Bohnacker" /></meta><meta name="dc.Creator" content="Anna  Melone" /></meta><meta name="dc.Creator" content="Romina  Marone" /></meta><meta name="dc.Creator" content="Eileen  Jackson" /></meta><meta name="dc.Creator" content="Xuxiao  Zhang" /></meta><meta name="dc.Creator" content="Alexander  Sele" /></meta><meta name="dc.Creator" content="Chiara  Borsari" /></meta><meta name="dc.Creator" content="Jürgen  Mestan" /></meta><meta name="dc.Creator" content="Paul  Hebeisen" /></meta><meta name="dc.Creator" content="Petra  Hillmann" /></meta><meta name="dc.Creator" content="Bernd  Giese" /></meta><meta name="dc.Creator" content="Marketa  Zvelebil" /></meta><meta name="dc.Creator" content="Doriano  Fabbro" /></meta><meta name="dc.Creator" content="Roger L.  Williams" /></meta><meta name="dc.Creator" content="Denise  Rageot" /></meta><meta name="dc.Creator" content="Matthias P.  Wymann" /></meta><meta name="dc.Description" content="Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe th..." /></meta><meta name="Description" content="Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe th..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 1, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00930" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00930" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00930" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00930" /></link>
        
    
    

<title>5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00930" /></meta><meta property="og:title" content="5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0010.jpeg" /></meta><meta property="og:description" content="Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concentrations. No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays. Moreover, 1 did not bind tubulin, which was observed for the structurally related 4 (BKM120, buparlisib). Compound 1 is orally available, crosses the blood–brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs. Compound 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model. This, together with the compound’s safety profile, identifies 1 as a clinical candidate with a broad application range in oncology, including treatment of brain tumors or CNS metastasis. Compound 1 is currently in phase II clinical trials for advanced solid tumors and refractory lymphoma." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00930"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00930">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00930&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00930&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00930&amp;href=/doi/10.1021/acs.jmedchem.7b00930" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7524-7538</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00888" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00926" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Florent++Beaufils">Florent Beaufils</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Natasa++Cmiljanovic">Natasa Cmiljanovic</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vladimir++Cmiljanovic">Vladimir Cmiljanovic</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Bohnacker">Thomas Bohnacker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Melone">Anna Melone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Romina++Marone">Romina Marone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eileen++Jackson">Eileen Jackson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xuxiao++Zhang">Xuxiao Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Sele">Alexander Sele</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chiara++Borsari">Chiara Borsari</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-4688-8362" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%BCrgen++Mestan">Jürgen Mestan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Hebeisen">Paul Hebeisen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Petra++Hillmann">Petra Hillmann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bernd++Giese">Bernd Giese</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marketa++Zvelebil">Marketa Zvelebil</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Doriano++Fabbro">Doriano Fabbro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roger+L.++Williams">Roger L. Williams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Denise++Rageot">Denise Rageot</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthias+P.++Wymann">Matthias P. Wymann</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-3349-4281" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, U.K.</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">PIQUR Therapeutics AG, Hochbergerstrasse 60C, 4057 Basel, Switzerland</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Chemistry, University of Basel, St. Johanns-Ring 19, 4056 Basel, Switzerland</span></div><div class="corresp-info"><strong>*</strong>D.R.: e-mail, <a href="/cdn-cgi/l/email-protection#88ccede6e1fbeda6dae9efede7fcc8fde6e1eae9fba6ebe0"><span class="__cf_email__" data-cfemail="a1e5c4cfc8d2c48ff3c0c6c4ced5e1d4cfc8c3c0d28fc2c9">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>M.P.W.: phone, +41 61 207 5046; fax, +41 61 207 3566; e-mail, <a href="/cdn-cgi/l/email-protection#94d9f5e0e0fcfdf5e7bac3edf9f5fafad4c1fafdd6f5e7bad7dc"><span class="__cf_email__" data-cfemail="b3fed2c7c7dbdad2c09de4caded2ddddf3e6dddaf1d2c09df0fb">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00930&amp;href=/doi/10.1021%2Facs.jmedchem.7b00930" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7524–7538</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 22, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 June 2017</li><li><span class="item_label"><b>Published</b> online</span>1 September 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 September 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00930" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00930</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00930"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8878</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">58</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00930" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Florent&quot;,&quot;last_name&quot;:&quot;Beaufils&quot;},{&quot;first_name&quot;:&quot;Natasa&quot;,&quot;last_name&quot;:&quot;Cmiljanovic&quot;},{&quot;first_name&quot;:&quot;Vladimir&quot;,&quot;last_name&quot;:&quot;Cmiljanovic&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Bohnacker&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Melone&quot;},{&quot;first_name&quot;:&quot;Romina&quot;,&quot;last_name&quot;:&quot;Marone&quot;},{&quot;first_name&quot;:&quot;Eileen&quot;,&quot;last_name&quot;:&quot;Jackson&quot;},{&quot;first_name&quot;:&quot;Xuxiao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Sele&quot;},{&quot;first_name&quot;:&quot;Chiara&quot;,&quot;last_name&quot;:&quot;Borsari&quot;},{&quot;first_name&quot;:&quot;Jürgen&quot;,&quot;last_name&quot;:&quot;Mestan&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Hebeisen&quot;},{&quot;first_name&quot;:&quot;Petra&quot;,&quot;last_name&quot;:&quot;Hillmann&quot;},{&quot;first_name&quot;:&quot;Bernd&quot;,&quot;last_name&quot;:&quot;Giese&quot;},{&quot;first_name&quot;:&quot;Marketa&quot;,&quot;last_name&quot;:&quot;Zvelebil&quot;},{&quot;first_name&quot;:&quot;Doriano&quot;,&quot;last_name&quot;:&quot;Fabbro&quot;},{&quot;first_name&quot;:&quot;Roger&quot;,&quot;last_name&quot;:&quot;L. Williams&quot;},{&quot;first_name&quot;:&quot;Denise&quot;,&quot;last_name&quot;:&quot;Rageot&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;P. Wymann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;7524-7538&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00930&quot;},&quot;abstract&quot;:&quot;Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concentrations. No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays. Moreover, 1 did not bind tubulin, which was observed for the structurally related 4 (BKM120, buparlisib). Compound 1 is orally available, crosses the blood–brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs. Compound 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model. This, together with the compound’s safety profile, identifies 1 as a clinical candidate with a broad application range in oncology, inc&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00930&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00930" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00930&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00930" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00930&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00930" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00930&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00930&amp;href=/doi/10.1021/acs.jmedchem.7b00930" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00930" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00930" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26pmid%3D28829592%26genre%3Darticle%26aulast%3DBeaufils%26date%3D2017%26atitle%3D5-%25284%252C6-Dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2B%2528PQR309%2529%252C%2Ba%2BPotent%252C%2BBrain-Penetrant%252C%2BOrally%2BBioavailable%252C%2BPan-Class%2BI%2BPI3K%252FmTOR%2BInhibitor%2Bas%2BClinical%2BCandidate%2Bin%2BOncology%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D17%26spage%3D7524%26epage%3D7538%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/jmcmar.2017.60.issue-17/20170914/jmcmar.2017.60.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound <b>1</b> (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concentrations. No off-target interactions were detected for <b>1</b> in a wide panel of protein kinase, enzyme, and receptor ligand assays. Moreover, <b>1</b> did not bind tubulin, which was observed for the structurally related <b>4</b> (BKM120, buparlisib). Compound <b>1</b> is orally available, crosses the blood–brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs. Compound <b>1</b> demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model. This, together with the compound’s safety profile, identifies <b>1</b> as a clinical candidate with a broad application range in oncology, including treatment of brain tumors or CNS metastasis. Compound <b>1</b> is currently in phase II clinical trials for advanced solid tumors and refractory lymphoma.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53582" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53582" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that play a central role in the control of cancer cell growth, proliferation, and metastasis.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> The PI3K family is divided into three classes according to sequence homology and substrate specificity: so-called class I PI3Ks are activated downstream of cell surface receptors, including receptor protein tyrosine kinases (RTKs), immunoglobulin receptors, and G-protein-coupled receptors (GPCRs). Class IA PI3Ks consist of the catalytic subunits p110α, p110β, and p110δ. These interact with dedicated phosphorylated tyrosine motifs on growth factor receptors or their substrates via two src-homology 2 (SH2) domains present in their tightly associated p85 regulatory subunits. The class IB PI3Kγ operates downstream of GPCRs and is composed of a catalytic subunit p110γ and an adapter subunit, which is either p84 or p101.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Class I PI3Ks phosphorylate phosphatidylinositol (4,5)-bisphosphate [PtdIns(4,5)<i>P</i><sub>2</sub>] to yield phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)<i>P</i><sub>3</sub>]. PtdIns(3,4,5)<i>P</i><sub>3</sub>, produced at the inner leaflet of the plasma membrane, provides a docking site for effector proteins with pleckstrin-homology (PH) domains. The serine/threonine kinases phosphoinositide-dependent kinase 1 (PDK-1) and protein kinase B (PKB/Akt) contain a PH domain and are thus activated by PI3K and relay the activation of the mammalian target of rapamycin complex <b>1</b> (mTORC1). In tumor cells, hyperactivation of the PI3K/mTOR pathway can occur on multiple levels, including mutation or overexpression of cell surface receptors such as HER2,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> oncogenes, the protein tyrosine phosphatase nonreceptor 12 (PTPN12),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> or the presence of activating hotspot mutations in PIK3CA (encoding the catalytic PI3Kα subunit p110α).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Other key regulators of the PI3K pathway include the lipid phosphatase PTEN, hydrolyzing PtdIns(3,4,5)<i>P</i><sub>3</sub> back to PtdIns(4,5)<i>P</i><sub>2</sub>,<a onclick="showRef(event, 'ref2 ref8'); return false;" href="javascript:void(0);" class="ref ref2 ref8">(2, 8)</a> and the inositol polyphosphate 4-phosphatase type II (INPP4B)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> degrading PtdIns(3,4)<i>P</i><sub>2</sub>. Loss of either lipid phosphatase activities or gain of function mutations at the level of PI3K, and aberrations up- and downstream in the pathway can thus lead to the constitutive activation of PI3K, PKB/Akt, and mTOR.</div><div class="NLM_p">Besides promotion of tumor cell growth and angiogenesis, an overactivated PI3K/mTOR pathway has been associated with resistance to other cancer treatments, e.g., receptor tyrosine kinase inhibitors. PI3K inactivating agents are currently in various clinical trials as monotherapy or in combination with other drugs.<a onclick="showRef(event, 'ref2 ref3 ref10'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref10">(2, 3, 10)</a></div><div class="NLM_p last">In our search for the development of a dual pan-PI3K/mTOR inhibitor, we focused on dimorpholino substituted compounds with a triazine core, as their symmetry supports rapid access to a compound library with various aryl substituents. Furthermore, our goal was to develop brain-penetrable compounds to allow for the treatment of brain metastasis and brain tumors. Here we describe a SAR study around the aryl moiety at the C2-position of bismorpholinotriazines, which led to the identification of <b>1</b> (PQR309, bimiralisib),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> a clinical candidate and brain penetrable pan-PI3K/mTOR inhibitor.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>1</b> evolved as the lead compound of a series of dimorpholinotriazine based compounds and is currently tested in phase II clinical trials (clinicaltrials.gov). Initially inspired by 2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine (ZSTK474),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> a pan PI3K inhibitor with a triazine core, development of <b>1</b> aimed to (i) maximize compound solubility and bioavailability, (ii) achieve blood–brain barrier penetration, (iii) avoid microtubule interactions as observed for <b>4</b> (BKM120, buparlisib),<a onclick="showRef(event, 'ref11 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref13">(11, 13)</a> and (iv) introduce moderate mTOR inhibition. The rationale for PI3K/mTOR dual activity was based on the observation that persistent mTOR signaling was reported to confer resistance to PI3K inhibition,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> while selective targeting of the mTOR complex 1 (TORC1) initiates positive feedback leading to PI3K hyperactivation.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> To avoid this, we selected for compounds with a higher potency for PI3K than mTOR kinase. Moreover, drugs targeting both PI3K and mTOR have been shown early on to be more effective in tumors with multiple pathway activation such as melanoma<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> and to potentially support drug combinations.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">A number of clinically advanced PI3K inhibitors with a pyrimidine, triazine, or fused pyrimidine core contain at least one morpholine moiety. This morpholine was demonstrated to be a crucial feature for PI3K binding, as the morpholine oxygen atom forms a hydrogen bond interaction with the hinge region backbone NH of the amino acid residue Val851 in PI3Kα (Val882 in PI3Kγ, and Val2240 in mTOR). Structurally related compounds, which display distinct PI3K and mTOR kinase inhibitory profiles (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), are shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>: <b>1</b>, <b>4</b>,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and <b>6</b> (GDC-0980, apitolisib/RG7422)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> target PI3K and mTOR kinase with some preference for PI3Kα, while <b>3</b> (PIK-587, gedatolisib/PF-05212384)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> is a potent dual PI3K/mTOR inhibitor and <b>5</b> (GDC-0941, pictilisib)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> targets PI3K.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of triazine core PI3K inhibitors <b>1</b>, reference compound <b>2</b>, reported clinical candidate <b>3</b>, and pyrimidine or fused pyrimidine core containing molecules <b>4</b>, <b>5</b>, and <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Affinity of Triazine and Pyrimidine Core-Containing Molecules to PI3K and PI3K-Related Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="10" align="center">binding constant <i>K</i><sub>d</sub> [nM]<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">PI3Kα</th><th class="colsep0 rowsep0" align="center">PI3Kβ</th><th class="colsep0 rowsep0" align="center">PI3Kγ</th><th class="colsep0 rowsep0" align="center">PI3Kδ</th><th class="colsep0 rowsep0" align="center">mTOR</th><th class="colsep0 rowsep0" align="center">PI3KC2β</th><th class="colsep0 rowsep0" align="center">VPS34</th><th class="colsep0 rowsep0" align="center">PI4KCβ</th><th class="colsep0 rowsep0" align="center">DNAPK</th><th class="colsep0 rowsep0" align="center">mTOR/PI3Kα</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">820</td><td class="colsep0 rowsep0" align="left">230</td><td class="colsep0 rowsep0" align="left">40000</td><td class="colsep0 rowsep0" align="left">1600</td><td class="colsep0 rowsep0" align="left">8.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">61</td><td class="colsep0 rowsep0" align="left">540</td><td class="colsep0 rowsep0" align="left">130</td><td class="colsep0 rowsep0" align="left">27000</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">0.94</td><td class="colsep0 rowsep0" align="left">0.46</td><td class="colsep0 rowsep0" align="left">5100</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">0.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">130</td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">2100</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">40000</td><td class="colsep0 rowsep0" align="left">1800</td><td class="colsep0 rowsep0" align="left">5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">0.76</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">7.7</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">40000</td><td class="colsep0 rowsep0" align="left">1300</td><td class="colsep0 rowsep0" align="left">63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">0.62</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">580</td><td class="colsep0 rowsep0" align="left">250</td><td class="colsep0 rowsep0" align="left">>30000</td><td class="colsep0 rowsep0" align="left">9800</td><td class="colsep0 rowsep0" align="left">5.3</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center">IC<sub>50</sub>, kinase assay [nM]<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">PI3Kα</th><th class="colsep0 rowsep0" align="center">PI3Kβ</th><th class="colsep0 rowsep0" align="center">PI3Kγ</th><th class="colsep0 rowsep0" align="center">PI3Kδ</th><th class="colsep0 rowsep0" align="center">mTOR</th><th class="colsep0 rowsep0" align="center">α542K/545K/1047R<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">VPS34</th><th class="colsep0 rowsep0" align="center">DNAPK</th><th class="colsep0 rowsep0" align="center">mTOR/PI3Kα</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">661</td><td class="colsep0 rowsep0" align="left">708</td><td class="colsep0 rowsep0" align="left">451</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">63/136/36</td><td class="colsep0 rowsep0" align="left">8486</td><td class="colsep0 rowsep0" align="left">8567</td><td class="colsep0 rowsep0" align="left">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">607</td><td class="colsep0 rowsep0" align="left">778</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">111/216/87</td><td class="colsep0 rowsep0" align="left">2581</td><td class="colsep0 rowsep0" align="left">6917</td><td class="colsep0 rowsep0" align="left">13</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Dissociation constants (<i>K</i><sub>d</sub>) were determined using ScanMax technology (DiscoveRx)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> with 11-point 3-fold serial dilutions of the indicated compounds. <i>K</i><sub>d</sub> is the mean value from experiments performed in duplicate and calculated from standard dose–response curves using the Hill equation depicted in <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> (<i>n</i> ≥ 2). A TreeSpot representation of a full kinase panel and kinase residual binding values are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Supporting Information Figure S1 and Table S2</a> for all above compounds except compound <b>2</b>.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Prokinase activity assays of the indicated enzymes and PI3Kα mutants.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Inhibition of PI3Kα E542K, E545K, and H2047R mutant activities are indicated. For these values, the wild type PI3Kα reference IC<sub>50</sub> values were 122 nM for <b>1</b> and 142 nM for <b>4</b>.</p></div></div></div><div class="NLM_p">The above compounds are substituted with various aryl moieties (e.g., indazole, pyrimidine, pyridine, benzoimidazole, or aniline), which are situated in the PI3K’s ATP-binding site toward the affinity binding pocket. The primary amine of <b>4</b><a onclick="showRef(event, 'ref11 ref19'); return false;" href="javascript:void(0);" class="ref ref11 ref19">(11, 19)</a> and <b>6</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> interacts via hydrogen bonding with the carboxyl groups of the amino acid residues Asp841 and Asp836 in PI3Kγ. For <b>3</b> it has been proposed that the urea-NH groups form hydrogen bonds with Asp810 and the urea oxygen engages the wortmannin-reactive Lys802<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> in PI3Kα.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Finally, <b>5</b> exploits its indazole N-NH atoms to form hydrogen bonds with Tyr867 and Asp841 in PI3Kγ. As illustrated by the exchange of the aryl moiety from 4-(trifluoromethyl)pyridin-2-amine in <b>1</b> to 4-(trifluoromethyl)pyrimidin-2-amine in compound <b>2</b>, the aryl substitution can be used to fine-tune PI3K vs mTOR activity.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">To achieve a balanced PI3K and mTOR inhibition and to adjust physicochemical properties, a library of 4,6-dimorpholino-1,3,5-triazines substituted with various C-2-aryl moieties was prepared from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The chlorine was displaced by aniline or heteroaryl moieties using Suzuki cross-coupling reactions with boronic acid pinacol esters. The desired products were obtained in moderate to good yield (11–86%) depending on the used boronic acid pinacol ester derivative. Moreover, compound <b>1</b> was transformed by acetylation and diazotization followed by bromination and Sandmeyer reaction in order to obtain derivatives bearing different substituents at the C-2 pyridine (<b>17</b>–<b>21</b>). All final compounds were analyzed for purity by analytical HPLC (>95%).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of C-2-Aryl-Substituted 4,6-Dimorpholino-1,3,5-triazine Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ArBpin, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2–16 h, then HCl (aq), 60 °C, 2–8 h; (ii) ArBpin, Pd(dppf)Cl<sub>2</sub> (cat.), Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane/H<sub>2</sub>O, 90 °C, 16 h; (iii) ArBpin, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2 h; (iv) AcCl, K<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C → rt, 3.5 h; (v) HCl (conc), NaNO<sub>2</sub>, 0 °C → rt, 1 h, then CuCl, rt, 1 h; (vi) isopentyl nitrite, CH<sub>2</sub>Br<sub>2</sub>, rt, 5 min, then (CH<sub>3</sub>)<sub>3</sub>SiBr, rt, 1 h; (vii) CH<sub>3</sub>ONH<sub>2</sub>·HCl, NaHCO<sub>3</sub>, DMSO, 100 °C, 6 h. <sup><i>b</i></sup>Compound <b>1</b> was prepared according to the procedure recently reported.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> ArBpin: boronic acid pinacol ester (the amino group was protected in certain cases).</p></p></figure><div class="NLM_p last">We have recently reported an optimized synthetic route to compound <b>1</b>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> This strategy allowed for rapid access to large quantities of <b>1</b> starting from cyanuric chloride (81% yield) for preclinical and clinical development.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Determination of Cellular Potency and PI3K vs mTOR Kinase Activities</h3><div class="NLM_p">In the following studies, the role of the aryl moiety was investigated systematically for enzymatic activity and selectivity for class IA PI3K versus mTOR (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). A first series of compounds including variations of nitrogen atoms number and position was prepared to study the effect of the polarity of the aryl group (<b>9</b>–<b>12</b>). Interestingly, <b>10</b> and <b>11</b> substituted with 2-aminopyridine and 2-aminopyrimidine, respectively, were both found to be active in cellular and enzymatic assays. The calculated PSA (polar surface area) value for the pyridine-substituted <b>10</b>  (PSA = 103) was slightly lower as compared to pyrimidine <b>11</b> (PSA = 115), predicting a better brain penetration for <b>10</b>. Therefore, pyridines were substituted with lipophilic substituents such as methyl and trifluoromethyl at pyridine C3 and C4 positions to generate compounds <b>13</b>–<b>15</b>. Introduction of a C4-trifluoromethyl group significantly increased cellular potency and enzymatic targeting: compared with <b>13</b>, <b>1</b> showed excellent cellular activities, good potency in vitro (<i>K</i><sub>i</sub> for PI3Kα of 17 nM), targeted mutated forms of the catalytic PI3Kα subunit, and displayed the desired selectivity profile targeting PI3Kα>mTOR (<i>K</i><sub>i</sub> ratio of mTOR/p110α of ∼3.6 [∼8.0 from KINOMEscan; see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>]). On the contrary, introduction of a lipophilic substituent at the C3-position (methyl in <b>14</b> and trifluoromethyl in <b>15</b>) diminished binding to PI3Kα as well as to mTOR.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Direction of PI3K/mTOR Selectivity with Aromatic Substituents for Dimorpholinotriazine</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0008.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Cellular phosphorylation of PKB/Akt on Ser473 and ribosomal S6 on Ser235/236 were analyzed in inhibitor treated A2058 melanoma cells using in-cell Western detection. Each experiment was performed in triplicate or as a multiple of <i>n</i> = 3.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub> values of A2058 or SKOV3 cell proliferation were determined from 10-point 2-fold serial dilutions (<i>n</i> = 3).</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Compounds were tested in a time-resolved FRET (TR) assay (LanthaScreen), and inhibitor <i>K</i><sub>i</sub> values were calculated for PI3Kα and mTOR as described in <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. The mTOR/PI3Kα column depicts the ratio of compound-specific mTOR <i>K</i><sub>i</sub> over the <i>K</i><sub>i</sub> for PI3Kα. Each experiment was performed at least twice or as a multiple of <i>n</i> = 2.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Marvin/JChem 16.10.17 was used for calculation of log <i>P</i> (partition coefficient) and PSA (polar surface area) values.</p></div></div><div></div></div><div class="NLM_p">While compound <b>11</b>, bearing an unsubstituted 2-aminopyrimidine, turned out to be a balanced inhibitor for PI3Kα and for mTOR in vitro, (<i>K</i><sub>i</sub>(mTOR)/<i>K</i><sub>i</sub>(PI3Kα) ≈ 2.3), a substitution at the pyrimidine C4-position with methyl (<b>16</b>) or trifluoromethyl (<b>2</b>) enhanced cellular and in vitro activity toward PI3Kα and diminished affinity for mTOR, raising the mTOR/PI3Kα <i>K</i><sub>i</sub> ratio to ∼16–25. Modifications at the C2-pyridine position of the most potent compound <b>1</b> were also investigated (<b>17</b>–<b>21</b>). These changes alter both the steric and the electronic properties of the amine group and are likely to affect hydrogen bond interactions with the aspartate carboxy groups in the affinity binding pocket (Asp841 and Asp836 in PI3Kγ). Hydroxylamine and amide moieties replacing primary amine functionality in <b>1</b> impaired binding to mTOR (<i>K</i><sub>i</sub> > 1 μM), and replacing the primary amine moiety by a hydroxylamine, amide, hydroxy, or halide decreased cellular potency considerably. Compound <b>17</b> retained its affinity for PI3Kα in spite of an amide extension, likely due to a hydrogen bond of the amide carbonyl with Lys802 (Lys833 in PI3Kγ: in analogy to compound <b>26</b> in ref <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">27</a> [see also PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IBE">3IBE</a>]).</div><div class="NLM_p last">The SAR study depicted above led to the identification of two potent compounds <b>1</b> and <b>2</b>, both substituted with a trifluoromethyl group on their aryl moiety. Both of them showed excellent potency for PI3Kα, cellular activity profiles, and a calculated log <i>P</i> value of ∼3. Compound <b>1</b> was investigated in more detail, as it displayed a mTOR/PI3Kα <i>K</i><sub>i</sub> selectivity ratio in the range of 3–8, while <b>2</b> had reduced impact on mTOR (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). An additional point in favor of compound <b>1</b> was a lower calculated PSA value of 102 as compared to 115 for <b>2</b>, predicting a better brain penetration for <b>1</b>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Binding Mode of Compound <b>1</b> to PI3K and mTOR Kinase</h3><div class="NLM_p">Binding of compound <b>1</b> to the PI3Kγ catalytic subunit p110γ ATP-binding site was confirmed by a 2.7 Å complex crystal structure and identified key interactions of <b>1</b> with residues of p110γ. As reported for other morpholino-substituted PI3K inhibitors including compound <b>4</b>,<a onclick="showRef(event, 'ref11 ref19'); return false;" href="javascript:void(0);" class="ref ref11 ref19">(11, 19)</a> one morpholine of <b>1</b> forms a hydrogen bridge with the backbone amide of Val882, a well-known and crucial interaction.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The compound <b>1</b>/PI3Kγ complex crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>; <a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S1 in Supporting Information</a>) also showed that the amino group of the 2-amino-4-(trifluoromethyl)pyridine moiety forms H-bonds with Asp836, Asp841, and Asp964 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). Given the high homology of class I PI3K catalytic pockets and the nanomolar in vitro dissociation constants of <b>1</b> for all class I PI3Ks (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), an identical binding mode for all PI3K isoforms can be assumed. Besides the high affinity for class I PI3K isoforms (highest affinity for PI3Kα), compound <b>1</b>’s affinity for mTOR kinase is comparable to PI3Kβ, PI3Kγ, and PI3Kδ (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Interactions of <b>1</b> with the ATP-binding site of PI3Kγ catalytic subunit p110γ and mTOR kinase. (A) Crystal structure of <b>1</b> in PI3Kγ with a resolution of 2.7 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>; <a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S1</a>). Compound <b>1</b> interacts with the hinge valine V882 in PI3Kγ, and its heteroaryl amine function forms hydrogen bonds with the carboxyl groups of aspartates D836, D841, and D964. (B) Overlay of the compound <b>1</b>/PI3Kγ complex coordinates with the compound <b>4</b>/PI3Kγ data from PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5">3SD5</a>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The pyrimidine core nitrogen atom positions are corrected for the orientation as proposed in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a> (∗ denotes the position of C–H in compound <b>4</b>); the two molecules are oriented exactly as in (A). (C) The coordinates of a mTOR kinase/PI103 complex resolved to 3.6 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>; docked, yellow) and mTOR at a resolution of 3.2 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a>; relaxed, turquoise) were used to dock <b>1</b> into the ATP-binding site of mTOR kinase. The yellow structure represents the results of a manual predocking process (docked) where PI103 was replaced by <b>1</b> with subsequent energy minimization. The turquoise structure represents the best fit of dynamic docking procedures to <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a> (relaxed starting conditions). Dotted lines indicate proposed H-bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The current compound <b>1</b>/PI3Kγ X-ray crystal structure combined with our previous structural studies on <b>4</b> and an asymmetrically substituted triazine (PIKiN3, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB">5JHB</a>)<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> underlines the importance of Asp836, Asp841, and Asp964 and associated structured water molecules for the binding of this compound class. Changes in the basicity of the amino-heteroaryl (2-amino-4-(trifluoromethyl)pyridine in <b>1</b> are therefore expected to affect the affinity for PI3K, as it was the case for 2-aminopyrimidine <b>2</b>. The situation in the mTOR catalytic pocket is less well-defined: (i) modeling compound <b>1</b>/mTOR interactions starting with a predocked inhibitor generate an interaction pattern similar to PI3K, where carboxyl groups of Asp2357, Glu2190, and Asp2195 are at a distance of 3.5–4 Å from the heteroaryl amino group and could execute hydrogen bonding; (ii) starting with less constraints, the inhibitor is slightly displaced by docking procedures, and the sole residue in hydrogen bonding distance remains Glu2190. Although less conventional, the latter structure offers some explanation for the differential effects of heteroaryl modifications for PI3K and mTOR affinity shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> On- and Off-Target Activities</h3><div class="NLM_p">In line with its activities against PI3K and mTOR, compound <b>1</b> induced a G1 cell cycle arrest in A2058 melanoma cells (mutated B-Raf, loss of PTEN) and SKOV3 cells (PI3Kα mutated at H1047R), which have both constitutively activated PI3K/mTOR signaling pathways. In contrast, compound <b>4</b> triggered a mitotic arrest and cells accumulated in G2/M or subG1 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), which is in agreement with the reported binding of <b>4</b> to the colchicine-binding site of tubulin.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In spite of compound <b>4</b>’s off-target effect, the compound attenuated PI3K and mTOR signaling as determined by protein kinase B (PKB/Akt) phosphorylation on Ser473 and Thr308 and by S6 kinase (S6K, Thr389) and S6 phosphorylation on Ser235 and Ser236. Here, <b>4</b> closely matched the action of <b>1</b>, <b>5</b>, <b>6</b>, <b>3</b>, and <b>2</b>, while rapamycin by its specific action on TORC1 triggered an upregulation of PI3K activity, which is in agreement with earlier observations.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Action of indicated compounds on cell cycle and PI3K and mTOR signaling. Cell cycle distribution of A2058 (A) and SKOV3 (B) cells after 24 h exposure to 5 μM (A) or 2 μM (B) of indicated drugs (<b>1</b>, green; <b>4</b>, red) or DMSO. After drug exposure cells were collected, fixed, permeabilized and the DNA was stained using propidium iodide. Cell cycle profiles were acquired by fluorescence activated cell sorting. Left panels: Examples of cell cycle histograms. Right panels: Quantification of cells in cell cycle phases G1, S, G2/M, and sub-G1 (as % of total, <i>n</i> = 9, mean ± SD, one way ANOVA test with Dunnett’s multiple comparison test for each cell cycle phase related to DMSO; ns, not significant, (∗∗) <i>p</i> > 0.0021, (∗∗∗∗) <i>p</i> > 0.0001). (C, D) A2058 or SKOV3 cells were exposed to 1 μM drug (rapamycin 100 nM) for 1 h, subsequently lysed, and the denatured lysates subjected to SDS–PAGE, Western blotting, and immune detection. (C) Detection of total and phosphorylated (pT308 and pS473) PKB/Akt, and α-tubulin (left, A2058; right, SKOV3). Top: Quantification of phospho-PKB/Akt levels related to DMSO control (blue, pT308; red, pS473; <i>n</i> = 3, mean ± SEM). (D) Detection of total and phosphorylated (pS235/236) ribosomal protein S6 and of total and phosphorylated (S6K T389) S6 kinase (left, A2058; right, SKOV3). Top: Quantification of phospho-protein levels, related to DMSO control (blue, phospho S6; red, phospho S6K; <i>n</i> = 3, mean ± SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To validate the specificity of <b>1</b>, the compound was tested in a KINOMEScan panel for interactions with a wide range of protein (>400) and lipid kinases in parallel with <b>4</b>, <b>5</b>, <b>6</b>, and <b>3</b>. At 10 μM concentration <b>1</b>, <b>4</b>, <b>5</b>, and <b>3</b> did show negligible interference with protein kinase activities (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Figure S1, Table S2</a>), while the dual PI3K/mTOR kinase inhibitor <b>6</b> displayed multiple hits. Compound <b>1</b> reached excellent selectivity scores of <i>S</i>(35) = 0.025, <i>S</i>(10) = 0.018, as calculated according to ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>.</div><div class="NLM_p">The impact of compound <b>1</b> on cell proliferation was analyzed in four independent human tumor cell line collections of different tissue origin (NCI60;<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> NTRC, The Netherlands; Horizon Discoveries, U.K.; Clovis, U.K.; 135 different cell lines in total). Combined across the four cell panels the mean half-maximal growth inhibition (GI<sub>50</sub>) was reached at ∼0.7 μM (median: ∼0.5 μM) for <b>1</b> as depicted in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cell proliferation in response to <b>1</b> represented as a waterfall blot. Concentrations of half-maximal growth inhibition (GI<sub>50</sub>) for <b>1</b> were obtained from dose–response growth curves derived from 4 different tumor cell line panels (a total of 135 cell lines; if a cell line was contained in several panels, its GI<sub>50</sub> was averaged). Individual GI<sub>50</sub> of a cell line was related to the mean GI<sub>50</sub> of all cells lines, and cell lines were sorted by lowest to highest sensitivity for <b>1</b> from left to right. Individual cell lines and values for the four cell panels are given in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have previously compared IC<sub>50</sub>-independent parameters such as Hill slopes of proliferation inhibition curves and dose-dependent induction of nuclear condensation and histone H3 phosphorylation in a 44 cell line panel treated with either <b>1</b>, <b>4</b>, <b>5</b>, or <b>6</b>, which showed a coclustering of the PI3K inhibitors <b>1</b>, <b>5</b>, and <b>6</b> and grouped <b>4</b> with inhibitors of mitosis such as colchicine, nocodazole, and MTD147, a microtubule-binder derived from <b>4</b>,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> corroborating that <b>1</b> is free of the microtubule-binding off-target action of <b>4</b>.</div><div class="NLM_p last">To evaluate other off-target effects, compound <b>1</b> was tested at 10 μM in a CEREP BioPrint panel, where no or only very weak competition with radioligands for cell surface and nuclear receptors, membrane channels, transporters (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S4</a>) and enzyme activities of kinases, proteases, and phosphodiesterases (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S5</a>) were detected. Altogether, <b>1</b> qualifies as a specific pan-class I PI3K inhibitor without predicted off-target effects.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Pharmacological Parameters of Compound <b>1</b></h3><div class="NLM_p">Before translation of the in vitro and cellular activities to in vivo tumor models, pharmacological properties and metabolic stability of <b>1</b> were assessed. Compound <b>1</b> showed little clearance when exposed to rat, dog, and human liver microsomes, with a quicker turnover of <b>1</b> in mouse liver microsomes, where 40% of the compound was eliminated within 30 min (<a class="ref internalNav" href="#tbl3A" aria-label="Table 3">Table 3</a>). Stability in microsome assays was matched with clearance and half-live measurements in human, cynomolgus monkey, rat, dog, and mouse hepatocyte cultures, where <b>1</b> showed a low clearance in all species except for mouse. In the presence of human hepatocytes, the half-life of compound <b>1</b> was 9.4 h and ∼45 min in mouse hepatocytes (<a class="ref internalNav" href="#tbl3B" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl3A"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Stability in Liver Microsomes of Compound <b>1</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">% remaining in liver microsomes<a class="ref internalNav" href="#t3Afn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">84.6 ± 2.2</td><td class="colsep0 rowsep0" align="left">99.9 ± 0.5</td><td class="colsep0 rowsep0" align="left">92.4 ± 1.6</td><td class="colsep0 rowsep0" align="left">60.7 ± 4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7-EC<a class="ref internalNav" href="#t3Afn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">7.45 ± 0.8</td><td class="colsep0 rowsep0" align="left">28.5 ± 3.1</td><td class="colsep0 rowsep0" align="left">1.8 ± 1.0</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">propranolol<a class="ref internalNav" href="#t3Afn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">54.8 ± 6.7</td><td class="colsep0 rowsep0" align="left">2.9 ± 0.1</td><td class="colsep0 rowsep0" align="left">30.1 ± 2.6</td><td class="colsep0 rowsep0" align="left">6.8 ± 0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3Afn1"><div class="footnote" id="t3Afn1"><sup>a</sup><p class="last">Percentage of compound remaining after 30 min (mean ± SD, <i>n</i> = 2).</p></div><div class="footnote" id="t3Afn2"><sup>b</sup><p class="last">Assay reference compounds. 7-EC: 7-ethoxycoumarin.</p></div></div></div><div class="NLM_table-wrap" id="tbl3B"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Stability of Compound <b>1</b> in Hepatocyte Cultures<a class="ref internalNav" href="#tbl3B-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">CL<sub>int</sub><a class="ref internalNav" href="#t3Bfn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2.5 ± 0.4</td><td class="colsep0 rowsep0" align="left">3.5 ± 0.1</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.1</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.1</td><td class="colsep0 rowsep0" align="left">30.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [min]</td><td class="colsep0 rowsep0" align="left">562.6 ± 95.5</td><td class="colsep0 rowsep0" align="left">396.4 ± 16.0</td><td class="colsep0 rowsep0" align="left">731.7 ± 54.5</td><td class="colsep0 rowsep0" align="left">577.6 ± 0.1</td><td class="colsep0 rowsep0" align="left">45.7 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7-EC<a class="ref internalNav" href="#t3Bfn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">CL<sub>int</sub><a class="ref internalNav" href="#t3Bfn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">37.8 ± 0.8</td><td class="colsep0 rowsep0" align="left">61.1 ± 3.5</td><td class="colsep0 rowsep0" align="left">16.0 ± 0.8</td><td class="colsep0 rowsep0" align="left">151.4 ± 2.8</td><td class="colsep0 rowsep0" align="left">180.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [min]</td><td class="colsep0 rowsep0" align="left">36.7 ± 0.8</td><td class="colsep0 rowsep0" align="left">22.7 ± 1.3</td><td class="colsep0 rowsep0" align="left">86.8 ± 4.6</td><td class="colsep0 rowsep0" align="left">9.2 ± 0.2</td><td class="colsep0 rowsep0" align="left">7.7 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7-HC<a class="ref internalNav" href="#t3Bfn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">CL<sub>int</sub><a class="ref internalNav" href="#t3Bfn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">98.2 ± 5.1</td><td class="colsep0 rowsep0" align="left">92.5 ± 3.5</td><td class="colsep0 rowsep0" align="left">192.8 ± 14.4</td><td class="colsep0 rowsep0" align="left">178.3 ± 0.7</td><td class="colsep0 rowsep0" align="left">188.1 ± 8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [min]</td><td class="colsep0 rowsep0" align="left">14.1 ± 0.7</td><td class="colsep0 rowsep0" align="left">15.0 ± 0.6</td><td class="colsep0 rowsep0" align="left">7.2 ± 0.5</td><td class="colsep0 rowsep0" align="left">7.8 ± 0.1</td><td class="colsep0 rowsep0" align="left">7.4 ± 0.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3B-fn1"><div class="footnote" id="tbl3B-fn1"><sup>a</sup><p class="last">Results are expressed as mean ± SD, <i>n</i> = 2.</p></div><div class="footnote" id="t3Bfn1"><sup>b</sup><p class="last">CL<sub>int</sub> [(μL/min)/10<sup>6</sup> cells].</p></div><div class="footnote" id="t3Bfn2"><sup>c</sup><p class="last">Assay reference compounds: 7-EC, 7-ethoxycoumarin; 7-HC, 7-hydroxycoumarin.</p></div></div></div><div class="NLM_p">Subsequently, in vivo pharmacological parameters were determined in female CD-1 mice, female Sprague-Dawley rats, and male Beagle dogs to assess optimal dosing schedules for efficacy studies. Compound <b>1</b> was delivered by either a single intravenous (5 mg/kg) bolus or a single oral application (10 mg/kg). Drug levels in extracts of plasma, brain, and liver were determined by LC–MS/MS (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>; PK parameters are summarized in <a class="ref internalNav" href="#tbl4" aria-label="Table 5">Table 5</a>). In female mice, plasma concentrations of <b>1</b> depended on the drug administration route, resulting in half-lives of approximately 13–36 min for po administration vs 9–10 min for iv administration. The fact that oral administration yielded similar concentrations of <b>1</b> in brain and plasma samples illustrates that compound <b>1</b> readily passes the blood–brain barrier. In mice, both po and iv application routes showed a rapid drop below 200 ng/mL (∼0.5 μM, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A) of <b>1</b> within <1 h (iv) to <2 h (po) after administration, which reflects the time point when the drug reaches the median GI<sub>50</sub> determined in tumor cell lines.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK/PD assessment of <b>1</b> in mice, rats, and dogs: time course of <b>1</b> abundance in vivo. Compound <b>1</b> was administered in all species as single dose either per os (po, 10 mg/kg) or via intravenous injection (iv, 5 mg/kg). At indicated time-points <b>1</b> was extracted from tissue and its abundance determined using HPLC/MS–MS. (A) Levels of <b>1</b> in CD1-mice tissue. Right graph: Zoomed view on early time points, indicated in left graph by dashed square (<i>n</i> = 3, mean ± SD). (B) Concentrations of <b>1</b> in tissues from Sprague-Dawly rats. Right graph: Zoomed view on early time points, indicated in left graph by dashed square (<i>n</i> = 3, mean ± SD). (C) Plasma levels of <b>1</b> in male Beagle dogs. Panels on the right: zoomed in to dotted line boxes to visualize early time points (<i>n</i> = 3, mean ± SD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PK Analysis of <b>1</b> in Plasma of Mice, Rats, and Dogs<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" colspan="2" align="center">female CD-1 mouse</th><th class="colsep0 rowsep0" colspan="2" align="center">female Sprague-Dawley rats</th><th class="colsep0 rowsep0" colspan="2" align="center">male Beagle dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">route</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="left">po</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose [mg/kg]</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> [ng/mL]</td><td class="colsep0 rowsep0" align="left">3084 ± 379</td><td class="colsep0 rowsep0" align="left">1514 ± 334</td><td class="colsep0 rowsep0" align="left">3047 ± 557</td><td class="colsep0 rowsep0" align="left">4028 ± 1179</td><td class="colsep0 rowsep0" align="left">8760</td><td class="colsep0 rowsep0" align="left">583</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> [min]</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">120–240</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [h]</td><td class="colsep0 rowsep0" align="left">0.15–0.33</td><td class="colsep0 rowsep0" align="left">0.22–0.60</td><td class="colsep0 rowsep0" align="left">5.6–8.2</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC [h·ng/mL]</td><td class="colsep0 rowsep0" align="left">1583 AUC<sub>0–8h</sub></td><td class="colsep0 rowsep0" align="left">2151 AUC<sub>0–8h</sub></td><td class="colsep0 rowsep0" align="left">13974 AUC<sub>0.25–12h</sub></td><td class="colsep0 rowsep0" align="left">15313 AUC<sub>0.25–12h</sub></td><td class="colsep0 rowsep0" align="left">12500 AUC<sub>0.25–24h</sub></td><td class="colsep0 rowsep0" align="left">6395 AUC<sub>0.017–24h</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl [mL h<sup>–1</sup> kg<sup>–1</sup>]</td><td class="colsep0 rowsep0" align="left">3180</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">266</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">411</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BA [%]</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">68</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">23</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">iv, intravenous (5 mg/kg); po, per os (10 mg/kg); <i>C</i><sub>max</sub>, maximal concentration; <i>T</i><sub>max</sub>, time of maximal concentration in hours; <i>t</i><sub><b>1/2</b></sub>, half-life elimination in hours; AUC, area under curve; Cl, clearance; BA, bioavailability. <i>n</i> = 3, mean ± SD for each time point, species, and route.</p></div></div></div><div class="NLM_p">In female rats a single oral dose (10 mg/kg) achieved similar drug levels as a single intravenous injection (5 mg/kg) with regard to <i>C</i><sub>max</sub> (see <a class="ref internalNav" href="#tbl4" aria-label="Table 5">Table 5</a>). The half-life of 5–8 h and an AUC<sub>0.25–12</sub> of around 14 000 h·ng/mL contributed to an excellent oral bioavailability of <b>1</b> (>50%). Twenty-four hours after po administration, plasma levels of <b>1</b> were still >2 μM (800–1000 ng/mL). Moreover, after 1–2 h exposure to <b>1</b>, drug levels in rat brain samples were comparable to plasma levels (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B), confirming rapid access of <b>1</b> to the brain.</div><div class="NLM_p">Male Beagle dogs, exposed to <b>1</b> at 10 mg/kg po, showed maximal drug plasma concentrations <i>C</i><sub>max</sub> of 583 ng/mL (approximately 1.5 μM) after 60–90 min and a half-life of >7 h, which results in drug levels of approximately 0.38 μM (150 ng/mL) after 24 h. Intravenous delivery of 5 mg/kg of <b>1</b> resulted in high immediate concentrations (>7000 ng/mL after 1 min), and plasma levels decreased within 8 h to similar concentrations as observed for oral dosing (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). The oral bioavailability in male Beagle dogs was estimated to be 23%.</div><div class="NLM_p">In vitro and in vivo toxicokinetic parameters were assessed and are summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S6</a>. In rodents and Beagle dogs, compound <b>1</b> showed moderate but reversible target organ toxicity, which is expected for this drug class and mechanism of action. Altogether the PK studies in the three models show rapid absorption of <b>1</b> and good oral bioavailability. Except for mice with a rapid clearance of <b>1</b>, the late phase concentrations of <b>1</b> in rats and dogs are in the expected range of predicted efficacy, independent of the administration route, and are already reached after a single dose. The collected parameters are compatible with oral dosing in humans once daily (QD).</div><div class="NLM_p last">Altogether, compound <b>1</b> displays a superior solubility (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S7</a>) as compared with compound <b>2</b>, is orally bioavailable and brain penetrable, and does not display a microtubule-binding off-target effect like compound <b>4</b>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Efficacy Models</h3><div class="NLM_p">Due to the short half-live of compound <b>1</b> in mice, a PC3 xenograft model in nude rats was used to assess the antiproliferative effects of <b>1</b> in vivo. Rats were injected with 2 × 10<sup>7</sup> human PC3 prostate cancer cells into one flank and randomized after 16 days. From day 17 the control group received vehicle once daily. Compound <b>1</b> was orally administered at 5 mg/kg, 10 mg/kg (both daily, QD), or 15 mg/kg [5 consecutive days, 2 days off drug (QD × 5, 2 days off)] for 28 days to match the timelines of regulatory toxicology studies. A vinorelbine-treated group (2.5 mg/kg iv weekly) was included as a “standard of care” control, with best treated-to-control ratios (<i>T</i>/<i>C</i>) of 17%.</div><div class="NLM_p">Treatment with <b>1</b> led to significant tumor size reductions: tumor growth was inhibited dose-dependently (best <i>T</i>/<i>C</i> of 31–12%, <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A). Compound <b>1</b> was best tolerated at 5 mg/kg without significant body weight changes (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). At 10 mg/kg, <b>1</b> caused a reduction of body weight, which accumulated to a reduction of 15% after 28 days of treatment. Similarly, 15 mg/kg of <b>1</b> led to body weight loss after 5 days of treatment, which was reversible during the recovery period. After 28 days of drug exposure (day 44 of the experiment), animals with body weight loss fully recovered within a treatment-free period (days 45–50) without overt signs of tumor cell proliferation. In a subsequent treatment period tumor growth remained inhibited and body weight loss was only observed in the 15 mg/kg group.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Efficacy model for antitumor activity of <b>1</b> in PC3 xenografts in nude rats. (A) Tumor volume: Indicated amounts of <b>1</b> (po, daily) or vinorelbine (iv, weekly) were given from day 17 to day 44 and from day 51 to day 58 after tumor inoculation (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>; <i>n</i> = 4–8, mean ± SEM). (B) Body weight changes in nude rats (treated as in (A), <i>n</i> = 4–8, mean ± SEM). (C) Time course of <b>1</b> abundance in nude rats. Compound <b>1</b> was administered as single dose per os (po, 15 mg/kg). At indicated time points <b>1</b> was extracted from tissue and its abundance determined using HPLC/MS–MS (<i>n</i> = 3, mean ± SD). (D) Time course of blood glucose and insulin levels tumor bearing rats after a single dose of <b>1</b> (15 mg/kg po; <i>n</i> = 3, mean ± SEM; except for time points with values above detection limit). (E) Plasma insulin and (F) plasma glucose concentrations on day 57 of the efficacy model, 4 h after the last administration of <b>1</b> at indicated doses (<i>n</i> = 6–7, mean ± SEM; for insulin levels below detection level, values were set constant to 0.04 [lowest measured value]; for glucose levels above quantification limit, levels were set 20 [upper quantification limit of kit]). (G) Time course of phosphorylation of Ser473 in PKB/Akt in PC3 tumor xenograft lysates after a single dose of <b>1</b> (15  mg/kg po or 10 mg/kg iv). Lysates were subjected to SDS–PAGE and Western blotting. Phosphorylated Ser473 levels were corrected for total PKB/Akt levels and compared to vehicle-treated xenografts (<i>n</i> = 3, mean ± SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>C, <i>C</i><sub>max</sub> of compound <b>1</b> is reached 15 min after a po single dose in PC3-tumor bearing nude rats and triggered a rapid and dose-dependent rise in plasma insulin and glucose levels (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>D–F), which are reliable markers for the on-target action of drugs, as reported for other PI3K inhibitors targeting the PI3Kα isoform.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p last">To further corroborate on-target activity of compound <b>1</b> in vivo, phosphorylation of pPKB/AKT was measured in tumor-derived cell lysates. A single dose of <b>1</b> (15 mg/kg po or 10 mg/kg iv) rapidly reduced pPKB/AKT levels as compared to untreated control mice up to 12 h (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>G), which matches high levels of <b>1</b> in the xenograft tumors at early time points (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>C). After 24 h, PI3K signaling fully recovered, correlating with a decrease of compound <b>1</b>’s concentration in tissue and tumors. Pharmacokinetics in plasma, brain, and tumor samples were very similar, suggesting that <b>1</b> distributes rapidly and targets PI3K and mTOR in tumor and tissues. Proportionally elevated levels of <b>1</b> were detected in the liver, without signs of liver toxicity. The fast reversibility of PI3K inhibition might be of advantage in patients, where mechanism-based adverse effects are expected to resolve with falling drug levels. Moreover, it has been observed that tumor cells reduce cell size in response to PI3K inhibitors, while normal hepatocytes do not show mass reduction.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This, and the observation that interruption of drug administration (see 15 mg/kg schedule above) leads to body weight recovery but not tumor regrowth, suggests that PI3K inhibition triggers latency in tumor growth that allows for the development of intermittent scheduling protocols. To validate this treatment scheme, PC3 tumor-bearing nude rats were treated every second, third, and fourth day with 15 mg/kg po, which yielded a comparable efficacy but substantially alleviated the loss of body weight (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Figure S2</a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11076" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11076" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The preclinical results presented here document that compound <b>1</b> is a highly selective pan-PI3K inhibitor with a balanced targeting of mTOR kinase. Compound <b>1</b>’s potent antiproliferative action in vitro and antitumor activity in vivo, paired with mild and reversible, mostly mechanism-based toxicities, have validated the molecule as a clinical candidate. Compound <b>1</b> passed phase I studies and is now in phase II studies in relapsed and refractory lymphoma and advanced solid tumors (clinicaltrials.gov).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Information</h3><div class="NLM_p last">Reagents were purchased at the highest commercial quality from Acros, Sigma-Aldrich, or Fluorochem and used without further purification. Solvents were purchased from Acros Organics in AcroSeal bottles over molecular sieves. Column chromatographic purifications were performed on Merck KGaA silica gel (pore size 60 Å, 230–400 mesh particle size). Cross-coupling reactions were carried out under nitrogen atmosphere in anhydrous solvents, and glassware was oven-dried prior to use. TLC plates were obtained from Merck KGaA (Polygram SIL/UV254, 0.2 mm silica with fluorescence indicator), and UV light (254 nm) was used to visualize the respective compounds. <sup>1</sup>H, <sup>19</sup>F, and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance 400 spectrometer. NMR spectra were obtained in deuterated solvents such as CDCl<sub>3</sub> or (CD<sub>3</sub>)<sub>2</sub>SO. The chemical shifts (δ values) are reported in ppm and corrected to the signal of the deuterated solvents (7.26 ppm (<sup>1</sup>H NMR) and 77.16 ppm (<sup>13</sup>C NMR) for CDCl<sub>3</sub> and 2.50 ppm (<sup>1</sup>H NMR) and 39.52 ppm (<sup>13</sup>C NMR) for (CD<sub>3</sub>)<sub>2</sub>SO). <sup>19</sup>F NMR spectra were calibrated relative to CFCl<sub>3</sub> (δ = 0 ppm) as external standard. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), dd (doublet of doublets), m (multiplet), br (broadened). Coupling constants, when given, are reported in hertz (Hz). High resolution mass spectra (HRMS) were recorded on a Thermo Fisher Scientific LTQ Orbitrap XL (ESI-MS) spectrometer. MALDI-ToF mass spectra were obtained on a Voyager-De Pro measured in <i>m</i>/<i>z</i>. The chromatographic purities of the final compounds were determined by high performance liquid chromatography (HPLC) analyses on an Ultimate 3000SD system from ThermoFisher with LPG-3400SD pump system, ACC-3000 autosampler and column oven, and DAD-3000 diode array detector. An Acclaim-120 C18 reversed-phase column from ThermoFisher was used as stationary. Gradient elution (5:95 for 0.2 min, 5:95 → 100:0 over 10 min, 100:0 for 3 min) of the mobile phase consisting of CH<sub>3</sub>CN/MeOH:H<sub>2</sub>O<sub>(10:90)</sub> was used at a flow rate of 0.5 mL/min at 40 °C. The purity of all final compounds was >95%.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure 1</h3><div class="NLM_p last">4,4′-(6-Chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 1.0 equiv), the respective boronic acid pinacol ester  (1.0–1.5 equiv), potassium phosphate tribasic (3.0 equiv), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 0.05–0.10 equiv) were charged in a flask. Under nitrogen atmosphere, 1,4-dioxane (approximately 1 mL/0.2 mmol) and deionized H<sub>2</sub>O (approximately 1 mL/0.4 mmol) were added, and the resulting mixture was placed into an oil bath preheated to 95 °C and stirred at this temperature for 2–16 h. After completion of the reaction, the mixture was allowed to cool to room temperature before addition of a 3 M aqueous HCl solution and then heated at 60 °C for 2–8 h. Then the mixture was allowed to cool to room temperature, the pH was adjusted to 8–9 by addition of a 2 M aqueous NaOH solution, and the aqueous layer was extracted with ethyl acetate (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Procedure 2</h3><div class="NLM_p last">To a solution of the respective boronic acid pinacol ester (4.0 equiv), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.05 equiv) and 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 1.0 equiv) in 1,2-dimethoxyethane (approximately 1 mL/0.2 mmol) under nitrogen atmosphere, a 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> solution (3.0 equiv) was added. The resulting reaction mixture was heated at 90 °C for 16 h. Then the mixture was allowed to cool to room temperature, poured onto an aqueous saturated NH<sub>4</sub>Cl solution, and the aqueous layer was extracted with ethyl acetate (3×). The combined organic layers were washed with deionized H<sub>2</sub>O, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated to dryness under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedure 3</h3><div class="NLM_p last"><i>N</i>,<i>N</i>-Dimethylformamide dimethyl acetal (1.5 equiv) and the respective amine (1.0 equiv) were dissolved in tetrahydrofuran (approximately 1 mL/0.3 mmol), and the resulting reaction mixture was stirred at 70 °C overnight. The solvent was evaporated under reduced pressure and the residue was triturated with acetonitrile (3×x) before it was dried under <i>vacuum</i>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>1</b>)</h3><div class="NLM_p last"><b>1</b> was prepared according to the reported procedure in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyrimidin-2-amine (<b>2</b>)</h3><div class="NLM_p last"><b>2</b> was prepared according to general procedure 1 from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 300 mg, 1.05 mmol, 1.0 equiv) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyrimidin-2-amine (455 mg, 1.58 mmol, 1.5 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 2:3 → 3:2) gave product <b>2</b> as a colorless solid (225 mg, 546 μmol, 52%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.94 (s, 1 H), 5.65 (br s, 2 H), 3.39–3.78 (m, 8 H), 3.76–3.69 (m, 8 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ −63.8 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.5 (s, 1 C), 164.7 (s, 2 C), 163.1 (s, 1 C), 162.7 (s, 1 C), 154.6 (q, <sup>2</sup><i>J</i><sub><i>C,F</i></sub> = 35 Hz, 1 C), 121.1 (s, 1 C), 120.8 (q, <sup>1</sup><i>J</i><sub><i>C,F</i></sub> = 276 Hz, 1 C), 66.9 (s, 4 C), 43.7 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>20</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub>, 413.1656; found, 413.1662. HPLC: <i>t</i><sub>R</sub> = 7.39 min (>99.9% purity).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4,4′-(6-Chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>)</h3><div class="NLM_p last"><b>7</b> was prepared according to ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 4,4′-(6-Iodo-1,3,5-triazine-2,4-diyldimorpholine (<b>8</b>)</h3><div class="NLM_p last">To an aqueous hydriodic acid solution (57 wt %, 2.00 mL, 15.2 mmol, excess) diluted with deionized H<sub>2</sub>O (2.00 mL), 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 500 mg, 1.75 mmol, 1.0 equiv) was added at 0 °C. The reaction mixture was allowed to warm to room temperature overnight and then poured onto a 1 M aqueous NaOH solution. The product was extracted with ethyl acetate (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 1:1) to afford product <b>8</b> as a colorless solid (409 mg, 1.08 mmol, 61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.87–3.63 (m, 16 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 162.1 (s, 2 C), 140.6 (s, 1 C), 66.8 (s, 4 C), 44.0 (s, 4 C). MALDI-MS: <i>m</i>/<i>z</i> = 378.1 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 4-(4,6-Dimorpholino-1,3,5-triazin-2-yl)aniline (<b>9</b>)</h3><div class="NLM_p last"><b>9</b> was prepared according to general procedure 1 from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 150 mg, 525 μmol, 1.0 equiv) and <i>tert</i>-butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (<b>22</b>, 250 mg, 783 μmol, 1.5 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 3:2) gave product <b>9</b> as a colorless solid (80.9 mg, 236 μmol, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.22 (d, <sup>3</sup><i>J</i><sub><i>H,H</i></sub> = 8.7 Hz, 2 H), 6.69 (d, <sup>3</sup><i>J</i><sub><i>H,H</i></sub> = 8.7 Hz, 2 H), 3.99–3.81 (m, 10 H), 3.79–3.72 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 170.3 (s, 1 C), 165.3 (s, 2 C), 149.7 (s, 1 C), 130.1 (s, 2 C), 127.5 (s, 1 C), 114.2 (s, 2 C), 67.0 (s, 4 C), 43.7 (br s, 4 C). MALDI-MS: <i>m</i>/<i>z</i> = 343.2 ([M + H]<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 7.27 min (>99.9% purity). The spectroscopic data are consistent with previous literature reports.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)pyridin-2-amine (<b>10</b>)</h3><div class="NLM_p last"><b>10</b> was prepared according to general procedure 2 from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 200 mg, 702 μmol, 1.0 equiv) and 2-aminopyridine-5-boronic acid pinacol ester (616 mg, 2.80 mmol, 4.0 equiv). Purification by column chromatography on silica gel (dichloromethane/methanol 9:1) gave compound <b>10</b> as a colorless solid (166 mg, 483 μmol, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.07 (d, <sup>4</sup><i>J</i><sub><i>H,H</i></sub> = 2.3 Hz, 1 H), 8.37 (dd, <sup>3</sup><i>J</i><sub><i>H,H</i></sub> = 8.7 Hz, <sup>4</sup><i>J</i><sub><i>H,H</i></sub> = 2.3 Hz, 1 H), 6.50 (d, <sup>3</sup><i>J</i><sub><i>H,H</i></sub> = 8.6 Hz, 1 H), 4.71 (br s, 2 H), 3.88 (br s, 8 H), 3.79–3.71 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.2 (s, 1 C), 165.1 (s, 2 C), 160.4 (s, 1 C), 150.0 (s, 1 C), 137.9 (s, 1 C), 123.6 (s, 1 C), 107.5 (s, 1 C), 67.0 (s, 4 C), 43.7 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>, 344.1829; found, 344.1832. HPLC: <i>t</i><sub>R</sub> = 8.59 min (96.2% purity).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)pyrimidin-2-amine (<b>11</b>)</h3><div class="NLM_p last"><b>11</b> was prepared according to general procedure 2 from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 50.0 mg, 170 μmol, 1.0 equiv) and 2-aminopyrimidine-5-boronic acid pinacol ester (155 mg, 700 μmol, 4.0 equiv). Purification by column chromatography on silica gel (ethyl acetate/methanol 1:0 → 20:1) gave compound <b>11</b> as a colorless solid (10.0 mg, 29.0 μmol, 17%). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 9.05 (s, 2 H), 7.26 (br s, 2 H), 3.94–3.62 (m, 8 H), 3.64 (br s, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 167.2 (s, 1 C), 164.8 (s, 1 C), 164.2 (s, 2 C), 158.6 (s, 2 C), 118.5 (s, 1 C), 66.0 (s, 4 C), 43.2 (br s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>21</sub>N<sub>8</sub>O<sub>2</sub>, 345.1782; found, 345.1784. HPLC: <i>t</i><sub>R</sub> = 6.06 min (95.4% purity).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)pyrazin-2-amine (<b>12</b>)</h3><div class="NLM_p last">4,4′-(6-Iodo-1,3,5-triazine-2,4-diyl)dimorpholine (<b>8</b>, 200 mg, 530 μmol, 1.0 equiv), 5-aminopyrazin-2-ylboronic acid pinacol ester (350 mg, 1.58 mmol, 3.0 equiv), potassium phosphate tribasic (339 mg, 1.60 mmol, 3.0 equiv), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (41.7 mg, 53.0 mmol, 0.10 equiv) were charged in a flask. Under nitrogen atmosphere, 1,4-dioxane (5 mL) and deionized H<sub>2</sub>O (1.5 mL) were added, and the resulting mixture was placed into an oil bath preheated and allowed to stir for 2 h at 95 °C. After completion of the reaction, the mixture was allowed to cool to room temperature. Dichloromethane and a 2 M aqueous NaOH solution were added. The aqueous layer was separated and extracted with dichloromethane (3×). The combined organic layers were then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel (dichloromethane/methanol 1:0 → 9:1) to obtain compound <b>12</b> as a colorless solid (20.1 mg, 58.4 μmol, 11%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.08 (br s, 1 H), 8.10 (br s, 1 H), 4.86 (br s, 2 H), 4.08–3.81 (m, 8 H), 3.81–3.71 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.8 (s, 1 C), 165.2 (s, 2 C), 155.2 (s, 1 C), 144.5 (s, 1 C), 140.1 (s, 1 C), 131.6 (s, 1 C), 67.0 (s, 4 C), 43.8 (br s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>21</sub>N<sub>8</sub>O<sub>2</sub>, 345.1782; found, 345.1780. HPLC: <i>t</i><sub>R</sub> = 5.37 min (95.2% purity).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-methylpyridin-2-amine (<b>13</b>)</h3><div class="NLM_p last"><b>13</b> was prepared according to general procedure 2 from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 40.0 mg, 140 μmol, 1.0 equiv) and 2-amino-4-methylpyridine-5-boronic acid pinacol ester (132 mg, 560 μmol, 4.0 equiv). Purification by column chromatography on silica gel (ethyl acetate/methanol 1:0 → 10:1) gave product <b>13</b> as a colorless solid (13.1 mg, 36.7 μmol, 26%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.78 (s, 1 H), 6.33 (s, 1 H), 4.54 (br s, 2 H), 3.90–3.80 (m, 8 H), 3.77–3.72 (m, 8 H), 2.60 (s, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 171.4 (s, 1 C), 165.0 (s, 2 C), 159.3 (s, 1 C), 151.4 (s, 1 C), 149.4 (s, 1 C), 124.1 (s, 1 C), 109.8 (s, 1 C), 66.8 (s, 4 C), 43.7 (br s, 4 C), 22.3 (s, 1 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub>, 358.1986; found, 358.1983. HPLC: <i>t</i><sub>R</sub> = 6.57 min (98.5% purity).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-3-methylpyridin-2-amine (<b>14</b>)</h3><div class="NLM_p last"><b>14</b> was prepared according to general procedure 1 from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 150 mg, 525 μmol, 1.0 equiv) and boronic acid pinacol ester <b>23</b> (180 mg, 622 μmol, 1.2 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 4:1) gave product <b>14</b> as a colorless solid (116 mg, 32.5 μmol, 62%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.89 (d, <sup>4</sup><i>J</i><sub><i>H,H</i></sub> = 2.2 Hz, 1 H), 8.22 (br s, 1 H), 5.25 (br s, 2 H), 4.02–3.68 (m, 16 H), 2.19 (s, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.9 (s, 1 C), 165.0 (s, 2 C), 158.9 (s, 1 C), 145.2 (s, 1 C), 138.1 (s, 1 C), 123.5 (s, 1 C), 116.3 (s, 1 C), 67.0 (s, 4 C), 43.7 (br s, 4 C), 17.0 (s, 1 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub>, 358.1986; found, 358.1981. HPLC: <i>t</i><sub>R</sub> = 6.91 min (99.3% purity).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-3-(trifluoromethyl)pyridin-2-amine (<b>15</b>)</h3><div class="NLM_p last"><b>15</b> was prepared according to general procedure 1 from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 83.3 mg, 292 μmol, 1.0 equiv) and boronic acid pinacol ester <b>24</b> (100 mg, 292 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 1:1) gave product <b>15</b> as a colorless solid (89.5 mg, 218 μmol, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.19 (s, 1 H), 8.63 (d, <sup>4</sup><i>J</i><sub><i>H,F</i></sub> = 2.2 Hz, 1 H), 5.24 (br s, 2 H), 4.01–3.80 (m, 8 H), 3.80–3.71 (m, 8 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ −63.1 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 167.3 (s, 1 C), 164.2 (s, 2 C), 157.3 (s, 1 C), 153.1 (s, 1 C), 134.5 (br s, 1 C), 124.1 (q, <sup>1</sup><i>J</i><sub><i>C,F</i></sub> = 271 Hz, 1 C), 119.9 (s, 1 C), 105.1 (q, <sup>2</sup><i>J</i><sub><i>C,F</i></sub> = 31 Hz, 1 C), 66.0 (s, 4 C), 43.2 (br s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub>, 412.1703; found, 412.1703. HPLC: <i>t</i><sub>R</sub> = 8.40 min (>99.9% purity).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-methylpyrimidin-2-amine (<b>16</b>)</h3><div class="NLM_p last"><b>16</b> was prepared according to general procedure 2 from 4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>7</b>, 40.0 mg, 140 μmol, 1.0 equiv) and 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (132 mg, 560 μmol, 4.0 equiv). Purification by column chromatography on silica gel (ethyl acetate 100%) gave product <b>16</b> as a colorless solid (17.6 mg, 49.2 μmol, 34%). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.90 (s, 1 H), 7.02 (br s, 2 H), 3.81–3.69 (m, 8 H), 3.66–3.59 (m, 8 H), 2.63 (s, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 170.1 (s, 1 C), 168.9 (s, 1 C), 164.6 (s, 2 C), 162.6 (s, 1 C), 160.9 (s, 1 C), 121.3 (s, 1 C), 66.9 (s, 4 C), 43.7 (br s, 4 C), 25.2 (s, 1 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>23</sub>N<sub>8</sub>O<sub>2</sub>, 359.1938; found, 359.1939. HPLC: <i>t</i><sub>R</sub> = 6.22 min (97.3% purity).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide (<b>17</b>)</h3><div class="NLM_p last">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>1</b>, 200 mg, 480 μmol, 1.0 equiv) and K<sub>2</sub>CO<sub>3</sub> (134 mg, 972 mmol, 2.0 equiv) were mixed in dichloromethane (4 mL) and stirred at room temperature for 5 min. Then, the reaction mixture was cooled to 0 °C and acetyl chloride (41.4 μL, 583 mmol, 1.2 equiv) was added dropwise. The resulting mixture was stirred for 3.5 h and allowed to warm up to room temperature. Then, deionized H<sub>2</sub>O was added, the layers were separated, and the aqueous layer was extracted with dichloromethane (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel (cyclohexane/ethyl acetate 1:1 → 1:3) to afford compound <b>17</b> (120 mg, 265 mmol, 60%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.81 (s, 1 H), 8.61 (s, 1 H), 8.34 (s, 1 H), 3.85 (br s, 8 H), 3.78–3.67 (m, 8 H), 2.26 (s, 3 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −59.5 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.3 (s, 1 C), 168.7 (s, 1 C), 164.5 (s, 2 C), 152.6 (s, 1 C), 151.0 (s, 1 C), 138.8 (q, <sup>2</sup><i>J</i><sub><i>C,F</i></sub> = 33 Hz, 1 C), 128.4 (s, 1 C), 122.5 (q, <sup>1</sup><i>J</i><sub><i>C,F</i></sub> = 275 Hz, 1 C), 110.5 (q, <sup>3</sup><i>J</i><sub><i>C,F</i></sub> = 5.1 Hz, 1 C), 66.7 (s, 4 C), 43.5 (br s, 4 C), 24.7 (s, 1 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>23</sub>F<sub>3</sub>N<sub>7</sub>O<sub>3</sub>, 454.1809; found, 454.1797. HPLC: <i>t</i><sub>R</sub> = 7.94 min (>99.9% purity).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-ol (<b>18</b>) and 4,4′-(6-(6-Chloro-4-(trifluoromethyl)pyridin-3-yl)-1,3,5-triazine-2,4-diyl)dimorpholine (<b>19</b>)</h3><div class="NLM_p">To a conc HCl solution (36%, 5.12 mL) at 0 °C, 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (<b>1</b>, 500 mg, 1.21 mmol, 1.0 equiv) was added dropwise followed by NaNO<sub>2</sub> (1.70 g, 24.6 mmol, 20 equiv). The resulting mixture was then allowed to warm to room temperature over 1 h, and CuCl (4.10 g, 41.4 mmol, 34 equiv) was added. After 1 h, the reaction mixture was quenched with a 2 M aqueous NaOH solution and extracted with ethyl acetate (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The products were separated by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 1:1). Compound <b>19</b> (247 mg, 573 μmol, 47%) and compound <b>18</b> (166 mg, 403 μmol, 33%) were obtained in two separate fractions and isolated as colorless solids.</div><div class="NLM_p"><i>Compound <b>19</b>.</i><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.91 (s, 1 H), 7.66 (s, 1 H), 3.89–3.78 (m, 8 H), 3.78–3.68 (m, 8 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −59.7 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.0 (s, 1 C), 164.6 (s, 2 C), 153.2 (s, 1 C), 153.0 (s, 1 C), 154.1 (q, <sup>2</sup><i>J</i><sub><i>C,F</i></sub> = 34 Hz, 1 C), 131.5 (s, 1 C), 122.1 (q, <sup>1</sup><i>J</i><sub><i>C,F</i></sub> = 275 Hz, 1 C), 121.4 (q, <sup>3</sup><i>J</i><sub><i>C,F</i></sub> = 5.4 Hz, 1 C), 66.9 (s, 4 C), 43.8 (br s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>19</sub>F<sub>3</sub>ClN<sub>6</sub>O<sub>2</sub>, 431.1205; found, 431.1199. HPLC: <i>t</i><sub>R</sub> = 9.91 min (>99.9% purity).</div><div class="NLM_p last"><i>Compound <b>18</b>.</i><sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 12.6 (br s, 1 H), 8.15 (s, 1 H), 6.80 (s, 1 H), 3.79–3.67 (m, 8 H), 3.66–3.55 (m, 8 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ −59.4 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 168.0 (s, 1 C), 164.0 (s, 2 C), 161.2 (s, 1 C), 141.4 (br s, 1 C), 138.9 (q, <sup>2</sup><i>J</i><sub><i>C,F</i></sub> = 32 Hz, 1 C), 122.3 (q, <sup>1</sup><i>J</i><sub><i>C,F</i></sub> = 275 Hz, 1 C), 119.2 (br s, 1 C), 113.3 (br s, 1 C), 65.9 (s, 4 C), 43.2 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>20</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub>, 413.1543; found, 413.1535. HPLC: <i>t</i><sub>R</sub> = 6.79 min (99.6% purity).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)-<i>O</i>-methylhydroxylamine (<b>20</b>)</h3><div class="NLM_p last">4,4′-(6-(6-Chloro-4-(trifluoromethyl)pyridin-3-yl)-1,3,5-triazine-2,4-diyl)dimorpholine (<b>19</b>, 200 mg, 464 μmol, 1.0 equiv), methoxyamine hydrochloride (77.5 mg, 928 μmol, 2.0 equiv), and NaHCO<sub>3</sub> (79.0 mg, 940 μmol, 2.0 equiv) were mixed in dimethyl sulfoxide (3.0 mL). The resulting reaction mixture was stirred at 100 °C for 6 h. The solvent was partially evaporated under reduced pressure. Then, deionized H<sub>2</sub>O and dichloromethane were added. The aqueous layer was separated and extracted with dichloromethane (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated to dryness under reduced pressure. The crude product was purified by column chromatography on silica gel (cyclohexane/ethyl acetate 1:1 → 0:1) to afford compound <b>20</b> (30.0 mg, 34.0 mmol, 15%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.77 (s, 1 H), 7.77 (br s, 1 H), 7.23 (s, 1 H), 3.90–3.79 (m, 11 H), 3.77–3.70 (m, 8 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −59.6 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.6 (s, 1 C), 164.8 (s, 2 C), 156.0 (s, 1 C), 151.8 (s, 1 C), 138.6 (q, <sup>2</sup><i>J</i><sub><i>C,F</i></sub> = 274 Hz, 1 C), 127.5 (s, 1 C), 122.6 (q, <sup>1</sup><i>J</i><sub><i>C,F</i></sub> = 275 Hz, 1 C), 110.1 (q, <sup>3</sup><i>J</i><sub><i>C,F</i></sub> = 6.2 Hz, 1 C), 66.9 (s, 4 C), 63.1 (s, 1 C), 43.8 (br s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>F<sub>3</sub>N<sub>7</sub>O<sub>3</sub>, 442.1809; found, 442.1799. HPLC: <i>t</i><sub>R</sub> = 8.33 min (98.9% purity).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4,4′-(6-(6-Bromo-4-(trifluoromethyl)pyridin-3-yl)-1,3,5-triazine-2,4-diyl)dimorpholine (<b>21</b>)</h3><div class="NLM_p last">Compound <b>1</b> (1.00 g, 2.43 mmol, 1.0 equiv) was dissolved in dibromomethane (10 mL), and isopentyl nitrite (392 μL, 2.92 mmol, 1.2 equiv) was added. After 5 min, a solution of bromotrimethylsilane (401 μL, 3.04 mmol, 1.3 equiv) in dibromomethane (1.5 mL) was added and the resulting reaction mixture was allowed to stir at room temperature for 1 h. After this time, an aqueous saturated NaHCO<sub>3</sub> solution was added, the layers were separated, and the aqueous layer was extracted with dichloromethane (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/ethyl acetate 1:0 → 1:1) gave compound <b>21</b> (909 mg, 1.91 mmol, 79% yield) as colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.88 (s, 1 H), 7.81 (s, 1 H), 3.88–3.78 (m, 8 H), 3.78–3.68 (m, 8 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −59.6 (s, 3 F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.0 (s, 1 C), 164.6 (s, 2 C), 153.2 (s, 1 C), 143.7 (s, 1 C), 138.5 (q, <sup>2</sup><i>J</i><sub><i>C,F</i></sub> = 34 Hz, 1 C), 131.8–131.7 (m, 1 C), 125.1 (q, <sup>3</sup><i>J</i><sub><i>C,F</i></sub> = 5.3 Hz, 1 C), 122.0 (q, <sup>1</sup><i>J</i><sub><i>C,F</i></sub> = 275 Hz, 1 C), 66.8 (s, 4 C), 43.7 (br s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>19</sub>BrF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>, 475.0699; found, 475.0710. HPLC: <i>t</i><sub>R</sub> = 10.11 min (97.8% purity).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>tert</i>-Butyl (4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (<b>22</b>)</h3><div class="NLM_p last"><b>22</b> was prepared according to the literature.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>,<i>N</i>-Dimethyl-<i>N</i>′-(3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)formimidamide (<b>23</b>)</h3><div class="NLM_p last"><b>23</b> was prepared according to general procedure 3 from 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (200 mg, 854 μmol, 1.0 equiv). The desired product <b>23</b> was obtained in quantitative yield as a brownish solid and was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.50 (s, 1 H), 8.25 (s, 1 H), 7.61 (s, 1 H), 3.10 (s, 3 H), 3.02 (s, 3 H), 2.19 (s, 3 H), 1.27 (s, 12 H).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>,<i>N</i>-Dimethyl-<i>N</i>′-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)pyridin-2-yl)formimidamide (<b>24</b>)</h3><div class="NLM_p last"><b>24</b> was prepared according to general procedure 3 from 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)pyridin-2-amine (300 mg, 1.04 mmol, 1.0 equiv). The desired product <b>24</b> was obtained in quantitative yield as a yellowish solid and was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.70 (s, 1 H), 8.54 (d, <i>J</i> = 1.8 Hz, 1 H), 7.96 (d, <i>J</i> = 1.9 Hz, 1 H), 3.16 (s, 3 H), 3.06 (s, 3 H), 1.29 (s, 12 H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ −61.6 (s, 3 F).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Protein Production and Purification</h3><div class="NLM_p last">The ΔABDp110γ was expressed in Sf9 cells using a baculovirus expression system as has been described previously.<a onclick="showRef(event, 'ref24 ref35'); return false;" href="javascript:void(0);" class="ref ref24 ref35">(24, 35)</a> Briefly, human ΔABDp110γ was expressed with a C-terminal His<sub>6</sub> tag and purified by immobilized metal-affinity chromatography, heparin chromatography, and gel filtration. The protein in gel filtration buffer (20 mM Tris-HCl, 0.5 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 5 mM DTT, 1% ethylene glycol, and 0.02% CHAPS) was concentrated to 8 mg/mL and then frozen in liquid nitrogen and stored at −80 °C.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Crystallization of PI3Kγ. Soaking with Compound <b>1</b></h3><div class="NLM_p last">Drops containing 1 μL of ΔABDp110γ protein at 4 mg/mL and 1 μL of crystallization buffer (16% PEG4K, 250 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.1 M Tris-HCl, pH 7.5, at rt) were hair seeded with crushed ΔABDp110γ crystals and incubated at 17 °C. The crystals reached their maximum size (0.2 mm × 0.1 mm × 0.1 mm) in about 10 days. The inhibitor <b>1</b> was prepared in DMSO and diluted in cryoprotectant containing 25% PEG 4000, 15% glycerol, 250 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and 100 mM Tris, pH 7.5, to a final concentration of 1 mM. The inhibitor in cryoprotectant solution was added to the drop containing the crystals in a stepwise manner. The crystals were soaked in the final 1 mM inhibitor solution for 4 h. Crystals were then transferred to fresh inhibitor in cryoprotectant solution for 30 s and flash frozen in liquid nitrogen.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Data Collection and Structure Determination</h3><div class="NLM_p last">Diffraction data sets were collected at the ESRF beamline ID23-1 on an ADSC Quantum Q315r detector, using 1.007 20 Å wavelength radiation. Images were processed using Mosflm<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> or XDS<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and scaled with SCALA.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The crystal structure of the ΔABDp110γ/compound <b>1</b> complex was solved by molecular replacement using Phaser,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> with the previously published human ΔABDp110γ as the search model (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E8Y">1E8Y</a>). Coot was used to manually build inhibitors in the unaccounted <i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> difference electron density within the active site of the map.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Initial models of the inhibitors were generated from SMILES strings using the ELBOW module of PHENIX.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Refmac refinement<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> was iterated with manual rebuilding using Coot until the structure converged. In the final model for the ΔABDp110γ/compound <b>1</b> complex, 89.2% of residues were in the core regions of the Ramachandran plot, with one residue in a disallowed region.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Cellular PI3K and mTOR Signaling</h3><div class="NLM_p last">Downstream signals of PI3K and mTOR were determined in in-cell Western assays detecting phosphorylation of Ser473 of PKB/Akt (pPKB/Akt) and Ser235/236 on the ribosomal protein S6 (pS6), respectively. Briefly, 2 × 10<sup>4</sup> A2058 cells/well in 96-well plates (Cell Carrier, PerkinElmer) were grown for 24 h, before inhibitors or DMSO was added (1 h; 37 °C, 5%CO<sub>2</sub>). Cells were subsequently fixed (4% PFA in PBS for 30 min at rt) and then blocked (1% BSA/0.1% Triton X-100/5% goat serum in PBS for 30 min, rt). pPKB/Akt was detected with a rabbit polyclonal antibody (Cell Signaling Technology, no. 4058), and pS6 with a rabbit monoclonal antibody (Cell Signaling Technology, no. 4856). Tubulin staining (mouse anti-α-tubulin, Sigma no. T9026) was assessed as internal standard. As readout, IRDye680-conjugated goat anti-mouse and IRDye800-conjugated goat anti-rabbit antibodies (LICOR no. 926-68070 and no. 926-32211) were used, and fluorescence was measured on an Odyssey CLx infrared imaging scanner (LICOR). Percentage of remaining phospho-substrate signals were calculated in relation to cellular tubulin. Further details and calculations are explained in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a>.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Determination of Inhibitor Dissociation Constants</h3><div class="NLM_p last">Dissociation constants of compounds (<i>K</i><sub>i</sub>) for p110α and mTOR were determined by LanthaScreen technology (Life Technologies) as described in detail in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a>. Briefly, the AlexaFluor647-labeled kinase tracer 314 (no. PV6087) was used for p110α with a determined <i>K</i><sub>d</sub> of 2.2 nM at 20 nM, and for mTOR with a <i>K</i><sub>d</sub> of 19 nM used at a final concentration of 10 nM. While recombinant p110α was N-terminally (His)<sub>6</sub>-tagged and combined with a biotinylated anti-(His)<sub>6</sub>-tag antibody (2 nM, no. PV6089) and LanthaScreen Eu-streptavidin (2 nM, no. PV5899), truncated mTOR (amino acids 1360–2549, no. PR8683B) fused to the C-terminus of GST was detected with a LanthaScreen Eu-labeled anti-GST antibody (2 nM, no. PV5594). The p110α assay buffer was composed of 50 mM HEPES, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, and 0.01% (v/v) Brij-35, and the mTOR assay buffer contained 50 mM HEPES, 5 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.01% Pluronic F-127. Further details and calculations are described in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Cell Cycle Analysis</h3><div class="NLM_p last">A2058 cells ((1–2) × 10<sup>5</sup> cells/mL) or SKOV3 cells ((0.25–0.5) × 10<sup>5</sup> cells/mL) were seeded in DMEM supplemented with 10% heat-inactivated FCS, 1% <span class="smallcaps smallerCapital">l</span>-glutamine, and 1% penicillin–streptomycin (2 mL/well of six-well plates). The day after, inhibitors (5 μM for A2058, 2 μM for SKOV3) were added for 24 h. Subsequently nonadherent cells were collected by centrifugation, adherent cells were detached, fixed, and permeabilized (combined with the previously nonadherent cell) in PBS supplemented with 4% paraformaldehyde/1% bovine serum albumin/0.1% TritonX-100 for 30 min at 4 °C and then washed with 1% bovine serum albumin/0.1% TritonX-100 in PBS followed by DNA-staining with 50 μg/mL propidium iodide in 0.1% TritonX-100/0.1% sodium citrate solution (pH 7.4) containing 10 μg/mL DNase-free RNase (>1 h, rt, in the dark). Cell cycle profiles were acquired by fluorescence activated cell sorting (FACSCanto II, Becton Dickinson) and analyzed with FlowJo (Treestar) software.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Western Blotting</h3><div class="NLM_p last">Cells were lysed in NP40-based lysis buffer (20 mM Tris-HCl, pH 8, 138 mM NaCl, 2.7 mM KCl, 5% glycerol, 1% NP-40) supplemented with protease and phosphatase inhibitors, cleared by centrifugation, and denatured by adding 5× sample buffer and boiling at 96 °C for 6 min. Equal amount of proteins were subjected to SDS–PAGE and transferred to Immobilon FL membranes (Millipore). Primary antibodies to pSer473-PKB/Akt (no. 4058L), pThr308-PKB/Akt (no. 4056L), PKB/AKT (no. 2929S), pT389-S6K1 (no. 9206S), pS235/236 ribosomal protein S6 (no. 4856S), S6K1 (no. 9202S), and ribosomal protein S6 (no. 2317S) were from Cell Signaling Technology, and primary antibody to α-tubulin (no. T9026) was from Sigma. HRP-conjugated secondary antibodies were visualized using enhanced chemiluminescence (Millipore) on a Fusion FX (Vilber Lourmat) imaging system. Levels of phosphorylated proteins were quantified using ImageJ and normalized to their respective nonphosphorylated proteins.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Kinome Profiling</h3><div class="NLM_p last">The inhibitory capacity and selectivity of compound were determined using the ScanMax platform provided by DiscoverX.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In short, binding of immobilized ligand to DNA-tagged kinases was competed with 10 μM compound. The amount of kinase bound to the immobilized ligand was measured by quantitative PCR of the respective DNA tags and is given as percentage of control. Binding constants of compounds for kinases of interest were determined by competing the immobilized ligand kinase interactions with an 11-point 3-fold serial dilution of compound starting from 30 μM and subsequent quantitative PCR of DNA tags. Binding constants were calculated by a standard dose–response curve using the Hill equation: response = background + (signal – background)/(1 + 10<sup>[log <i>K</i><sub>d</sub>–log dose](Hill slope)</sup>), with Hill slope set to −1.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Cell Proliferation Assay Panels</h3><div id="sec4_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> NCI60</h4><div class="NLM_p">Detailed procedures on compound and cell handling are available from <a href="https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm" class="extLink">https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm</a>. Briefly, human tumor cell lines were seeded into 96-well microtiter plates and exposed to five (<sup>1</sup>/<sub>2</sub> log serial) drug dilutions plus control, followed by 48 h (except for two controls of each cell line which were fixed with TCA (cell population at <i>t</i> = 0 h [Tz]). The assay was terminated by fixation with TCA (10% final). Cell density was determined using a sulforhodamine B staining protocol and the absorbance measured at 515 nm. Using seven absorbance measurements [Tz; control growth (<i>C</i>); growth with drugs added (Ti)], the percentage growth was calculated at each of the drug concentrations levels. Percentage growth inhibition is calculated as<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/jm-2017-00930r_m001.gif" alt="" /></img></span>for concentrations for which Ti ≥ Tz, and<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/jm-2017-00930r_m002.gif" alt="" /></img></span>for concentrations for which Ti < Tz.</div><div class="NLM_p">The NTRC Oncolines 44 cell lines were exposed for 72 h to 9-point 3-fold serial dilutions of <b>1</b> as described in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a>. The concentration of 50% growth inhibition is associated with the signal ((luminescence<sub>untreated,<i>t</i>=72h</sub> – luminescence<sub><i>t</i>=0</sub>)/2) + luminescence<sub><i>t</i>=0</sub>. The data set integrated here was used for IC<sub>50</sub> calculations in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a>.</div><div class="NLM_p last">IC<sub>50</sub> values of A2058 or SKOV3 cell proliferation given in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were determined and calculated as described in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a> for the indicated compounds.</div></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> PC3 Xenograft Model in Nude Rats</h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Compound Preparation and Dosing</h4><div class="NLM_p last">Compound <b>1</b> was dissolved in DMSO to 40 mg/mL. This solution was diluted with 20% HPBCD [(2-hydroxypropyl)-β-cyclodextrin] in water for injection (Lavoisier, batch no. 2F274 5) in order to reach a final concentration of <b>1</b> of 4 mg/mL. Successive dilutions in vehicle (DMSO/20% HPBCD solution, 10/90, v/v) were performed to reach 1, 2, and 3 mg/mL final concentrations. Vinorelbine was diluted in 0.9% NaCl solution to 0.5 mg/mL. Treatment doses for <b>1</b> were 5, 10, and 15 mg/kg, and it was 2.5 mg/kg for vinorelbine. Rats were given compound <b>1</b> by oral gavage (po) and given vinorelbine intravenously (iv, as bolus) into the tail vain. The po administration volume and the iv injection volume were 5 mL/kg.</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Animals and Animal Handling</h4><div class="NLM_p last">Healthy male nude NIH rats (Crl:NIH-Foxn1 rnu, Charles River, Germany) bread in a specific pathogen-free (SPF) animal care unit were fed sterile, irradiated food granules (V1246-703, Soest, Germany). Animal procedures were reviewed by the Animal Care and Use Committee of Pharmacy and Medicine University of Dijon or Oncodesign’s ethical committee.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Cell Culture</h4><div class="NLM_p last">PC-3 prostatic adenocarcinoma tumor cells (ATCC, CRL-1435) were grown as monolayer in complete RPMI1640 medium, supplemented with 10% FBS (37 °C, 5% CO<sub>2</sub>). Tumor cells were detached with trypsin-Versene (Lonza; 5 min in in Hanks’ medium without Ca<sup>2+</sup> or Mg<sup>2+</sup>) and then resuspended in complete RPMI1640.</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Tumor Model</h4><div class="NLM_p last">2 ×10<sup>7</sup> PC-3 cells were injected subcutaneously at day 0 (D0) in 200 μL of RPMI1640 into the right flank of male nude rats, 24 h after a whole-body irradiation with a γ-source (5 Gy, <sup>60</sup>Co). Tumor-bearing rats were randomized on day 16 (mean volume of 330 ± 70 mm<sup>3</sup> according to their individual tumor volume into five groups of each eight animals using Vivo manager software (Bio-systemes, Couternon, France). Analysis of variance was performed to test for homogeneity between groups.</div></div><div id="sec4_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Treatment Schedule</h4><div class="NLM_p">Daily administration on D17–D44 and from D51 to D57: group 1, vehicle; group 2, compound <b>1</b> at 5 mg/kg; group 3, <b>1</b> at 10 mg/kg. Group 4: <b>1</b> at 15 mg/kg from D17 to D21, from D24 to D28, from D34 to D38, from D41 to D4, and from D51 to D56. Group 5: one iv injection of vinorelbine at 2.5 mg/kg on D17, D24, D31, and D38. Final termination of rats was performed on D87.</div><div class="NLM_p last">Body weight was measured at least twice a week. Length and width of tumors were measured and recorded twice a week with calipers, and the tumor volume was estimated by the formula<span class="NLM_disp-formula" id="ueq3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/jm-2017-00930r_m003.gif" alt="" /></img></span></div></div><div id="sec4_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Glucose and Insulin Levels Determination</h4><div class="NLM_p last">Glucose was measured using kit CBA086 from Calbiochem and insulin was determined using kit EZRMI-13K from EMD Millipore, according to the manufacturers’ instructions.</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> PK/PD Studies in Nude Rat PC3 Xenograft Model</h3><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Pharmacokinetic Study of Compound <b>1</b> in PC-3 Tumor Bearing Rats</h4><div class="NLM_p last">Induction of PC-3 subcutaneous tumors is described above. Animals were randomized on D21 when the tumors reached 575 ± 267 mm<sup>3</sup> (D20). Twenty-seven animals were randomized according to their individual tumor volume into 3 groups (one group of 3 rats and two groups of 12 rats) using Vivo manager software (Biosystemes, Couternon, France).</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Treatment Q1D × 1. Group 1</h4><div class="NLM_p last">Three rats single iv injection of vehicle. Group 2: 12 and 3 satellite rats single iv injection of <b>1</b> (10.3 mg/kg). Group 3: 12 and 3 satellite rats single po administration of compound <b>1</b> (16.55 mg/kg). On selected time points blood, brain, liver, and tumor from 3 rats from each group were collected to determine levels of <b>1</b>, glucose, and insulin or pPKB/Akt was analyzed in tissues.</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Solubility Assays</h3><div class="NLM_p last">Stock solutions of compounds were prepared in DMSO at 20 mM. From these, 200 μM solutions were made up by a direct dilution of the stock solution with a phosphate buffer (PBS, pH 7.4) or citrate buffer (pH 4.0). Reference solutions were made up in 100% MeOH. Solutions in buffer (200 μL) were incubated and agitated at room temperature for 1 h and then centrifuged at 13 000 rpm for 10 min. A volume of 100 μL of the supernatants was diluted with 100 μL of MeOH/PBS/citrate 8:1:1 and analyzed by LC/MS.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Structure Modeling of Compound <b>1</b>/mTOR Kinase Complexes</h3><div class="NLM_p last">The coordinates of mTOR kinase <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a> (3.6 Å) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a> (3.2 Å) were used as starting points to dock <b>1</b> into the ATP-binding site of mTOR kinase. Docking of the ligand <b>1</b> to mTOR was performed using SwissDock (<a href="http://swissdock.ch/" class="extLink">swissdock.ch</a>), and energy minimization was performed using YASARA’s default settings. Alternatively, the PI103 ligand in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a> was manually replaced by <b>1</b> docking one of its morpholino groups to Val2240 before energy minimizations were performed. The docking procedures were validated by redocking <b>1</b> into the apoprotein of the <b>1</b>/PI3Kγ complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-4"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00930">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65134" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65134" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00930" class="ext-link">10.1021/acs.jmedchem.7b00930</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">X-ray crystallography parameters and refinement values for <b>1</b> (Table S1); a TREEspot representation (Figure S1) and its raw data (Table S2); the antiproliferative action of compound <b>1</b> in four cell line panels (Table S3); extended Tables S4 and S5 with in vitro pharmacology data; the safety profile of <b>1</b> (Table S6); comparative solubility of <b>1</b> (Table S7); efficacy of compound <b>1</b> intermittent dosing in tumor bearing rats (Figure S2); <sup>1</sup>H NMR spectra; <sup>19</sup>F{<sup>1</sup>H} NMR spectra; <sup>13</sup>C{<sup>1</sup>} NMR spectra; ESI-HRMS spectra; MALDI-MS spectra; HPLC chromatograms; and appendix of chemical formula of compounds synthesized here (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_001.csv">jm7b00930_si_001.csv (1.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf">jm7b00930_si_002.pdf (8.59 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of compound <b>1</b> in PI3Kγ have been deposited with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a> at <a href="http://wwpdb.org" class="extLink">wwpdb.org</a> and <a href="http://rcsb.org" class="extLink">rcsb.org</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00930" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30087" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30087" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denise Rageot</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2b6f4e4542584e05794a4c4e445f6b5e4542494a58054843"><span class="__cf_email__" data-cfemail="0145646f6872642f536066646e7541746f686360722f6269">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias P. Wymann</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3349-4281" title="Orcid link">http://orcid.org/0000-0003-3349-4281</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bbf6dacfcfd3d2dac895ecc2d6dad5d5fbeed5d2f9dac895f8f3"><span class="__cf_email__" data-cfemail="5c113d282834353d2f720b25313d32321c0932351e3d2f721f14">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florent Beaufils</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natasa Cmiljanovic</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vladimir Cmiljanovic</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Bohnacker</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Melone</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Romina Marone</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eileen Jackson</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuxiao Zhang</span> - <span class="hlFld-Affiliation affiliation">MRC
Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Sele</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiara Borsari</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4688-8362" title="Orcid link">http://orcid.org/0000-0002-4688-8362</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jürgen Mestan</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60C, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Hebeisen</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60C, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Petra Hillmann</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60C, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernd Giese</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Basel, St. Johanns-Ring 19, 4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marketa Zvelebil</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doriano Fabbro</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60C, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roger L. Williams</span> - <span class="hlFld-Affiliation affiliation">MRC
Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>F.B., N.C., and V.C. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): F.B., N.C., V.C., J.M., P.He., P.Hi., and D.F. are current or past employees of PIQUR Therapeutics AG, Basel; and N.C., V.C., J.M., P.He., P.Hi., D.F., B.G., and M.P.W. are shareholders of PIQUR Therapeutics AG.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4845-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80371" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80371" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank A. Pfaltz, R.A. Ettlin, W. Dieterle, J.-B. Langlois, S. Mukherjee, and M. Lang for advice and discussions; S. Bünger and A. Dall Asen for technical assistance; Master students of the Department of Chemistry for early synthetic efforts; M. Neuburger and D. Häussinger for chemical structure determination. We are grateful to G. Zaman and the NTRC team for help and expertise with high content screening assays. This work was supported by the Swiss Commission for Technology and Innovation (CTI) by PFLS-LS Grants 14032.1, 15811.2, and 17241.1; the Stiftung für Krebsbekämpfung Grant 341; Swiss National Science Foundation Grants 310030_153211 and 316030_133860 (to M.P.W.) and Grant 310030B_138659 and in part by European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement 675392 and by the MRC to R.L.W. (Grant MC_U105184308).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i68" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i68"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i69" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i69"> Abbreviations Used</h2><tr><td class="NLM_term">DNA-PK</td><td class="NLM_def"><p class="first last">DNA-dependent protein kinase</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PKB/Akt</td><td class="NLM_def"><p class="first last">protein kinase B/Akt</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">PtdIns(4,5)<i>P</i><sub>2</sub></td><td class="NLM_def"><p class="first last">phosphatidylinositol (4,5)-bisphosphate</p></td></tr><tr><td class="NLM_term">PtdIns(3,4,5)<i>P</i><sub>3</sub></td><td class="NLM_def"><p class="first last">phosphatidylinositol (3,4,5)-trisphosphate</p></td></tr><tr><td class="NLM_term">S6</td><td class="NLM_def"><p class="first last">ribosomal protein S6</p></td></tr><tr><td class="NLM_term">S6K</td><td class="NLM_def"><p class="first last">S6 kinase</p></td></tr><tr><td class="NLM_term">SH2</td><td class="NLM_def"><p class="first last">src-homology 2</p></td></tr><tr><td class="NLM_term">TORC1</td><td class="NLM_def"><p class="first last">mTOR complex 1</p></td></tr><tr><td class="NLM_term">VPS34</td><td class="NLM_def"><p class="first last">vacuolar protein sorting 34, the class III PI3K</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneiter, R.</span><span> </span><span class="NLM_article-title">Lipid signalling in disease</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span><span class="refDoi"> DOI: 10.1038/nrm2335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrm2335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=18216772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=162-176&author=M.+P.+Wymannauthor=R.+Schneiter&title=Lipid+signalling+in+disease&doi=10.1038%2Fnrm2335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid signalling in disease</span></div><div class="casAuthors">Wymann, Matthias P.; Schneiter, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-176</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling lipids such as eicosanoids, phosphoinositides, sphingolipids and fatty acids control important cellular processes, including cell proliferation, apoptosis, metab. and migration.  Extracellular signals from cytokines, growth factors and nutrients control the activity of a key set of lipid-modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase.  These enzymes and their downstream targets constitute a complex lipid signaling network with multiple nodes of interaction and cross-regulation.  Imbalances in this network contribute to the pathogenesis of human disease.  Although the function of a particular signaling lipid is traditionally studied in isolation, this review attempts a more integrated overview of the key role of these signaling lipids in inflammation, cancer and metabolic disease, and discusses emerging strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYZ1NX2T9QbVg90H21EOLACvtfcHk0liaDNPYGj-6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D&md5=c96aabfdfa8e93c9e98386f1a407de85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2335%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DSchneiter%26aufirst%3DR.%26atitle%3DLipid%2520signalling%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D162%26epage%3D176%26doi%3D10.1038%2Fnrm2335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Thorpe, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuzugullu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1038/nrc3860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc3860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=25533673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=7-24&author=L.+M.+Thorpeauthor=H.+Yuzugulluauthor=J.+J.+Zhao&title=PI3K+in+cancer%3A+divergent+roles+of+isoforms%2C+modes+of+activation+and+therapeutic+targeting&doi=10.1038%2Fnrc3860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting</span></div><div class="casAuthors">Thorpe, Lauren M.; Yuzugullu, Haluk; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-24</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli.  Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers.  In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxh6fOPe86x7Vg90H21EOLACvtfcHk0liaDNPYGj-6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N&md5=0b609a62c2ec9fcc6efae437d2ed7a24</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc3860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3860%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DL.%2BM.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DPI3K%2520in%2520cancer%253A%2520divergent%2520roles%2520of%2520isoforms%252C%2520modes%2520of%2520activation%2520and%2520therapeutic%2520targeting%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D7%26epage%3D24%26doi%3D10.1038%2Fnrc3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Targeting PI3K signalling in cancer: opportunities, challenges and limitations</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nrc2664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc2664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19629070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFylsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=550-562&author=J.+A.+Engelman&title=Targeting+PI3K+signalling+in+cancer%3A+opportunities%2C+challenges+and+limitations&doi=10.1038%2Fnrc2664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K signalling in cancer: opportunities, challenges and limitations</span></div><div class="casAuthors">Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">550-562</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There are ample genetic and lab. studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells.  Inhibitors targeting this pathway are entering the clinic at a rapid pace.  In this Review, the therapeutic potential of drugs targeting PI3K-Akt signaling for the treatment of cancer is discussed.  I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCwdUnGEC20LVg90H21EOLACvtfcHk0liaDNPYGj-6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFylsrg%253D&md5=f0d4cc1fabf879e95f8b76e48cc9c1ad</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2664%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520PI3K%2520signalling%2520in%2520cancer%253A%2520opportunities%252C%2520challenges%2520and%2520limitations%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D550%26epage%3D562%26doi%3D10.1038%2Fnrc2664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Wymann, M.</span><span> </span><span class="NLM_article-title">PI3Ks-Drug targets in inflammation and cancer</span> <span class="citation_source-journal">Subcell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1007/978-94-007-3012-0_5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1007%2F978-94-007-3012-0_5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=22403076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCqsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=111-181&author=M.+Wymann&title=PI3Ks-Drug+targets+in+inflammation+and+cancer&doi=10.1007%2F978-94-007-3012-0_5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Ks - drug targets in inflammation and cancer</span></div><div class="casAuthors">Wymann, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Subcellular Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">Phosphoinositides I: Enzymes of Synthesis and Degradation</span>),
    <span class="NLM_cas:pages">111-181</span>CODEN:
                <span class="NLM_cas:coden">SBCBAG</span>;
        ISSN:<span class="NLM_cas:issn">0306-0225</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3Ks) control cell growth, proliferation, cell survival, metabolic activity, vesicular trafficking, degranulation, and migration.  Through these processes, PI3Ks modulate vital physiol.  When over-activated in disease, PI3K promotes tumor growth, angiogenesis, metastasis or excessive immune cell activation in inflammation, allergy and autoimmunity.  This chapter will introduce mol. activation and signaling of PI3Ks, and connections to target of rapamycin (TOR) and PI3K-related protein kinases (PIKKs).  The focus will be on class I PI3Ks, and extend into current developments to exploit mechanistic knowledge for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyaS7PZJpOk7Vg90H21EOLACvtfcHk0liaDNPYGj-6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCqsLzM&md5=9145cabbb88503a95ad462617cf708ab</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2F978-94-007-3012-0_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-94-007-3012-0_5%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%26atitle%3DPI3Ks-Drug%2520targets%2520in%2520inflammation%2520and%2520cancer%26jtitle%3DSubcell.%2520Biochem.%26date%3D2012%26volume%3D58%26spage%3D111%26epage%3D181%26doi%3D10.1007%2F978-94-007-3012-0_5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puglisi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span> </span><span class="NLM_article-title">Treatment of HER2-positive breast cancer: current status and future perspectives</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2011.177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrclinonc.2011.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1CqtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=16-32&author=C.+L.+Arteagaauthor=M.+X.+Sliwkowskiauthor=C.+K.+Osborneauthor=E.+A.+Perezauthor=F.+Puglisiauthor=L.+Gianni&title=Treatment+of+HER2-positive+breast+cancer%3A+current+status+and+future+perspectives&doi=10.1038%2Fnrclinonc.2011.177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of HER2-positive breast cancer: current status and future perspectives</span></div><div class="casAuthors">Arteaga, Carlos L.; Sliwkowski, Mark X.; Osborne, C. Kent; Perez, Edith A.; Puglisi, Fabio; Gianni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-32</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the advent of HER2-directed therapies, many patients with HER2-pos. early stage breast cancer relapse and die of this disease.  Trials to define, refine and optimize the use of the approved HER2-targeted agents are ongoing.  New approaches are being developed and a series of large trials in the adjuvant and neoadjuvant settings are planned or in progress.  In this Review, Arteaga et al. describe the current treatment for HER2-pos. breast cancer and provide an update on ongoing clin. trials and translational research.  The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-pos. early stage breast cancer.  However, a significant proportion of these patients still relapse and die of breast cancer.  Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-pos. early stage breast cancer are ongoing.  In addn., promising new approaches are being developed including monoclonal antibodies and small-mol. tyrosine kinase inhibitors targeting HER2 or other HER family members, antibodies linked to cytotoxic moieties or modified to improve their immunol. function, immunostimulatory peptides, and targeting the PI3K and IGF-1R pathways.  Improved understanding of the HER2 signaling pathway, its relationship with other signaling pathways and mechanisms of resistance has also led to the development of rational combination therapies and to a greater insight into treatment response in patients with HER2-pos. breast cancer.  Based on promising results with new agents in HER2-pos. advanced-stage disease, a series of large trials in the adjuvant and neoadjuvant settings are planned or ongoing.  This Review focuses on current treatment for patients with HER2-pos. breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clin. trials and translational research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxxTh8iuH1BLVg90H21EOLACvtfcHk0lhRyH-yjnFg9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1CqtbbI&md5=5d0f876567faecaf49327eb3f1b4b7f1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.177%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DPuglisi%26aufirst%3DF.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DTreatment%2520of%2520HER2-positive%2520breast%2520cancer%253A%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D16%26epage%3D32%26doi%3D10.1038%2Fnrclinonc.2011.177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Sun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aceto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meerbrey, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, D. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlova, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardi, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dephoure, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilsenbeck, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzny, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentires-Alj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elledge, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, T. F.</span><span> </span><span class="NLM_article-title">Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">703</span><span class="NLM_x">–</span> <span class="NLM_lpage">718</span><span class="refDoi"> DOI: 10.1016/j.cell.2011.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.cell.2011.02.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=703-718&author=T.+Sunauthor=N.+Acetoauthor=K.+L.+Meerbreyauthor=J.+D.+Kesslerauthor=C.+Zhouauthor=I.+Migliaccioauthor=D.+X.+Nguyenauthor=N.+N.+Pavlovaauthor=M.+Boteroauthor=J.+Huangauthor=R.+J.+Bernardiauthor=E.+Schmittauthor=G.+Huauthor=M.+Z.+Liauthor=N.+Dephoureauthor=S.+P.+Gygiauthor=M.+Raoauthor=C.+J.+Creightonauthor=S.+G.+Hilsenbeckauthor=C.+A.+Shawauthor=D.+Muznyauthor=R.+A.+Gibbsauthor=D.+A.+Wheelerauthor=C.+K.+Osborneauthor=R.+Schiffauthor=M.+Bentires-Aljauthor=S.+J.+Elledgeauthor=T.+F.+Westbrook&title=Activation+of+multiple+proto-oncogenic+tyrosine+kinases+in+breast+cancer+via+loss+of+the+PTPN12+phosphatase&doi=10.1016%2Fj.cell.2011.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DT.%26aulast%3DAceto%26aufirst%3DN.%26aulast%3DMeerbrey%26aufirst%3DK.%2BL.%26aulast%3DKessler%26aufirst%3DJ.%2BD.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DMigliaccio%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DD.%2BX.%26aulast%3DPavlova%26aufirst%3DN.%2BN.%26aulast%3DBotero%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DBernardi%26aufirst%3DR.%2BJ.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DM.%2BZ.%26aulast%3DDephoure%26aufirst%3DN.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DShaw%26aufirst%3DC.%2BA.%26aulast%3DMuzny%26aufirst%3DD.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DWheeler%26aufirst%3DD.%2BA.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DBentires-Alj%26aufirst%3DM.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26atitle%3DActivation%2520of%2520multiple%2520proto-oncogenic%2520tyrosine%2520kinases%2520in%2520breast%2520cancer%2520via%2520loss%2520of%2520the%2520PTPN12%2520phosphatase%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D703%26epage%3D718%26doi%3D10.1016%2Fj.cell.2011.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Samuels, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ericson, K.</span><span> </span><span class="NLM_article-title">Oncogenic PI3K and its role in cancer</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1097/01.cco.0000198021.99347.b9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1097%2F01.cco.0000198021.99347.b9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16357568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlahu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2006&pages=77-82&author=Y.+Samuelsauthor=K.+Ericson&title=Oncogenic+PI3K+and+its+role+in+cancer&doi=10.1097%2F01.cco.0000198021.99347.b9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic PI3K and its role in cancer</span></div><div class="casAuthors">Samuels, Yardena; Ericson, Kajsa</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-82</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The purpose of this review is to examine the contribution of the PI3K signaling pathway to the development of human tumors and to propose further studies to elucidate how to develop therapeutics for patients with mutations in this pathway.  Recent findings: More than 30% of various solid tumor types were recently found to contain mutations in PIK3CA, the catalytic subunit of PI3K.  Further anal. of key genes in this pathway identified an addnl. eight genes altered in tumors.  These were generally found to be mutated in a mutually exclusive manner, thus increasing the mutation frequency of the pathway to 40% in colorectal cancers and emphasizing the importance of the PI3K pathway in tumorigenesis.  Functional analyses of PIK3CA mutations revealed that they increase its enzymic activity, stimulate AKT signaling, allow growth factor-independent growth as well as increasing cell invasion and metastasis.  Summary: The PI3K signaling pathway is dysregulated by a variety of mechanisms in a large fraction of human tumors.  Both mutational and functional analyses have shown that PIK3CA is an oncogene that plays an important role in tumor progression.  Mutant members of the PI3K pathway, including PIK3CA, are good targets for therapeutic intervention because most of them are kinases, making them attractive for drug development.  Gaining further insights into PIK3CA oncogenic mechanisms may produce new biomarkers and help the development of targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5GUGZgvUSVrVg90H21EOLACvtfcHk0lhRyH-yjnFg9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlahu73P&md5=6a4504dd3201451956dc862b105e610e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2F01.cco.0000198021.99347.b9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cco.0000198021.99347.b9%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DEricson%26aufirst%3DK.%26atitle%3DOncogenic%2520PI3K%2520and%2520its%2520role%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2006%26volume%3D18%26spage%3D77%26epage%3D82%26doi%3D10.1097%2F01.cco.0000198021.99347.b9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hollander, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, P. A.</span><span> </span><span class="NLM_article-title">PTEN loss in the continuum of common cancers, rare syndromes and mouse models</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1038/nrc3037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc3037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=21430697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1CqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=289-301&author=M.+C.+Hollanderauthor=G.+M.+Blumenthalauthor=P.+A.+Dennis&title=PTEN+loss+in+the+continuum+of+common+cancers%2C+rare+syndromes+and+mouse+models&doi=10.1038%2Fnrc3037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN loss in the continuum of common cancers, rare syndromes and mouse models</span></div><div class="casAuthors">Hollander, M. Christine; Blumenthal, Gideon M.; Dennis, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-301</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PTEN is among the most frequently inactivated tumor suppressor genes in sporadic cancer.  PTEN has dual protein and lipid phosphatase activity, and its tumor suppressor activity is dependent on its lipid phosphatase activity, which neg. regulates the PI3K-AKT-mTOR pathway.  Germline mutations in PTEN have been described in a variety of rare syndromes that are collectively known as the PTEN hamartoma tumor syndromes (PHTS).  Cowden syndrome is the best-described syndrome within PHTS, with approx. 80% of patients having germline PTEN mutations.  Patients with Cowden syndrome have an increased incidence of cancers of the breast, thyroid and endometrium, which correspond to sporadic tumor types that commonly exhibit somatic PTEN inactivation.  Pten deletion in mice leads to Cowden syndrome-like phenotypes, and tissue-specific Pten deletion has provided clues to the role of PTEN mutation and loss in specific tumor types.  Studying PTEN in the continuum of rare syndromes, common cancers and mouse models provides insight into the role of PTEN in tumorigenesis and will inform targeted drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn2C-Gc5BQ_bVg90H21EOLACvtfcHk0ljieIlTIa3Q1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1CqsLc%253D&md5=328ccdcbc50d15d2772ae8fb0d6580a4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc3037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3037%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DM.%2BC.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DDennis%26aufirst%3DP.%2BA.%26atitle%3DPTEN%2520loss%2520in%2520the%2520continuum%2520of%2520common%2520cancers%252C%2520rare%2520syndromes%2520and%2520mouse%2520models%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D289%26epage%3D301%26doi%3D10.1038%2Fnrc3037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gewinner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teruya-Feldstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etemadmoghadam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowtell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rameh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmena, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1016/j.ccr.2009.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.ccr.2009.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19647222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCjsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=115-125&author=C.+Gewinnerauthor=Z.+C.+Wangauthor=A.+Richardsonauthor=J.+Teruya-Feldsteinauthor=D.+Etemadmoghadamauthor=D.+Bowtellauthor=J.+Barretinaauthor=W.+M.+Linauthor=L.+Ramehauthor=L.+Salmenaauthor=P.+P.+Pandolfiauthor=L.+C.+Cantley&title=Evidence+that+inositol+polyphosphate+4-phosphatase+type+II+is+a+tumor+suppressor+that+inhibits+PI3K+signaling&doi=10.1016%2Fj.ccr.2009.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</span></div><div class="casAuthors">Gewinner, Christina; Wang, Zhigang C.; Richardson, Andrea; Teruya-Feldstein, Julie; Etemadmoghadam, Dariush; Bowtell, David; Barretina, Jordi; Lin, William M.; Rameh, Lucia; Salmena, Leonardo; Pandolfi, Pier Paolo; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that knocking down the expression of inositol polyphosphate 4-phosphatase type II (INPP4B) in human epithelial cells, like knockdown of PTEN, resulted in enhanced Akt activation and anchorage-independent growth and enhanced overall motility.  In xenograft expts., overexpression of INPP4B resulted in reduced tumor growth.  INPP4B preferentially hydrolyzes phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) with no effect on phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3), suggesting that PI(3,4)P2 and PI(3,4,5)P3 may cooperate in Akt activation and cell transformation.  Dual knockdown of INPP4B and PTEN resulted in cellular senescence.  Finally, we found loss of heterozygosity (LOH) at the INPP4B locus in a majority of basal-like breast cancers, as well as in a significant fraction of ovarian cancers, which correlated with lower overall patient survival, suggesting that INPP4B is a tumor suppressor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOv8VFGY_XorVg90H21EOLACvtfcHk0ljieIlTIa3Q1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCjsrfL&md5=c7c4d81e03f1f8b515a7a6cb3c6864f9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DGewinner%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%2BC.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DEtemadmoghadam%26aufirst%3DD.%26aulast%3DBowtell%26aufirst%3DD.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DW.%2BM.%26aulast%3DRameh%26aufirst%3DL.%26aulast%3DSalmena%26aufirst%3DL.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DEvidence%2520that%2520inositol%2520polyphosphate%25204-phosphatase%2520type%2520II%2520is%2520a%2520tumor%2520suppressor%2520that%2520inhibits%2520PI3K%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D115%26epage%3D125%26doi%3D10.1016%2Fj.ccr.2009.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span><span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0ljieIlTIa3Q1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">Inhibition of the PI3K/AKT/mTOR pathway in solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3803</span><span class="NLM_x">–</span> <span class="NLM_lpage">3815</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.0018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1200%2FJCO.2014.59.0018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=3803-3815&author=P.+M.+LoRusso&title=Inhibition+of+the+PI3K%2FAKT%2FmTOR+pathway+in+solid+tumors&doi=10.1200%2FJCO.2014.59.0018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.0018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.0018%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DInhibition%2520of%2520the%2520PI3K%252FAKT%252FmTOR%2520pathway%2520in%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D3803%26epage%3D3815%26doi%3D10.1200%2FJCO.2014.59.0018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Bohnacker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaufils, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglis, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rageot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sele, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhmanova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">14683</span><span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+D%C3%ADazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eZB-pJRXSaj27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yaguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koshimizu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span> </span><span class="NLM_article-title">Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span><span class="refDoi"> DOI: 10.1093/jnci/djj133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1093%2Fjnci%2Fdjj133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16622124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XjslOjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=545-556&author=S.+Yaguchiauthor=Y.+Fukuiauthor=I.+Koshimizuauthor=H.+Yoshimiauthor=T.+Matsunoauthor=H.+Goudaauthor=S.+Hironoauthor=K.+Yamazakiauthor=T.+Yamori&title=Antitumor+activity+of+ZSTK474%2C+a+new+phosphatidylinositol+3-kinase+inhibitor&doi=10.1093%2Fjnci%2Fdjj133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor</span></div><div class="casAuthors">Yaguchi, Shin-ichi; Fukui, Yasuhisa; Koshimizu, Ichiro; Yoshimi, Hisashi; Matsuno, Toshiyuki; Gouda, Hiroaki; Hirono, Shuichi; Yamazaki, Kanami; Yamori, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: We previously synthesized a novel s-triazine deriv., ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], that strongly inhibited the growth of tumor cells.  We identified its mol. target, investigated its effects on cellular signaling pathways, and examd. its antitumor efficacy and toxicity in vivo.  Methods: We used COMPARE anal. of chemosensitivity measurements from 39 human cancer cell lines and identified phosphatidylinositol 3-kinase (PI3K) as a mol. target for ZSTK474.  PI3K was immunopptd. from A549 cell lysates, and its activity was measured by assessing the incorporation of 32P into phosphatidylinositol.  We used the crystal structure of the PI3K-LY294002 complex to model the binding of ZSTK474 to PI3K (where LY294002 is a known PI3K inhibitor).  PI3K downstream activity was analyzed by immunoblotting.  Antitumor activity of ZSTK474 was examd. against A549, PC-3, and WiDr xenografts in nude mice.  Phosphorylation of Akt, a serine/threonine protein kinase and a major signaling component downstream of PI3K, was assessed in vivo by immunohistochem.  Results: PI3K was identified as a mol. target for ZSTK474 by COMPARE anal.  We confirmed that ZSTK474 directly inhibited PI3K activity more efficiently than the PI3K inhibitor LY294002.  At concns. of 1 μM, ZSTK474 and LY2194002 reduced PI3K activity to 4.7% (95% confidence interval [CI] = 3.2% to 6.1%) and 44.6% (95% CI = 38.9% to 50.3%), resp., of the untreated control level.  Mol. modeling of the PI3K-ZSTK474 complex indicated that ZSTK474 could bind to the ATP-binding pocket of PI3K.  ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3β, and mediated a decrease in cyclin D1 levels.  ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in crit. organs.  Akt phosphorylation was reduced in xenograft tumors after oral administration of ZSTK474.  Conclusion: ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in crit. organs.  ZSTK474 merits further investigation as an anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0v8LFKdruLVg90H21EOLACvtfcHk0lgXioSfp_aEFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjslOjsLw%253D&md5=a2593024975536089ab2ee7e53234ebc</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjj133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjj133%26sid%3Dliteratum%253Aachs%26aulast%3DYaguchi%26aufirst%3DS.%26aulast%3DFukui%26aufirst%3DY.%26aulast%3DKoshimizu%26aufirst%3DI.%26aulast%3DYoshimi%26aufirst%3DH.%26aulast%3DMatsuno%26aufirst%3DT.%26aulast%3DGouda%26aufirst%3DH.%26aulast%3DHirono%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DYamori%26aufirst%3DT.%26atitle%3DAntitumor%2520activity%2520of%2520ZSTK474%252C%2520a%2520new%2520phosphatidylinositol%25203-kinase%2520inhibitor%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2006%26volume%3D98%26spage%3D545%26epage%3D556%26doi%3D10.1093%2Fjnci%2Fdjj133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamage, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baguley, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kestell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lill, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, P. R.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7105</span><span class="NLM_x">–</span> <span class="NLM_lpage">7126</span><span class="refDoi"> DOI: 10.1021/jm200688y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200688y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7105-7126&author=G.+W.+Rewcastleauthor=S.+A.+Gamageauthor=J.+U.+Flanaganauthor=R.+Frederickauthor=W.+A.+Dennyauthor=B.+C.+Baguleyauthor=P.+Kestellauthor=R.+Singhauthor=J.+D.+Kendallauthor=E.+S.+Marshallauthor=C.+L.+Lillauthor=W.+J.+Leeauthor=S.+Kolekarauthor=C.+M.+Buchananauthor=S.+M.+Jamiesonauthor=P.+R.+Shepherd&title=Synthesis+and+biological+evaluation+of+novel+analogues+of+the+pan+class+I+phosphatidylinositol+3-kinase+%28PI3K%29+inhibitor+2-%28difluoromethyl%29-1-%5B4%2C6-di%284-morpholinyl%29-1%2C3%2C5-triazin-2-yl%5D-1H-benzimidazole+%28ZSTK474%29&doi=10.1021%2Fjm200688y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-Kinase (PI3K) inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)</span></div><div class="casAuthors">Rewcastle, Gordon W.; Gamage, Swarna A.; Flanagan, Jack U.; Frederick, Raphael; Denny, William A.; Baguley, Bruce C.; Kestell, Philip; Singh, Ripudaman; Kendall, Jackie D.; Marshall, Elaine S.; Lill, Claire L.; Lee, Woo-Jeong; Kolekar, Sharada; Buchanan, Christina M.; Jamieson, Stephen M. F.; Shepherd, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7105-7126</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-activity relationship (SAR) study of the pan class I PI 3-kinase inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474) I identified substitution at the 4 and 6 positions of the benzimidazole ring as having significant effects on the potency of substituted derivs.  The 6-amino-4-methoxy analog II displayed a greater than 1000-fold potency enhancement over the corresponding 6-aza-4-methoxy III analog against all three class Ia PI 3-kinase enzymes (p110α, p110β, and p110δ) and also displayed significant potency against two mutant forms of the p110α isoform (H1047R and E545K).  This compd. was also evaluated in vivo against a U87MG human glioblastoma tumor xenograft model in Rag1-/- mice, and at a dose of 50 mg/kg given by i.p. injection at a qd × 10 dosing schedule it dramatically reduced cancer growth by 81% compared to untreated controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqirsalawdjHrVg90H21EOLACvtfcHk0ljZ3nWvGgG7Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7rJ&md5=250fb3eeb02505e2a5b24fd511ec94f3</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1021%2Fjm200688y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200688y%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DGamage%26aufirst%3DS.%2BA.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DFrederick%26aufirst%3DR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DKestell%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DMarshall%26aufirst%3DE.%2BS.%26aulast%3DLill%26aufirst%3DC.%2BL.%26aulast%3DLee%26aufirst%3DW.%2BJ.%26aulast%3DKolekar%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DC.%2BM.%26aulast%3DJamieson%26aufirst%3DS.%2BM.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520analogues%2520of%2520the%2520pan%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%2520inhibitor%25202-%2528difluoromethyl%2529-1-%255B4%252C6-di%25284-morpholinyl%2529-1%252C3%252C5-triazin-2-yl%255D-1H-benzimidazole%2520%2528ZSTK474%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7105%26epage%3D7126%26doi%3D10.1021%2Fjm200688y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Brachmann, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleylein-Sohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaulis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blommers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazic-Legueux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laborde, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattenberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaxelaire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guthy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruemmendorf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span> </span><span class="NLM_article-title">Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1747</span><span class="NLM_x">–</span> <span class="NLM_lpage">1757</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-1021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1158%2F1535-7163.MCT-11-1021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=22653967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1747-1757&author=S.+M.+Brachmannauthor=J.+Kleylein-Sohnauthor=S.+Gaulisauthor=A.+Kauffmannauthor=M.+J.+Blommersauthor=M.+Kazic-Legueuxauthor=L.+Labordeauthor=M.+Hattenbergerauthor=F.+Staufferauthor=J.+Vaxelaireauthor=V.+Romanetauthor=C.+Henryauthor=M.+Murakamiauthor=D.+Guthyauthor=D.+Sterkerauthor=S.+Berglingauthor=C.+Wilsonauthor=T.+Bruemmendorfauthor=C.+Fritschauthor=C.+Garcia-Echeverriaauthor=W.+R.+Sellersauthor=F.+Hofmannauthor=S.+M.+Maira&title=Characterization+of+the+mechanism+of+action+of+the+pan+class+I+PI3K+inhibitor+NVP-BKM120+across+a+broad+range+of+concentrations&doi=10.1158%2F1535-7163.MCT-11-1021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations</span></div><div class="casAuthors">Brachmann, Saskia M.; Kleylein-Sohn, Julia; Gaulis, Swann; Kauffmann, Audrey; Blommers, Marcel J. J.; Kazic-Legueux, Malika; Laborde, Laurent; Hattenberger, Marc; Stauffer, Fabian; Vaxelaire, Juliane; Romanet, Vincent; Henry, Chrystele; Murakami, Masato; Guthy, Daniel Alexander; Sterker, Dario; Bergling, Sebastian; Wilson, Christopher; Bruemmendorf, Thomas; Fritsch, Christine; Garcia-Echeverria, Carlos; Sellers, William R.; Hofmann, Francesco; Maira, Sauveur-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1747-1757</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The pan-phosphoinositide 3-kinase (PI3K) inhibitor BKM120 was found, at high concns., to cause cell death in various cellular systems, irresp. of their level of PI3K addiction.  Transcriptional and biochem. profiling studies were used to identify the origin of these unexpected and apparently PI3K-independent effects.  At 5- to 10-fold, the concn. needed to half-maximally inhibit PI3K signaling.  BKM120 treatment caused changes in expression of mitotic genes and the induction of a robust G2-M arrest.  Tubulin polymn. assays and NMR-binding studies revealed that BKM120 inhibited microtubule dynamics upon direct binding to tubulin.  To assess the contribution of this off-target activity vis-a-vis the antitumor activity of BKM120 in PI3K-dependent tumors, we used a mechanistic PI3K-α-dependent model.  We obsd. that, in vivo, daily treatment of mice with doses of BKM120 up to 40 mg/kg led to tumor regressions with no increase in the mitotic index.  Thus, strong antitumor activity can be achieved in PI3K-dependent models at exposures that are below those necessary to engage the off-target activity.  In comparison, the clin. data indicate that it is unlikely that BKM120 will achieve exposures sufficient to significantly engage the off-target activity at tolerated doses and schedules.  However, in preclin. settings, the consequences of the off-target activity start to manifest themselves at concns. above 1 μmol/L in vitro and doses above 50 mg/kg in efficacy studies using s.c. tumor-bearing mice.  Hence, careful concn. and dose range selection is required to ensure that any observation can be correctly attributed to BKM120 inhibition of PI3K.  Mol Cancer Ther; 11(8); 1747-57. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKHhs5m02qfrVg90H21EOLACvtfcHk0ljZ3nWvGgG7Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrM&md5=26f5cd3377b49f9e61a092191d86194b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1021%26sid%3Dliteratum%253Aachs%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DKleylein-Sohn%26aufirst%3DJ.%26aulast%3DGaulis%26aufirst%3DS.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DBlommers%26aufirst%3DM.%2BJ.%26aulast%3DKazic-Legueux%26aufirst%3DM.%26aulast%3DLaborde%26aufirst%3DL.%26aulast%3DHattenberger%26aufirst%3DM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DVaxelaire%26aufirst%3DJ.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DBergling%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBruemmendorf%26aufirst%3DT.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26atitle%3DCharacterization%2520of%2520the%2520mechanism%2520of%2520action%2520of%2520the%2520pan%2520class%2520I%2520PI3K%2520inhibitor%2520NVP-BKM120%2520across%2520a%2520broad%2520range%2520of%2520concentrations%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1747%26epage%3D1757%26doi%3D10.1158%2F1535-7163.MCT-11-1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Elkabets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juric, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muranen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrik-Outmezguine, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">196ra99</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3005747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1126%2Fscitranslmed.3005747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=23903756" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=196ra99&author=M.+Elkabetsauthor=S.+Voraauthor=D.+Juricauthor=N.+Morseauthor=M.+Mino-Kenudsonauthor=T.+Muranenauthor=J.+Taoauthor=A.+B.+Camposauthor=J.+Rodonauthor=Y.+H.+Ibrahimauthor=V.+Serraauthor=V.+Rodrik-Outmezguineauthor=S.+Hazraauthor=S.+Singhauthor=P.+Kimauthor=C.+Quadtauthor=M.+Liuauthor=A.+Huangauthor=N.+Rosenauthor=J.+A.+Engelmanauthor=M.+Scaltritiauthor=J.+Baselga&title=mTORC1+inhibition+is+required+for+sensitivity+to+PI3K+p110alpha+inhibitors+in+PIK3CA-mutant+breast+cancer&doi=10.1126%2Fscitranslmed.3005747"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005747%26sid%3Dliteratum%253Aachs%26aulast%3DElkabets%26aufirst%3DM.%26aulast%3DVora%26aufirst%3DS.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DMorse%26aufirst%3DN.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DMuranen%26aufirst%3DT.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DCampos%26aufirst%3DA.%2BB.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DY.%2BH.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DRodrik-Outmezguine%26aufirst%3DV.%26aulast%3DHazra%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DmTORC1%2520inhibition%2520is%2520required%2520for%2520sensitivity%2520to%2520PI3K%2520p110alpha%2520inhibitors%2520in%2520PIK3CA-mutant%2520breast%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26spage%3D196ra99%26doi%3D10.1126%2Fscitranslmed.3005747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Zoncu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efeyan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">mTOR: from growth signal integration to cancer, diabetes and ageing</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1038/nrm3025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrm3025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=21157483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGqsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=21-35&author=R.+Zoncuauthor=A.+Efeyanauthor=D.+M.+Sabatini&title=mTOR%3A+from+growth+signal+integration+to+cancer%2C+diabetes+and+ageing&doi=10.1038%2Fnrm3025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR: from growth signal integration to cancer, diabetes and ageing</span></div><div class="casAuthors">Zoncu, Roberto; Efeyan, Alejo; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-35</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In all eukaryotes, the target of rapamycin (TOR) signalling pathway couples energy and nutrient abundance to the execution of cell growth and division, owing to the ability of TOR protein kinase to simultaneously sense energy, nutrients and stress and, in metazoans, growth factors.  Mammalian TOR complex 1 (mTORC1) and mTORC2 exert their actions by regulating other important kinases, such as S6 kinase (S6K) and Akt.  In the past few years, a significant advance in our understanding of the regulation and functions of mTOR has revealed the crucial involvement of this signalling pathway in the onset and progression of diabetes, cancer and aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfHzFJues0NLVg90H21EOLACvtfcHk0lhBrQ5urCnhbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGqsbnK&md5=3631307dc34df2ecc2eb79900c10b74c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrm3025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3025%26sid%3Dliteratum%253Aachs%26aulast%3DZoncu%26aufirst%3DR.%26aulast%3DEfeyan%26aufirst%3DA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%253A%2520from%2520growth%2520signal%2520integration%2520to%2520cancer%252C%2520diabetes%2520and%2520ageing%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D21%26epage%3D35%26doi%3D10.1038%2Fnrm3025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Marone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Targeting phosphoinositide 3-kinase: moving towards therapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1784</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2007.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.bbapap.2007.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=17997386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1784&publication_year=2008&pages=159-185&author=R.+Maroneauthor=V.+Cmiljanovicauthor=B.+Gieseauthor=M.+P.+Wymann&title=Targeting+phosphoinositide+3-kinase%3A+moving+towards+therapy&doi=10.1016%2Fj.bbapap.2007.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase-Moving towards therapy</span></div><div class="casAuthors">Marone, Romina; Cmiljanovic, Vladimir; Giese, Bernd; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1784</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">159-185</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3K) orchestrate cell responses including mitogenic signaling, cell survival and growth, metabolic control, vesicular trafficking, degranulation, cytoskeletal rearrangement and migration.  Deregulation of the PI3K pathway occurs by activating mutations in growth factor receptors or the PIK3CA locus coding for PI3Kα, by loss of function of the lipid phosphatase and tensin homolog deleted in chromosome ten (PTEN/MMAC/TEP1), by the up-regulation of protein kinase B (PKB/Akt), or the impairment of the tuberous sclerosis complex (TSC1/2).  All these events are linked to growth and proliferation, and have thus prompted a significant interest in the pharmaceutical targeting of the PI3K pathway in cancer.  Genetic targeting of PI3Kγ (p110γ) and PI3Kδ (p110δ) in mice has underlined a central role of these PI3K isoforms in inflammation and allergy, as they modulate chemotaxis of leukocytes and degranulation in mast cells.  Proof-of-concept mols. selective for PI3Kγ have already successfully alleviated disease progress in murine models of rheumatoid arthritis and lupus erythematosus.  As targeting PI3K moves forward to therapy of chronic, non-fatal disease, safety concerns for PI3K inhibitors increase.  Many of the present inhibitor series interfere with target of rapamycin (TOR), DNA-dependent protein kinase (DNA-PKcs) and activity of the ataxia telangiectasia mutated gene product (ATM).  Here we review the current disease-relevant knowledge for isoform-specific PI3K function in the above mentioned diseases, and review the progress of > 400 recent patents covering pharmaceutical targeting of PI3K.  Currently, several drugs targeting the PI3K pathway have entered clin. trials (phase I) for solid tumors and suppression of tissue damage after myocardial infarction (phases I,II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwrI_aSA632bVg90H21EOLACvtfcHk0lhBrQ5urCnhbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D&md5=bf9f259b3da61067631823656658e0f7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2007.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2007.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520phosphoinositide%25203-kinase%253A%2520moving%2520towards%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2008%26volume%3D1784%26spage%3D159%26epage%3D185%26doi%3D10.1016%2Fj.bbapap.2007.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Marone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erhart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertz, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohnacker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">613</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1158%2F1541-7786.MCR-08-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19372588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1anur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=601-613&author=R.+Maroneauthor=D.+Erhartauthor=A.+C.+Mertzauthor=T.+Bohnackerauthor=C.+Schnellauthor=V.+Cmiljanovicauthor=F.+Staufferauthor=C.+Garcia-Echeverriaauthor=B.+Gieseauthor=S.+M.+Mairaauthor=M.+P.+Wymann&title=Targeting+melanoma+with+dual+phosphoinositide+3-kinase%2Fmammalian+target+of+rapamycin+inhibitors&doi=10.1158%2F1541-7786.MCR-08-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors</span></div><div class="casAuthors">Marone, Romina; Erhart, Dominik; Mertz, Ann C.; Bohnacker, Thomas; Schnell, Christian; Cmiljanovic, Vladimir; Stauffer, Frederic; Garcia-Echeverria, Carlos; Giese, Bernd; Maira, Sauveur-Michel; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-613</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K)/protein kinase B/Akt and Ras/mitogen-activated protein kinase pathways are often constitutively activated in melanoma and have thus been considered as promising drug targets.  Exposure of melanoma cells to NVP-BAG956, NVP-BBD130, and NVP-BEZ235, a series of novel, potent, and stable dual PI3K/mammalian target of rapamycin (mTOR) inhibitors, resulted in complete G1 growth arrest, redn. of cyclin D1, and increased levels of p27KIP1, but negligible apoptosis.  In contrast, treatment of melanoma with the pan-class I PI3K inhibitor ZSTK474 or the mTORC1 inhibitor rapamycin resulted only in minor redn. of cell proliferation.  In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity.  Metastatic melanoma in inhibitor-treated mice displayed reduced nos. of proliferating and significantly smaller tumor cells.  In addn., neovascularization was blocked and tumoral necrosis increased when compared with vehicle-treated mice.  In conclusion, compds. targeting PI3K and mTOR simultaneously were advantageous to attenuate melanoma growth and they develop their potential by targeting tumor growth directly, and indirectly via their interference with angiogenesis.  Based on the above results, NVP-BEZ235, which has entered phase I/II clin. trials in patients with advanced solid tumors, has a potential in metastatic melanoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo75H1e5k7uxrVg90H21EOLACvtfcHk0lhBrQ5urCnhbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1anur8%253D&md5=1098c3d2f8e0c169550adb0409fff1e2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0366%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DErhart%26aufirst%3DD.%26aulast%3DMertz%26aufirst%3DA.%2BC.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520melanoma%2520with%2520dual%2520phosphoinositide%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2009%26volume%3D7%26spage%3D601%26epage%3D613%26doi%3D10.1158%2F1541-7786.MCR-08-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Corcoran, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faber, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazarian, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winokur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">196ra98</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3005753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1126%2Fscitranslmed.3005753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=23903755" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=196ra98&author=R.+B.+Corcoranauthor=S.+M.+Rothenbergauthor=A.+N.+Hataauthor=A.+C.+Faberauthor=A.+Pirisauthor=R.+M.+Nazarianauthor=R.+D.+Brownauthor=J.+T.+Godfreyauthor=D.+Winokurauthor=J.+Walshauthor=M.+Mino-Kenudsonauthor=S.+Maheswaranauthor=J.+Settlemanauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=D.+A.+Haberauthor=J.+A.+Engelman&title=TORC1+suppression+predicts+responsiveness+to+RAF+and+MEK+inhibition+in+BRAF-mutant+melanoma&doi=10.1126%2Fscitranslmed.3005753"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005753%26sid%3Dliteratum%253Aachs%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DFaber%26aufirst%3DA.%2BC.%26aulast%3DPiris%26aufirst%3DA.%26aulast%3DNazarian%26aufirst%3DR.%2BM.%26aulast%3DBrown%26aufirst%3DR.%2BD.%26aulast%3DGodfrey%26aufirst%3DJ.%2BT.%26aulast%3DWinokur%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DTORC1%2520suppression%2520predicts%2520responsiveness%2520to%2520RAF%2520and%2520MEK%2520inhibition%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26spage%3D196ra98%26doi%3D10.1126%2Fscitranslmed.3005753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Burger, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atallah, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartulis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhagen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwanowicz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussiere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaror, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voliva, C. F.</span><span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">774</span><span class="NLM_x">–</span> <span class="NLM_lpage">779</span><span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.+J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.+M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0liKhj0GpIqRAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.%2BJ.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7579</span><span class="NLM_x">–</span> <span class="NLM_lpage">7587</span><span class="refDoi"> DOI: 10.1021/jm2009327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.+Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+class+I+phosphatidylinositol+3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+kinase+inhibitor+%28GDC-0980%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm2009327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lgsgnn7Y5Q6Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.%2BY.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587%26doi%3D10.1021%2Fjm2009327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Dehnhardt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delos-Santos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span> </span><span class="NLM_article-title">Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4773</span><span class="NLM_x">–</span> <span class="NLM_lpage">4778</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.06.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.bmcl.2011.06.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4773-4778&author=C.+M.+Dehnhardtauthor=A.+M.+Venkatesanauthor=Z.+Chenauthor=E.+Delos-Santosauthor=S.+Ayral-Kaloustianauthor=N.+Brooijmansauthor=K.+Yuauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=R.+Mallon&title=Identification+of+2-oxatriazines+as+highly+potent+pan-PI3K%2FmTOR+dual+inhibitors&doi=10.1016%2Fj.bmcl.2011.06.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.06.063%26sid%3Dliteratum%253Aachs%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDelos-Santos%26aufirst%3DE.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DMallon%26aufirst%3DR.%26atitle%3DIdentification%2520of%25202-oxatriazines%2520as%2520highly%2520potent%2520pan-PI3K%252FmTOR%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4773%26epage%3D4778%26doi%3D10.1016%2Fj.bmcl.2011.06.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span><span class="refDoi"> DOI: 10.1021/jm800295d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer&doi=10.1021%2Fjm800295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0lg1q3g-rGLPjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532%26doi%3D10.1021%2Fjm800295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Arcaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1042/bj2960297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1042%2Fbj2960297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=8257416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADyaK3sXms1yqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=1993&pages=297-301&author=A.+Arcaroauthor=M.+P.+Wymann&title=Wortmannin+is+a+potent+phosphatidylinositol+3-kinase+inhibitor%3A+the+role+of+phosphatidylinositol+3%2C4%2C5-trisphosphate+in+neutrophil+responses&doi=10.1042%2Fbj2960297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-triphosphate in neutrophil responses</span></div><div class="casAuthors">Arcaro, Alexandre; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">297-301</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">Phosphatidylinositol 3,4,5-trisphosphate (PtdInsP3) is rapidly produced upon exposure of neutrophils to the chemoattractant N-formylmethionyl-leucyl-phenylalanine (fMLP), and has been proposed to act as a second messenger mediating actin polymn. and respiratory burst activity.  Here the authors present evidence that wortmannin, a known inhibitor of respiratory burst activity, acts on PtdIns 3-kinase, the enzyme producing PtdInsP3 from PtdIns(4,5)P2.  Pretreatment of 32P-labeled human neutrophils with 100 nM wortmannin totally abolished fMLP-mediated PtdInsp3 prodn., raised PtdInsP2 levels, and did not affect cellular PtdInsP and PtdIns contents.  The inhibitory effect of PtdInsP3 formation in intact cells was dose-dependent, with an IC50 of ∼5 nM.  Similar results were obtained with PtdIns 3-kinase immunopptd. by antibodies against the p85 regulatory subunit: wortmannin totally inhibited PtdIns3P prodn. in immunoppts. at concns. of 10-100 nM (IC50 ∼ 1 nM).  These results illustrate the direct and specific inhibition of PtdIns 3-kinase by wortmannin.  Since agonist-mediated respiratory burst activation is most sensitive to wortmannin (IC50 = 12 nM), this suggests that agonist-mediated PtdInsP3 formation is indispensable for this cell response.  Neutrophils pretreated with wortmannin develop oscillatory changes in F-actin content, but actin polymn. in response to fMLP is not inhibited.  This, and the absence of PtdInsP3 under these conditions, are in agreement with a modulatory role for PtdInsP3 in cytoskeletal rearrangements, but imply that PtdInsP3 prodn. is not a primary event triggering elongation of actin filaments in neutrophils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_hGL9IT_4XLVg90H21EOLACvtfcHk0lg1q3g-rGLPjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXms1yqur4%253D&md5=f04ac034fa98e73237690ff27c163cd8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1042%2Fbj2960297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2960297%26sid%3Dliteratum%253Aachs%26aulast%3DArcaro%26aufirst%3DA.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DWortmannin%2520is%2520a%2520potent%2520phosphatidylinositol%25203-kinase%2520inhibitor%253A%2520the%2520role%2520of%2520phosphatidylinositol%25203%252C4%252C5-trisphosphate%2520in%2520neutrophil%2520responses%26jtitle%3DBiochem.%2520J.%26date%3D1993%26volume%3D296%26spage%3D297%26epage%3D301%26doi%3D10.1042%2Fbj2960297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulgarelli-Leva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panayotou, G.</span><span> </span><span class="NLM_article-title">Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1722</span><span class="NLM_x">–</span> <span class="NLM_lpage">1733</span><span class="refDoi"> DOI: 10.1128/MCB.16.4.1722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1128%2FMCB.16.4.1722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=8657148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADyaK28XhvVags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=1722-1733&author=M.+P.+Wymannauthor=G.+Bulgarelli-Levaauthor=M.+J.+Zvelebilauthor=L.+Pirolaauthor=B.+Vanhaesebroeckauthor=M.+D.+Waterfieldauthor=G.+Panayotou&title=Wortmannin+inactivates+phosphoinositide+3-kinase+by+covalent+modification+of+Lys-802%2C+a+residue+involved+in+the+phosphate+transfer+reaction&doi=10.1128%2FMCB.16.4.1722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</span></div><div class="casAuthors">Wymann, Matthias P.; Bulgarelli-Leva, Ginette; Zvelebil, Marketa J.; Pirola, Luciano; Vanhaesebroeck, Bart; Waterfield, Michael D.; Panayotou, George</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1722-33</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Wortmannin at nanomolar concns. is a potent and specific inhibitor of phosphoinositide (PI) 3-kinase and has been used extensively to demonstrate the role of this enzyme in diverse signal transduction processes.  At higher concns., wortmannin inhibits the ataxia telangiectasia gene (ATM)-related DNA dependent protein kinase (DNA-PKcs).  The authors report here the identification of the site of interaction of wortmannin in the catalytic subunit of PI3-kinase, p110α.  At physiol. pH (6.5 to 8) wortmannin reacted specifically with p110α.  Phosphatidylinositol-4,5-diphosphate, ATP, and ATP analogs [adenine and 5'-(4-fluorosulfonylbenzoyl)adenine] competed effectively with wortmannin, while substances contg. nucleophilic amino acid side chain functions had no effect at the same concns.  This suggests that the wortmannin target site is localized in proximity to the substrate-binding site and that residues involved in wortmannin binding have an increased nucleophilicity because of their protein environment.  Proteolytic fragments of wortmannin-treated, recombinant P110α were mapped with anti-wortmannin and anti-p110α peptide antibodies, thus limiting the target site within a 10-kDa fragment, colocalizing with the ATP-binding site.  Site-directed mutagenesis of all candidate residues within this region showed that only the conservative Lys-802-59-Arg mutation abolished wortmannin binding.  Inhibition of PI 3-kinase occurs, therefore, by the formation of an enamine following the attack of Lys-802 on the furan ring (at C-20) of wortmannin.  The Lys-802-t9-Arg mutant was also unable to bind FSBA and was catalytically inactive in lipid and protein kinase assays, indicating a crucial role for Lys-802 in the phosphotransfer reaction.  In contrast, an Arg-916-to-Pro mutation abolished the catalytic activity whereas covalent wortmannin binding remained intact.  The results provide the basis for the design of novel and specific inhibitors of an enzyme family, including PI kinases and ATM-related genes, that play a central role in many physiol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoobMQ6HMdUcbVg90H21EOLACvtfcHk0lg1q3g-rGLPjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVags7s%253D&md5=54ebe365b4ad8260555c8b962e03d28b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FMCB.16.4.1722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.16.4.1722%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DBulgarelli-Leva%26aufirst%3DG.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DPirola%26aufirst%3DL.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DPanayotou%26aufirst%3DG.%26atitle%3DWortmannin%2520inactivates%2520phosphoinositide%25203-kinase%2520by%2520covalent%2520modification%2520of%2520Lys-802%252C%2520a%2520residue%2520involved%2520in%2520the%2520phosphate%2520transfer%2520reaction%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D1722%26epage%3D1733%26doi%3D10.1128%2FMCB.16.4.1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Venkatesan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehnhardt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delos Santos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dos Santos, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khafizova, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2636</span><span class="NLM_x">–</span> <span class="NLM_lpage">2645</span><span class="refDoi"> DOI: 10.1021/jm901830p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901830p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2636-2645&author=A.+M.+Venkatesanauthor=C.+M.+Dehnhardtauthor=E.+Delos+Santosauthor=Z.+Chenauthor=O.+Dos+Santosauthor=S.+Ayral-Kaloustianauthor=G.+Khafizovaauthor=N.+Brooijmansauthor=R.+Mallonauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=K.+Yuauthor=J.+Gibbonsauthor=R.+T.+Abrahamauthor=I.+Chaudharyauthor=T.+S.+Mansour&title=Bis%28morpholino-1%2C3%2C5-triazine%29+derivatives%3A+potent+adenosine+5%E2%80%B2-triphosphate+competitive+phosphatidylinositol-3-kinase%2Fmammalian+target+of+rapamycin+inhibitors%3A+discovery+of+compound+26+%28PKI-587%29%2C+a+highly+efficacious+dual+inhibitor&doi=10.1021%2Fjm901830p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm901830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901830p%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDelos%2BSantos%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDos%2BSantos%26aufirst%3DO.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DKhafizova%26aufirst%3DG.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DBis%2528morpholino-1%252C3%252C5-triazine%2529%2520derivatives%253A%2520potent%2520adenosine%25205%25E2%2580%25B2-triphosphate%2520competitive%2520phosphatidylinositol-3-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitors%253A%2520discovery%2520of%2520compound%252026%2520%2528PKI-587%2529%252C%2520a%2520highly%2520efficacious%2520dual%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2636%26epage%3D2645%26doi%3D10.1021%2Fjm901830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgTq_EL8PP5bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svenson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5013</span><span class="NLM_x">–</span> <span class="NLM_lpage">5016</span><span class="refDoi"> DOI: 10.1021/jm900851f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900851f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5013-5016&author=A.+Zaskauthor=J.+C.+Verheijenauthor=K.+Curranauthor=J.+Kaplanauthor=D.+J.+Richardauthor=P.+Nowakauthor=D.+J.+Malwitzauthor=N.+Brooijmansauthor=J.+Bardauthor=K.+Svensonauthor=J.+Lucasauthor=L.+Toral-Barzaauthor=W.+G.+Zhangauthor=I.+Hollanderauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=S.+Ayral-Kaloustianauthor=T.+S.+Mansourauthor=K.+Yu&title=ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin%3A+design+and+synthesis+of+highly+potent+and+selective+pyrazolopyrimidines&doi=10.1021%2Fjm900851f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm900851f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900851f%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DSvenson%26aufirst%3DK.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%2BG.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%253A%2520design%2520and%2520synthesis%2520of%2520highly%2520potent%2520and%2520selective%2520pyrazolopyrimidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5013%26epage%3D5016%26doi%3D10.1021%2Fjm900851f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Walker, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span><span class="refDoi"> DOI: 10.1016/S1097-2765(05)00089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+determinants+of+phosphoinositide+3-kinase+inhibition+by+wortmannin%2C+LY294002%2C+quercetin%2C+myricetin%2C+and+staurosporine&doi=10.1016%2FS1097-2765%2805%2900089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0lg4E5E6dIvahw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520determinants%2520of%2520phosphoinositide%25203-kinase%2520inhibition%2520by%2520wortmannin%252C%2520LY294002%252C%2520quercetin%252C%2520myricetin%252C%2520and%2520staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919%26doi%3D10.1016%2FS1097-2765%2805%2900089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">O’Reilly, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1500</span><span class="NLM_x">–</span> <span class="NLM_lpage">1508</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0lg4E5E6dIvahw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lg4E5E6dIvahw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Shoemaker, R. H.</span><span> </span><span class="NLM_article-title">The NCI60 human tumour cell line anticancer drug screen</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">823</span><span class="refDoi"> DOI: 10.1038/nrc1951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc1951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16990858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVCmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=813-823&author=R.+H.+Shoemaker&title=The+NCI60+human+tumour+cell+line+anticancer+drug+screen&doi=10.1038%2Fnrc1951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The NCI60 human tumour cell line anticancer drug screen</span></div><div class="casAuthors">Shoemaker, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">813-823</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The US National Cancer Institute (NCI) 60 human tumor cell line anticancer drug screen (NCI60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumors in anticancer drug screening.  This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumor-cell kill.  Recently, its role has changed to that of a service screen supporting the cancer research community.  The author reviews the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0ysyTSc1-p7Vg90H21EOLACvtfcHk0lghyAycupnbgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVCmu7c%253D&md5=c6c1a074b9dc7e138f45734499769284</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrc1951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1951%26sid%3Dliteratum%253Aachs%26aulast%3DShoemaker%26aufirst%3DR.%2BH.%26atitle%3DThe%2520NCI60%2520human%2520tumour%2520cell%2520line%2520anticancer%2520drug%2520screen%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D813%26epage%3D823%26doi%3D10.1038%2Fnrc1951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">The insulin and insulin-like growth factor receptor family in neoplasia: an update</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1038/nrc3215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc3215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=22337149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit12jsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=159-169&author=M.+Pollak&title=The+insulin+and+insulin-like+growth+factor+receptor+family+in+neoplasia%3A+an+update&doi=10.1038%2Fnrc3215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin and insulin-like growth factor receptor family in neoplasia: an update</span></div><div class="casAuthors">Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">159-169</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Although several early phase clin. trials raised enthusiasm for the use of insulin-like growth factor I receptor (IGF1R)-specific antibodies for cancer treatment, initial Phase III results in unselected patients have been disappointing.  Further clin. studies may benefit from the use of predictive biomarkers to identify probable responders, the use of rational combination therapies and the consideration of alternative targeting strategies, such as ligand-specific antibodies and receptor-specific tyrosine kinase inhibitors.  Targeting insulin and IGF signalling also needs to be considered in the broader context of the pathophysiol. that relates obesity and diabetes to neoplasia, and the effects of anti-diabetic drugs, including metformin, on cancer risk and prognosis.  The insulin and IGFI receptor family is also relevant to the development of PI3K-AKT pathway inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNoGWXuldjobVg90H21EOLACvtfcHk0lghyAycupnbgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit12jsrs%253D&md5=23f0966929a8fecbcc183fc22541980f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrc3215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3215%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DThe%2520insulin%2520and%2520insulin-like%2520growth%2520factor%2520receptor%2520family%2520in%2520neoplasia%253A%2520an%2520update%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D159%26epage%3D169%26doi%3D10.1038%2Fnrc3215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Sugino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hisaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tohnai, N.</span><span> </span><span class="NLM_article-title">Amphiphilic inclusion spaces for various guests and regulation of fluorescence intensity of 1,8-bis(4-aminophenyl)anthracene crystals</span> <span class="citation_source-journal">Chem.—Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3069</span><span class="NLM_x">–</span> <span class="NLM_lpage">3076</span><span class="refDoi"> DOI: 10.1002/chem.201304541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1002%2Fchem.201304541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=24677343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=3069-3076&author=M.+Suginoauthor=K.+Hatanakaauthor=Y.+Arakiauthor=I.+Hisakiauthor=M.+Miyataauthor=N.+Tohnai&title=Amphiphilic+inclusion+spaces+for+various+guests+and+regulation+of+fluorescence+intensity+of+1%2C8-bis%284-aminophenyl%29anthracene+crystals&doi=10.1002%2Fchem.201304541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Amphiphilic Inclusion Spaces for Various Guests and Regulation of Fluorescence Intensity of 1,8-Bis(4-aminophenyl)anthracene Crystals</span></div><div class="casAuthors">Sugino, Misa; Hatanaka, Keisuke; Araki, Yusuke; Hisaki, Ichiro; Miyata, Mikiji; Tohnai, Norimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3069-3076</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A host framework for inclusion of various guest mols. was studied by prepn. of inclusion crystals of 1,8-bis(4-aminophenyl)anthracene (1,8-BAPA) with org. solvents.  X-ray crystallog. anal. revealed construction of the same inclusion space incorporating 1,8-BAPA and eight guest mols. including both nonpolar (benzene) and polar guests (DMF, DMF).  Fluorescence efficiencies varied depending on guest mol. polarity; DMF inclusion crystals exhibited the highest fluorescence intensity (ΦF = 0.40), four times as high as that of a benzene inclusion crystal (ΦF = 0.10).  According to systematic studies of inclusion phenomena, strong host-guest interactions and filling of the inclusion space led to a high fluorescence intensity.  Temp.-dependent fluorescence spectral measurements revealed these factors effectively immobilized the host framework.  Although hydrogen bonding commonly decreases fluorescence intensity, the present study demonstrated that such strong interactions provide excellent conditions for fluorescence enhancement.  Thus, this remarkable behavior has potential application toward sensing of highly polar mols., such as biogenic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSpyD5EYkKkLVg90H21EOLACvtfcHk0lghyAycupnbgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGgsbw%253D&md5=10ddc95c12a41e881e481e5711bfd356</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fchem.201304541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201304541%26sid%3Dliteratum%253Aachs%26aulast%3DSugino%26aufirst%3DM.%26aulast%3DHatanaka%26aufirst%3DK.%26aulast%3DAraki%26aufirst%3DY.%26aulast%3DHisaki%26aufirst%3DI.%26aulast%3DMiyata%26aufirst%3DM.%26aulast%3DTohnai%26aufirst%3DN.%26atitle%3DAmphiphilic%2520inclusion%2520spaces%2520for%2520various%2520guests%2520and%2520regulation%2520of%2520fluorescence%2520intensity%2520of%25201%252C8-bis%25284-aminophenyl%2529anthracene%2520crystals%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2014%26volume%3D20%26spage%3D3069%26epage%3D3076%26doi%3D10.1002%2Fchem.201304541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span> </span><span class="NLM_article-title">1,3,5-Triazine inhibitors of histone deacetylases: synthesis and biological activity</span> <span class="citation_source-journal">Med. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5188</span><span class="NLM_x">–</span> <span class="NLM_lpage">5196</span><span class="refDoi"> DOI: 10.1007/s00044-014-1084-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1007%2Fs00044-014-1084-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKlsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=5188-5196&author=X.+Zhaoauthor=Q.+Tanauthor=Z.+Zhangauthor=Y.+Zhao&title=1%2C3%2C5-Triazine+inhibitors+of+histone+deacetylases%3A+synthesis+and+biological+activity&doi=10.1007%2Fs00044-014-1084-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">1,3,5-Triazine inhibitors of histone deacetylases: synthesis and biological activity</span></div><div class="casAuthors">Zhao, Xiaodong; Tan, Qiu; Zhang, Zhitao; Zhao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5188-5196</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">A series of 1,3,5-triazine-based hydroxamic acids 6a-6i were designed and synthesized, and they were potent inhibitors of human histone deacetylases.  These compds. were evaluated for their antiproliferative activity by MTT assay, and most of them exhibited significant antiproliferative effect on HCT-116, MCF-7, and HeLa cancer cell lines.  DNA flow cytometric anal. revealed that compd. 6i induced apoptosis and cell cycle arrest at G2/M phase in HCT-116 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBjYH-wBNYebVg90H21EOLACvtfcHk0liE9utF6tr6CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKlsrbF&md5=bbd419ce273ad50c07c4f45e3e37828a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs00044-014-1084-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-014-1084-z%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3D1%252C3%252C5-Triazine%2520inhibitors%2520of%2520histone%2520deacetylases%253A%2520synthesis%2520and%2520biological%2520activity%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2014%26volume%3D23%26spage%3D5188%26epage%3D5196%26doi%3D10.1007%2Fs00044-014-1084-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+pharmacological+map+of+the+PI3-K+family+defines+a+role+for+p110alpha+in+insulin+signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0liE9utF6tr6CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520pharmacological%2520map%2520of%2520the%2520PI3-K%2520family%2520defines%2520a%2520role%2520for%2520p110alpha%2520in%2520insulin%2520signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span> </span><span class="NLM_article-title">Mosflm—a programme for processing X-ray diffraction data</span>.  <span class="citation_source-book">Joint CCP4/ESF-EACBM Newsletter on Protein Crystallography</span>; <span class="NLM_publisher-name">Daresbury Laboratory</span>: <span class="NLM_publisher-loc">Warrington, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">1992</span><span class="NLM_x">; </span>No. <span class="NLM_issue">26</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=A.+G.+W.+Leslie&title=Joint+CCP4%2FESF-EACBM+Newsletter+on+Protein+Crystallography"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26atitle%3DMosflm%25E2%2580%2594a%2520programme%2520for%2520processing%2520X-ray%2520diffraction%2520data%26btitle%3DJoint%2520CCP4%252FESF-EACBM%2520Newsletter%2520on%2520Protein%2520Crystallography%26pub%3DDaresbury%2520Laboratory%26date%3D1992%26issue%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1107/S0021889893005588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0021889893005588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADyaK2cXptFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=795-800&author=W.+Kabsch&title=Automatic+processing+of+rotation+diffraction+data+from+crystals+of+initially+unknown+symmetry+and+cell+constants&doi=10.1107%2FS0021889893005588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">795-800</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">An algorithm was developed for the automatic interpretation of a given set of obsd. reciprocal-lattice points.  It exts. a reduced cell and assigns indexes to each reflection by a graph-theor. implementation of the local indexing method.  All possible symmetries of the obsd. lattice compatible with the metric of the reduced cell are recognized and reported, together with the unit-cell consts. and the linear index transformation relating the conventional to the reduced cell.  This algorithm was incorporated into the program XDS (K., 1988), which is now able to process single-crystal area-detector data without prior knowledge of the symmetry and the unit-cell consts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1lV8_7cDv7Vg90H21EOLACvtfcHk0liE9utF6tr6CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXptFeltw%253D%253D&md5=2b703225206ce99af0d7e38acf6d75b3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1107%2FS0021889893005588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889893005588%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DAutomatic%2520processing%2520of%2520rotation%2520diffraction%2520data%2520from%2520crystals%2520of%2520initially%2520unknown%2520symmetry%2520and%2520cell%2520constants%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1993%26volume%3D26%26spage%3D795%26epage%3D800%26doi%3D10.1107%2FS0021889893005588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography</span>.  <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span>, DOI: <span class="refDoi"> DOI: 10.1107/S0907444994003112</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=15299374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A280%3ADC%252BD2czpsV2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+CCP4+suite%3A+programs+for+protein+crystallography.+Acta+Crystallogr.%2C+Sect.+D%3A+Biol.+Crystallogr.+1994%2C+50%2C+760%E2%80%93763%2C+DOI%3A+10.1107%2FS0907444994003112."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The CCP4 suite: programs for protein crystallography</span></div><div class="casAuthors">Anonymous</div><div class="citationInfo"><span class="NLM_cas:title">Acta crystallographica. Section D, Biological crystallography</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">Pt 5</span>),
    <span class="NLM_cas:pages">760-3</span>
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    </div><div class="casAbstract">The CCP4 (Collaborative Computational Project, number 4) program suite is a collection of programs and associated data and subroutine libraries which can be used for macromolecular structure determination by X-ray crystallography.  The suite is designed to be flexible, allowing users a number of methods of achieving their aims and so there may be more than one program to cover each function.  The programs are written mainly in standard Fortran77.  They are from a wide variety of sources but are connected by standard data file formats.  The package has been ported to all the major platforms under both Unix and VMS.  The suite is distributed by anonymous ftp from Daresbury Laboratory and is widely used throughout the world.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1Q-skJYIZ2IYPsCkJIw00fW6udTcc2eYo8JhM9W9fVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czpsV2gug%253D%253D&md5=92b759927d6071ea3f20c08b78ad1eb2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span> </span><span class="NLM_article-title">Solving structures of protein complexes by molecular replacement with Phaser</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1107/S0907444906045975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444906045975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=17164524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlSqu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=32-41&author=A.+J.+McCoy&title=Solving+structures+of+protein+complexes+by+molecular+replacement+with+Phaser&doi=10.1107%2FS0907444906045975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Solving structures of protein complexes by molecular replacement with Phaser</span></div><div class="casAuthors">McCoy, Airlie J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-41</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Mol. replacement (MR) generally becomes more difficult as the no. of components in the asym. unit requiring sep. MR models (i.e. the dimensionality of the search) increases.  When the proportion of the total scattering contributed by each search component is small, the signal in the search for each component in isolation is weak or non-existent.  Maximum-likelihood MR functions enable complex asym. units to be built up from individual components with a 'tree search with pruning' approach.  This method, as implemented in the automated search procedure of the program Phaser, has been very successful in solving many previously intractable MR problems.  However, there are a no. of cases in which the automated search procedure of Phaser is suboptimal or encounters difficulties.  These include cases where there are a large no. of copies of the same component in the asym. unit or where the components of the asym. unit have greatly varying B factors.  Two case studies are presented to illustrate how Phaser can be used to best advantage in the std. 'automated MR' mode and two case studies are used to show how to modify the automated search strategy for problematic cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAvs9W8hQ3l7Vg90H21EOLACvtfcHk0lgkfBjar4WMgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlSqu77F&md5=323a5297bdf622ebaf398a87c39dc794</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444906045975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444906045975%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26atitle%3DSolving%2520structures%2520of%2520protein%2520complexes%2520by%2520molecular%2520replacement%2520with%2520Phaser%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2007%26volume%3D63%26spage%3D32%26epage%3D41%26doi%3D10.1107%2FS0907444906045975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lgkfBjar4WMgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span> </span><span class="NLM_article-title">Electronic ligand builder and optimization workbench (eLBOW): a tool for ligand coordinate and restraint generation</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1074</span><span class="NLM_x">–</span> <span class="NLM_lpage">1080</span><span class="refDoi"> DOI: 10.1107/S0907444909029436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444909029436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19770504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKnsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=1074-1080&author=N.+W.+Moriartyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adams&title=Electronic+ligand+builder+and+optimization+workbench+%28eLBOW%29%3A+a+tool+for+ligand+coordinate+and+restraint+generation&doi=10.1107%2FS0907444909029436"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation</span></div><div class="casAuthors">Moriarty, Nigel W.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1074-1080</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The electronic Ligand Builder and Optimization Workbench (eLBOW) is a program module of the PHENIX suite of computational crystallog. software.  It is designed to be a flexible procedure that uses simple and fast quantum-chem. techniques to provide chem. accurate information for novel and known ligands alike.  A variety of input formats and options allow the attainment of a no. of diverse goals including geometry optimization and generation of restraints.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojnN4AVY_DwrVg90H21EOLACvtfcHk0lgkfBjar4WMgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKnsLnN&md5=3f9a9c6c31c9a4b014a9f151fb6aa8d9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444909029436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909029436%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26atitle%3DElectronic%2520ligand%2520builder%2520and%2520optimization%2520workbench%2520%2528eLBOW%2529%253A%2520a%2520tool%2520for%2520ligand%2520coordinate%2520and%2520restraint%2520generation%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2009%26volume%3D65%26spage%3D1074%26epage%3D1080%26doi%3D10.1107%2FS0907444909029436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lgAdScVYEQ2wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 58 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Elena Lenci, Lorenzo Calugi, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Trabocchi</span>. </span><span class="cited-content_cbyCitation_article-title">Occurrence of Morpholine in Central Nervous System Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 378-390. <a href="https://doi.org/10.1021/acschemneuro.0c00729" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00729</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00729%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DOccurrence%252Bof%252BMorpholine%252Bin%252BCentral%252BNervous%252BSystem%252BDrug%252BDiscovery%26aulast%3DLenci%26aufirst%3DElena%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D13112020%26date%3D11012021%26date%3D18012021%26volume%3D12%26issue%3D3%26spage%3D378%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, Anna Melone, Rohitha Sriramaratnam, Florent Beaufils, Matthias Hamburger, Paul Hebeisen, Wolfgang Löscher, Doriano Fabbro, Petra Hillmann, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13595-13617. <a href="https://doi.org/10.1021/acs.jmedchem.0c00620" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00620</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00620%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-%252528Difluoromethyl%252529-5-%2525284-%252528%2525283R%25252C5S%252529-3%25252C5-dimethylmorpholino%252529-6-%252528%252528R%252529-3-methylmorpholino%252529-1%25252C3%25252C5-triazin-2-yl%252529pyridin-2-amine%252B%252528PQR626%252529%25252C%252Ba%252BPotent%25252C%252BOrally%252BAvailable%25252C%252Band%252BBrain-Penetrant%252BmTOR%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BNeurological%252BDisorders%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15042020%26date%3D09112020%26volume%3D63%26issue%3D22%26spage%3D13595%26epage%3D13617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dinesh Mahajan, Somdutta Sen, Bilash Kuila, Amit Sharma, Reena Arora, Milind Sagar, Amal Ray Mahapatra, Lalita Babasaheb Gawade, <span class="NLM_string-name hlFld-ContribAuthor">Sundeep Dugar</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3Kα and mTOR Kinases for the Treatment of Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 11121-11130. <a href="https://doi.org/10.1021/acs.jmedchem.0c01061" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01061%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BSPR519%252Bas%252Ba%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BBioavailable%252BInhibitor%252Bof%252BPI3K%2525CE%2525B1%252Band%252BmTOR%252BKinases%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BTumors%26aulast%3DMahajan%26aufirst%3DDinesh%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19062020%26date%3D23092020%26date%3D08092020%26volume%3D63%26issue%3D19%26spage%3D11121%26epage%3D11130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Denise Rageot, Florent Beaufils, Chiara Borsari, Alix Dall’Asen, Markus Neuburger, Paul Hebeisen, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (11)
                                     , 2416-2424. <a href="https://doi.org/10.1021/acs.oprd.9b00312" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00312%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DScalable%25252C%252BEconomical%25252C%252Band%252BPractical%252BSynthesis%252Bof%252B4-%252528Difluoromethyl%252529pyridin-2-amine%25252C%252Ba%252BKey%252BIntermediate%252Bfor%252BLipid%252BKinase%252BInhibitors%26aulast%3DRageot%26aufirst%3DDenise%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D09072019%26date%3D10102019%26date%3D25092019%26volume%3D23%26issue%3D11%26spage%3D2416%26epage%3D2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chiara Borsari, Denise Rageot, Florent Beaufils, Thomas Bohnacker, Erhan Keles, Ivan Buslov, Anna Melone, Alexander M. Sele, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1473-1479. <a href="https://doi.org/10.1021/acsmedchemlett.9b00333" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00333</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00333%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPreclinical%252BDevelopment%252Bof%252BPQR514%25252C%252Ba%252BHighly%252BPotent%252BPI3K%252BInhibitor%252BBearing%252Ba%252BDifluoromethyl%2525E2%252580%252593Pyrimidine%252BMoiety%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22072019%26date%3D03092019%26date%3D11092019%26date%3D03092019%26volume%3D10%26issue%3D10%26spage%3D1473%26epage%3D1479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chiara Borsari, Denise Rageot, Alix Dall’Asen, Thomas Bohnacker, Anna Melone, Alexander M. Sele, Eileen Jackson, Jean-Baptiste Langlois, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (18)
                                     , 8609-8630. <a href="https://doi.org/10.1021/acs.jmedchem.9b00972" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00972</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00972%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BConformational%252BRestriction%252BStrategy%252Bfor%252Bthe%252BIdentification%252Bof%252Ba%252BHighly%252BSelective%252BPyrimido-pyrrolo-oxazine%252BmTOR%252BInhibitor%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19062019%26date%3D11092019%26date%3D29082019%26volume%3D62%26issue%3D18%26spage%3D8609%26epage%3D8630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A. McPhail, Reece M. Hoffmann, Anna Melone, Chiara Borsari, Rohitha Sriramaratnam, Alexander M. Sele, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, John E. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 6241-6261. <a href="https://doi.org/10.1021/acs.jmedchem.9b00525" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00525%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%252528S%252529-4-%252528Difluoromethyl%252529-5-%2525284-%2525283-methylmorpholino%252529-6-morpholino-1%25252C3%25252C5-triazin-2-yl%252529pyridin-2-amine%252B%252528PQR530%252529%25252C%252Ba%252BPotent%25252C%252BOrally%252BBioavailable%25252C%252Band%252BBrain-Penetrable%252BDual%252BInhibitor%252Bof%252BClass%252BI%252BPI3K%252Band%252BmTOR%252BKinase%26aulast%3DRageot%26aufirst%3DDenise%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26032019%26date%3D20062019%26date%3D07062019%26volume%3D62%26issue%3D13%26spage%3D6241%26epage%3D6261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yepeng Luan, Jerry Li, Jean A. Bernatchez, <span class="NLM_string-name hlFld-ContribAuthor">Rongshi Li</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3171-3183. <a href="https://doi.org/10.1021/acs.jmedchem.8b00189" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00189</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00189%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252Band%252BHistone%252BDeacetylase%252BHybrid%252BInhibitors%252Bfor%252BCancer%252BTherapy%26aulast%3DLuan%26aufirst%3DYepeng%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D05022018%26date%3D16112018%26date%3D12112018%26volume%3D62%26issue%3D7%26spage%3D3171%26epage%3D3183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari, Petra Hillmann, Alexander M. Sele, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John Burke, Doriano Fabbro, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 10084-10105. <a href="https://doi.org/10.1021/acs.jmedchem.8b01262" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01262</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01262%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BPreclinical%252BCharacterization%252Bof%252B5-%25255B4%25252C6-Bis%252528%25257B3-oxa-8-azabicyclo%25255B3.2.1%25255Doctan-8-yl%25257D%252529-1%25252C3%25252C5-triazin-2-yl%25255D-4-%252528difluoromethyl%252529pyridin-2-amine%252B%252528PQR620%252529%25252C%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BmTORC1%25252F2%252BInhibitor%252Bfor%252BCancer%252Band%252BNeurological%252BDisorders%26aulast%3DRageot%26aufirst%3DDenise%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09082018%26date%3D14112018%26date%3D25102018%26volume%3D61%26issue%3D22%26spage%3D10084%26epage%3D10105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Songwen Lin, Chunyang Wang, Ming Ji, Deyu Wu, Yuanhao Lv, Kehui Zhang, Yi Dong, Jing Jin, Jiajing Chen, Jingbo Zhang, Li Sheng, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 6087-6109. <a href="https://doi.org/10.1021/acs.jmedchem.8b00416" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00416%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252B2-Amino-4-methylquinazoline%252BDerivatives%252Bas%252BHighly%252BPotent%252BPhosphatidylinositol%252B3-Kinase%252BInhibitors%252Bfor%252BCancer%252BTreatment%26aulast%3DLin%26aufirst%3DSongwen%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D14032018%26date%3D09072018%26date%3D21062018%26volume%3D61%26issue%3D14%26spage%3D6087%26epage%3D6109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingxiang  Guo</span>, <span class="hlFld-ContribAuthor ">Chenhua  Yu</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongtao  Li</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi  Huang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhou</span>, <span class="hlFld-ContribAuthor ">Yao  Li</span>, <span class="hlFld-ContribAuthor ">Zhongxiang  Qin</span>, <span class="hlFld-ContribAuthor ">Cheng  Wang</span>, <span class="hlFld-ContribAuthor ">Ruifang  Gao</span>, <span class="hlFld-ContribAuthor ">Yongwei  Nie</span>, <span class="hlFld-ContribAuthor ">Yakun  Ma</span>, <span class="hlFld-ContribAuthor ">Yi  Shi</span>, <span class="hlFld-ContribAuthor ">Jianyu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Yan  Fan</span>, and <span class="hlFld-ContribAuthor ">Rong  Xiang</span>  . </span><span class="cited-content_cbyCitation_article-title">Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (3)
                                     , 881-904. <a href="https://doi.org/10.1021/acs.jmedchem.7b01402" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01402</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01402%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BSelective%25252C%252BPotent%25252C%252Band%252BOral%252BmTOR%252BInhibitor%252Bfor%252BTreatment%252Bof%252BCancer%252Bas%252BAutophagy%252BInducer%26aulast%3DGuo%26aufirst%3DQingxiang%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D21092017%26date%3D27012018%26date%3D08022018%26date%3D08012018%26volume%3D61%26issue%3D3%26spage%3D881%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical and Structural Strategies to Selectively Target mTOR Kinase. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1002/cmdc.202100332" title="DOI URL">https://doi.org/10.1002/cmdc.202100332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100332%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DChemical%252Band%252BStructural%252BStrategies%252Bto%252BSelectively%252BTarget%252BmTOR%252BKinase%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han-Yue  Qiu</span>, <span class="hlFld-ContribAuthor ">Peng-Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Min  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A patent review of mTOR inhibitors for cancer therapy (2011–2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em> </em>, 1-11. <a href="https://doi.org/10.1080/13543776.2021.1940137" title="DOI URL">https://doi.org/10.1080/13543776.2021.1940137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1940137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1940137%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Breview%252Bof%252BmTOR%252Binhibitors%252Bfor%252Bcancer%252Btherapy%252B%2525282011%2525E2%252580%2525932020%252529%26aulast%3DQiu%26aufirst%3DHan-Yue%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Richardson</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>3 </em>, 1-26. <a href="https://doi.org/10.1080/17460441.2021.1933427" title="DOI URL">https://doi.org/10.1080/17460441.2021.1933427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1933427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1933427%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DApplications%252Bof%252Bfluorine%252Bto%252Bthe%252Bconstruction%252Bof%252Bbioisosteric%252Belements%252Bfor%252Bthe%252Bpurposes%252Bof%252Bnovel%252Bdrug%252Bdiscovery%26aulast%3DRichardson%26aufirst%3DPaul%26date%3D2021%26date%3D2021%26volume%3D3%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hans-Georg  Wirsching</span>, <span class="hlFld-ContribAuthor ">Michael  Weller</span>, <span class="hlFld-ContribAuthor ">Stefan  Balabanov</span>, <span class="hlFld-ContribAuthor ">Patrick  Roth</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (12)
                                     , 3073. <a href="https://doi.org/10.3390/cancers13123073" title="DOI URL">https://doi.org/10.3390/cancers13123073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13123073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13123073%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeted%252BTherapies%252Band%252BImmune%252BCheckpoint%252BInhibitors%252Bin%252BPrimary%252BCNS%252BLymphoma%26aulast%3DWirsching%26aufirst%3DHans-Georg%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D12%26spage%3D3073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Le  Yu</span>, <span class="hlFld-ContribAuthor ">Jessica  Wei</span>, <span class="hlFld-ContribAuthor ">Pengda  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1016/j.semcancer.2021.06.019" title="DOI URL">https://doi.org/10.1016/j.semcancer.2021.06.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2021.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2021.06.019%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAttacking%252Bthe%252BPI3K%25252FAkt%25252FmTOR%252Bsignaling%252Bpathway%252Bfor%252Btargeted%252Btherapeutic%252Btreatment%252Bin%252Bhuman%252Bcancer%26aulast%3DYu%26aufirst%3DLe%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masamitsu  Tsukamoto</span>, <span class="hlFld-ContribAuthor ">Tadashi  Nakamura</span>, <span class="hlFld-ContribAuthor ">Hirohiko  Kimura</span>, <span class="hlFld-ContribAuthor ">Hitoshi  Nakayama</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and application of trifluoromethylpyridines as a key structural motif in active agrochemical and pharmaceutical ingredients. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pesticide Science</span><span> <strong>2021,</strong> <em>46 </em>
                                    (2)
                                     , 125-142. <a href="https://doi.org/10.1584/jpestics.D21-012" title="DOI URL">https://doi.org/10.1584/jpestics.D21-012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1584/jpestics.D21-012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1584%2Fjpestics.D21-012%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pesticide%2520Science%26atitle%3DSynthesis%252Band%252Bapplication%252Bof%252Btrifluoromethylpyridines%252Bas%252Ba%252Bkey%252Bstructural%252Bmotif%252Bin%252Bactive%252Bagrochemical%252Band%252Bpharmaceutical%252Bingredients%26aulast%3DTsukamoto%26aufirst%3DMasamitsu%26date%3D2021%26volume%3D46%26issue%3D2%26spage%3D125%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suwen  Hu</span>, <span class="hlFld-ContribAuthor ">Zi  Hui</span>, <span class="hlFld-ContribAuthor ">Frédéric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (5)
                                     , 435-452. <a href="https://doi.org/10.1080/13543776.2021.1866540" title="DOI URL">https://doi.org/10.1080/13543776.2021.1866540</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1866540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1866540%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall%252Bmolecule%252BDNA-PK%252Binhibitors%252Bas%252Bpotential%252Bcancer%252Btherapy%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%2525E2%252580%252593present%252529%26aulast%3DHu%26aufirst%3DSuwen%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D5%26spage%3D435%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Erhan  Keles</span>, <span class="hlFld-ContribAuthor ">Andrea  Treyer</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Paul  Hebeisen</span>, <span class="hlFld-ContribAuthor ">Matthias  Hamburger</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 579-583. <a href="https://doi.org/10.1039/D0MD00408A" title="DOI URL">https://doi.org/10.1039/D0MD00408A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00408A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00408A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSecond-generation%252Btricyclic%252Bpyrimido-pyrrolo-oxazine%252BmTOR%252Binhibitor%252Bwith%252Bpredicted%252Bblood%2525E2%252580%252593brain%252Bbarrier%252Bpermeability%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D579%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert  Gris-Oliver</span>, <span class="hlFld-ContribAuthor ">Yasir H.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Martín A.  Rivas</span>, <span class="hlFld-ContribAuthor ">Celina  García-García</span>, <span class="hlFld-ContribAuthor ">Mònica  Sánchez-Guixé</span>, <span class="hlFld-ContribAuthor ">Fiorella  Ruiz-Pace</span>, <span class="hlFld-ContribAuthor ">Cristina  Viaplana</span>, <span class="hlFld-ContribAuthor ">José M.  Pérez-García</span>, <span class="hlFld-ContribAuthor ">Antonio  Llombart-Cussac</span>, <span class="hlFld-ContribAuthor ">Judit  Grueso</span>, <span class="hlFld-ContribAuthor ">Mireia  Parés</span>, <span class="hlFld-ContribAuthor ">Marta  Guzmán</span>, <span class="hlFld-ContribAuthor ">Olga  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Pilar  Anton</span>, <span class="hlFld-ContribAuthor ">Patricia  Cozar</span>, <span class="hlFld-ContribAuthor ">Maria Teresa  Calvo</span>, <span class="hlFld-ContribAuthor ">Alejandra  Bruna</span>, <span class="hlFld-ContribAuthor ">Joaquín  Arribas</span>, <span class="hlFld-ContribAuthor ">Carlos  Caldas</span>, <span class="hlFld-ContribAuthor ">Rodrigo  Dienstmann</span>, <span class="hlFld-ContribAuthor ">Paolo  Nuciforo</span>, <span class="hlFld-ContribAuthor ">Mafalda  Oliveira</span>, <span class="hlFld-ContribAuthor ">Javier  Cortés</span>, <span class="hlFld-ContribAuthor ">Violeta  Serra</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Cancer</span><span> <strong>2021,</strong> <em>124 </em>
                                    (9)
                                     , 1581-1591. <a href="https://doi.org/10.1038/s41416-021-01293-1" title="DOI URL">https://doi.org/10.1038/s41416-021-01293-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41416-021-01293-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41416-021-01293-1%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Cancer%26atitle%3DPI3K%252Bactivation%252Bpromotes%252Bresistance%252Bto%252Beribulin%252Bin%252BHER2-negative%252Bbreast%252Bcancer%26aulast%3DGris-Oliver%26aufirst%3DAlbert%26date%3D2021%26date%3D2021%26volume%3D124%26issue%3D9%26spage%3D1581%26epage%3D1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruoyu  He</span>, <span class="hlFld-ContribAuthor ">Bingyong  Xu</span>, <span class="hlFld-ContribAuthor ">Li  Ping</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113249. <a href="https://doi.org/10.1016/j.ejmech.2021.113249" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113249%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Btowards%252Bpromising%252B%2525CE%2525B2-methyl-4-acrylamido%252Bquinoline%252Bderivatives%252Bas%252BPI3K%25252FmTOR%252Bdual%252Binhibitors%252Bfor%252Banti-cancer%252Btherapy%25253A%252BThe%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bbiological%252Bevaluation%26aulast%3DHe%26aufirst%3DRuoyu%26date%3D2021%26volume%3D214%26spage%3D113249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ab  Majeed Ganai</span>, <span class="hlFld-ContribAuthor ">Tabasum  Khan Pathan</span>, <span class="hlFld-ContribAuthor ">Girish A.  Hampannavar</span>, <span class="hlFld-ContribAuthor ">Chandrakant  Pawar</span>, <span class="hlFld-ContribAuthor ">Vincent A.  Obakachi</span>, <span class="hlFld-ContribAuthor ">Babita  Kushwaha</span>, <span class="hlFld-ContribAuthor ">Narva  Deshwar Kushwaha</span>, <span class="hlFld-ContribAuthor ">Rajshekhar  Karpoormath</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (7)
                                     , 1616-1660. <a href="https://doi.org/10.1002/slct.202004591" title="DOI URL">https://doi.org/10.1002/slct.202004591</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202004591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202004591%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BAdvances%252Bon%252Bthe%252Bs%2525E2%252580%252590Triazine%252BScaffold%252Bwith%252BEmphasis%252Bon%252BSynthesis%25252C%252BStructure%2525E2%252580%252590Activity%252Band%252BPharmacological%252BAspects%25253A%252BA%252BConcise%252BReview%26aulast%3DMajeed%2BGanai%26aufirst%3DAb%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D7%26spage%3D1616%26epage%3D1660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongzhao  Wang</span>, <span class="hlFld-ContribAuthor ">Zijian  Qin</span>, <span class="hlFld-ContribAuthor ">Aixia  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>69 </em><a href="https://doi.org/10.1007/s11030-020-10165-4" title="DOI URL">https://doi.org/10.1007/s11030-020-10165-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10165-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10165-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DClassification%252Bmodels%252Band%252BSAR%252Banalysis%252Bon%252BCysLT1%252Breceptor%252Bantagonists%252Busing%252Bmachine%252Blearning%252Balgorithms%26aulast%3DWang%26aufirst%3DHongzhao%26date%3D2021%26date%3D2021%26volume%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junbo  Hu</span>, <span class="hlFld-ContribAuthor ">Yanli  Zhang</span>, <span class="hlFld-ContribAuthor ">Na  Tang</span>, <span class="hlFld-ContribAuthor ">Yanju  Lu</span>, <span class="hlFld-ContribAuthor ">Peng  Guo</span>, <span class="hlFld-ContribAuthor ">Ziming  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>32 </em>, 115997. <a href="https://doi.org/10.1016/j.bmc.2021.115997" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.115997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.115997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.115997%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B1%25252C3%25252C5-triazine%252Bderivatives%252Bas%252Bpotent%252Binhibitor%252Bof%252Bcervical%252Bcancer%252Bvia%252Bdual%252Binhibition%252Bof%252BPI3K%25252FmTOR%26aulast%3DHu%26aufirst%3DJunbo%26date%3D2021%26volume%3D32%26spage%3D115997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosa M.  Álvarez</span>, <span class="hlFld-ContribAuthor ">Ana Belén  García</span>, <span class="hlFld-ContribAuthor ">Concepción  Riesco-Fagundo</span>, <span class="hlFld-ContribAuthor ">José I.  Martín</span>, <span class="hlFld-ContribAuthor ">Carmen  Varela</span>, <span class="hlFld-ContribAuthor ">Antonio  Rodríguez Hergueta</span>, <span class="hlFld-ContribAuthor ">Esther  González Cantalapiedra</span>, <span class="hlFld-ContribAuthor ">Julen  Oyarzabal</span>, <span class="hlFld-ContribAuthor ">Bruno  Di Geronimo</span>, <span class="hlFld-ContribAuthor ">Milagros  Lorenzo</span>, <span class="hlFld-ContribAuthor ">M Isabel  Albarrán</span>, <span class="hlFld-ContribAuthor ">Antonio  Cebriá</span>, <span class="hlFld-ContribAuthor ">David  Cebrián</span>, <span class="hlFld-ContribAuthor ">Sonia  Martínez-González</span>, <span class="hlFld-ContribAuthor ">Carmen  Blanco-Aparicio</span>, <span class="hlFld-ContribAuthor ">Joaquín  Pastor</span>. </span><span class="cited-content_cbyCitation_article-title">Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113109. <a href="https://doi.org/10.1016/j.ejmech.2020.113109" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113109%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOmipalisib%252Binspired%252Bmacrocycles%252Bas%252Bdual%252BPI3K%25252FmTOR%252Binhibitors%26aulast%3D%25C3%2581lvarez%26aufirst%3DRosa%2BM.%26date%3D2021%26volume%3D211%26spage%3D113109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Mologni</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>, <span class="hlFld-ContribAuthor ">Sara  Redaelli</span>, <span class="hlFld-ContribAuthor ">Alfonso  Zambon</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Kinase Targeting in Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 119. <a href="https://doi.org/10.3390/cancers13010119" title="DOI URL">https://doi.org/10.3390/cancers13010119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13010119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13010119%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDual%252BKinase%252BTargeting%252Bin%252BLeukemia%26aulast%3DMologni%26aufirst%3DLuca%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D1%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mudasir  Maqbool</span>, <span class="hlFld-ContribAuthor ">Joshna  Gadhavi</span>, <span class="hlFld-ContribAuthor ">Pravin  Hivare</span>, <span class="hlFld-ContribAuthor ">Sharad  Gupta</span>, <span class="hlFld-ContribAuthor ">Nasimul  Hoda</span>. </span><span class="cited-content_cbyCitation_article-title">Diphenyl triazine hybrids inhibit α-synuclein fibrillogenesis: Design, synthesis and in vitro efficacy studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112705. <a href="https://doi.org/10.1016/j.ejmech.2020.112705" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112705</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112705%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiphenyl%252Btriazine%252Bhybrids%252Binhibit%252B%2525CE%2525B1-synuclein%252Bfibrillogenesis%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bin%2525C2%2525A0vitro%252Befficacy%252Bstudies%26aulast%3DMaqbool%26aufirst%3DMudasir%26date%3D2020%26volume%3D207%26spage%3D112705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yifan  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Research progress of mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112820. <a href="https://doi.org/10.1016/j.ejmech.2020.112820" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112820</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112820%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DResearch%252Bprogress%252Bof%252BmTOR%252Binhibitors%26aulast%3DChen%26aufirst%3DYifan%26date%3D2020%26volume%3D208%26spage%3D112820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wiebke  Theilmann</span>, <span class="hlFld-ContribAuthor ">Birthe  Gericke</span>, <span class="hlFld-ContribAuthor ">Alina  Schidlitzki</span>, <span class="hlFld-ContribAuthor ">Syed Muhammad  Muneeb Anjum</span>, <span class="hlFld-ContribAuthor ">Saskia  Borsdorf</span>, <span class="hlFld-ContribAuthor ">Timon  Harries</span>, <span class="hlFld-ContribAuthor ">Steven L.  Roberds</span>, <span class="hlFld-ContribAuthor ">Dean J.  Aguiar</span>, <span class="hlFld-ContribAuthor ">Daniela  Brunner</span>, <span class="hlFld-ContribAuthor ">Steven C.  Leiser</span>, <span class="hlFld-ContribAuthor ">Dekun  Song</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Löscher</span>. </span><span class="cited-content_cbyCitation_article-title">Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2020,</strong> <em>180 </em>, 108297. <a href="https://doi.org/10.1016/j.neuropharm.2020.108297" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2020.108297</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2020.108297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2020.108297%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DNovel%252Bbrain%252Bpermeant%252BmTORC1%25252F2%252Binhibitors%252Bare%252Bas%252Befficacious%252Bas%252Brapamycin%252Bor%252Beverolimus%252Bin%252Bmouse%252Bmodels%252Bof%252Bacquired%252Bpartial%252Bepilepsy%252Band%252Btuberous%252Bsclerosis%252Bcomplex%26aulast%3DTheilmann%26aufirst%3DWiebke%26date%3D2020%26volume%3D180%26spage%3D108297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deze  Zhao</span>, <span class="hlFld-ContribAuthor ">Man  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaochun  Zhang</span>, <span class="hlFld-ContribAuthor ">Helei  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">The role of RICTOR amplification in targeted therapy and drug resistance. </span><span class="cited-content_cbyCitation_journal-name">Molecular Medicine</span><span> <strong>2020,</strong> <em>26 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s10020-020-0146-6" title="DOI URL">https://doi.org/10.1186/s10020-020-0146-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s10020-020-0146-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs10020-020-0146-6%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Medicine%26atitle%3DThe%252Brole%252Bof%252BRICTOR%252Bamplification%252Bin%252Btargeted%252Btherapy%252Band%252Bdrug%252Bresistance%26aulast%3DZhao%26aufirst%3DDeze%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting-Ting  Wu</span>, <span class="hlFld-ContribAuthor ">Qing-Qing  Guo</span>, <span class="hlFld-ContribAuthor ">Zi-Li  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Li  Wang</span>, <span class="hlFld-ContribAuthor ">Yao  Du</span>, <span class="hlFld-ContribAuthor ">Rui  Chen</span>, <span class="hlFld-ContribAuthor ">Yuan-Hu  Mao</span>, <span class="hlFld-ContribAuthor ">Sheng-Gang  Yang</span>, <span class="hlFld-ContribAuthor ">Jing  Huang</span>, <span class="hlFld-ContribAuthor ">Jian-Ta  Wang</span>, <span class="hlFld-ContribAuthor ">Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Tang</span>, <span class="hlFld-ContribAuthor ">Ji-Quan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112637. <a href="https://doi.org/10.1016/j.ejmech.2020.112637" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112637%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbioevaluation%252Bof%252Bnovel%252Bsubstituted%252Btriazines%252Bas%252Bpotential%252Bdual%252BPI3K%25252FmTOR%252Binhibitors%26aulast%3DWu%26aufirst%3DTing-Ting%26date%3D2020%26volume%3D204%26spage%3D112637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaowei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanbo  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects. </span><span class="cited-content_cbyCitation_journal-name">CNS & Neurological Disorders - Drug Targets</span><span> <strong>2020,</strong> <em>19 </em>
                                    (3)
                                     , 165-173. <a href="https://doi.org/10.2174/1871527319666200517112252" title="DOI URL">https://doi.org/10.2174/1871527319666200517112252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871527319666200517112252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871527319666200517112252%26sid%3Dliteratum%253Aachs%26jtitle%3DCNS%2520%2526%2520Neurological%2520Disorders%2520-%2520Drug%2520Targets%26atitle%3DTargeting%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252BSignaling%252BPathway%252Bin%252BPrimary%252BCentral%252BNervous%252BSystem%252BLymphoma%25253A%252BCurrent%252BStatus%252Band%252BFuture%252BProspects%26aulast%3DZhang%26aufirst%3DXiaowei%26date%3D2020%26volume%3D19%26issue%3D3%26spage%3D165%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">Velma Ganga  Reddy</span>, <span class="hlFld-ContribAuthor ">Sonal  Bhandari</span>, <span class="hlFld-ContribAuthor ">T. Srinivasa  Reddy</span>, <span class="hlFld-ContribAuthor ">Ramya  Tokala</span>, <span class="hlFld-ContribAuthor ">Akash P.  Sakla</span>, <span class="hlFld-ContribAuthor ">Suresh K.  Bhargava</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112457. <a href="https://doi.org/10.1016/j.ejmech.2020.112457" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112457%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploration%252Bof%252Bcarbamide%252Bderived%252Bpyrimidine-thioindole%252Bconjugates%252Bas%252Bpotential%252BVEGFR-2%252Binhibitors%252Bwith%252Banti-angiogenesis%252Beffect%26aulast%3DSana%26aufirst%3DSravani%26date%3D2020%26volume%3D200%26spage%3D112457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianyu  Ye</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Ruxin  Wang</span>, <span class="hlFld-ContribAuthor ">Pingzhen  Yan</span>, <span class="hlFld-ContribAuthor ">Shaowei  Chen</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 2,4-bismorpholinothieno[3,2-d]pyrimidine and 2-morpholinothieno[3,2-d]pyrimidinone derivatives as potent antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103796. <a href="https://doi.org/10.1016/j.bioorg.2020.103796" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103796</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103796%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-bismorpholinothieno%25255B3%25252C2-d%25255Dpyrimidine%252Band%252B2-morpholinothieno%25255B3%25252C2-d%25255Dpyrimidinone%252Bderivatives%252Bas%252Bpotent%252Bantitumor%252Bagents%26aulast%3DYe%26aufirst%3DTianyu%26date%3D2020%26volume%3D99%26spage%3D103796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Tarantelli</span>, <span class="hlFld-ContribAuthor ">Antonio  Lupia</span>, <span class="hlFld-ContribAuthor ">Anastasios  Stathis</span>, <span class="hlFld-ContribAuthor ">Francesco  Bertoni</span>. </span><span class="cited-content_cbyCitation_article-title">Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (3)
                                     , 1060. <a href="https://doi.org/10.3390/ijms21031060" title="DOI URL">https://doi.org/10.3390/ijms21031060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21031060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21031060%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DIs%252BThere%252Ba%252BRole%252Bfor%252BDual%252BPI3K%25252FmTOR%252BInhibitors%252Bfor%252BPatients%252BAffected%252Bwith%252BLymphoma%25253F%26aulast%3DTarantelli%26aufirst%3DChiara%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D3%26spage%3D1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob A.  McPhail</span>, <span class="hlFld-ContribAuthor ">John E.  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 203-222. <a href="https://doi.org/10.1007/978-3-030-50621-6_9" title="DOI URL">https://doi.org/10.1007/978-3-030-50621-6_9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-50621-6_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-50621-6_9%26sid%3Dliteratum%253Aachs%26atitle%3DDrugging%252Bthe%252BPhosphoinositide%252B3-Kinase%252B%252528PI3K%252529%252Band%252BPhosphatidylinositol%252B4-Kinase%252B%252528PI4K%252529%252BFamily%252Bof%252BEnzymes%252Bfor%252BTreatment%252Bof%252BCancer%25252C%252BImmune%252BDisorders%25252C%252Band%252BViral%25252FParasitic%252BInfections%26aulast%3DMcPhail%26aufirst%3DJacob%2BA.%26date%3D2020%26date%3D2020%26spage%3D203%26epage%3D222%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDruggable%252BLipid%252BSignaling%252BPathways%26aulast%3DKihara%26aufirst%3DYasuyuki%26date%3D2020%26volume%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Birthe  Gericke</span>, <span class="hlFld-ContribAuthor ">Claudia  Brandt</span>, <span class="hlFld-ContribAuthor ">Wiebke  Theilmann</span>, <span class="hlFld-ContribAuthor ">Lisa  Welzel</span>, <span class="hlFld-ContribAuthor ">Alina  Schidlitzki</span>, <span class="hlFld-ContribAuthor ">Friederike  Twele</span>, <span class="hlFld-ContribAuthor ">Edith  Kaczmarek</span>, <span class="hlFld-ContribAuthor ">Muneeb  Anjum</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Löscher</span>. </span><span class="cited-content_cbyCitation_article-title">Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2020,</strong> <em>162 </em>, 107817. <a href="https://doi.org/10.1016/j.neuropharm.2019.107817" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2019.107817</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2019.107817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2019.107817%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DSelective%252Binhibition%252Bof%252BmTORC1%25252F2%252Bor%252BPI3K%25252FmTORC1%25252F2%252Bsignaling%252Bdoes%252Bnot%252Bprevent%252Bor%252Bmodify%252Bepilepsy%252Bin%252Bthe%252Bintrahippocampal%252Bkainate%252Bmouse%252Bmodel%26aulast%3DGericke%26aufirst%3DBirthe%26date%3D2020%26volume%3D162%26spage%3D107817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monica M.  Kangussu-Marcolino</span>, <span class="hlFld-ContribAuthor ">Gretchen M.  Ehrenkaufer</span>, <span class="hlFld-ContribAuthor ">Emily  Chen</span>, <span class="hlFld-ContribAuthor ">Anjan  Debnath</span>, <span class="hlFld-ContribAuthor ">Upinder  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia. </span><span class="cited-content_cbyCitation_journal-name">International Journal for Parasitology: Drugs and Drug Resistance</span><span> <strong>2019,</strong> <em>11 </em>, 80-94. <a href="https://doi.org/10.1016/j.ijpddr.2019.10.003" title="DOI URL">https://doi.org/10.1016/j.ijpddr.2019.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpddr.2019.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpddr.2019.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520for%2520Parasitology%253A%2520Drugs%2520and%2520Drug%2520Resistance%26atitle%3DIdentification%252Bof%252Bplicamycin%25252C%252BTG02%25252C%252Bpanobinostat%25252C%252Blestaurtinib%25252C%252Band%252BGDC-0084%252Bas%252Bpromising%252Bcompounds%252Bfor%252Bthe%252Btreatment%252Bof%252Bcentral%252Bnervous%252Bsystem%252Binfections%252Bcaused%252Bby%252Bthe%252Bfree-living%252Bamebae%252BNaegleria%25252C%252BAcanthamoeba%252Band%252BBalamuthia%26aulast%3DKangussu-Marcolino%26aufirst%3DMonica%2BM.%26date%3D2019%26volume%3D11%26spage%3D80%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Hua</span>, <span class="hlFld-ContribAuthor ">Qingbin  Kong</span>, <span class="hlFld-ContribAuthor ">Hongying  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Ting  Luo</span>, <span class="hlFld-ContribAuthor ">Yangfu  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting mTOR for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2019,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-019-0754-1" title="DOI URL">https://doi.org/10.1186/s13045-019-0754-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-019-0754-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-019-0754-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DTargeting%252BmTOR%252Bfor%252Bcancer%252Btherapy%26aulast%3DHua%26aufirst%3DHui%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (22)
                                     , 5792. <a href="https://doi.org/10.3390/ijms20225792" title="DOI URL">https://doi.org/10.3390/ijms20225792</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20225792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20225792%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPI3K%25252FmTOR%252BPathway%252BInhibition%25253A%252BOpportunities%252Bin%252BOncology%252Band%252BRare%252BGenetic%252BDiseases%26aulast%3DHillmann%26aufirst%3DPetra%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D22%26spage%3D5792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Weiming  Duan</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Shuai  Mao</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>. </span><span class="cited-content_cbyCitation_article-title">Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (20)
                                     , 114930. <a href="https://doi.org/10.1016/j.bmc.2019.05.043" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.05.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.05.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.05.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAlkylsulfonamide-containing%252Bquinazoline%252Bderivatives%252Bas%252Bpotent%252Band%252Borally%252Bbioavailable%252BPI3Ks%252Binhibitors%26aulast%3DHei%26aufirst%3DYuan-Yuan%26date%3D2019%26volume%3D27%26issue%3D20%26spage%3D114930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guoyi  Yan</span>, <span class="hlFld-ContribAuthor ">Chunlan  Pu</span>, <span class="hlFld-ContribAuthor ">Suke  Lan</span>, <span class="hlFld-ContribAuthor ">Xinxin  Zhong</span>, <span class="hlFld-ContribAuthor ">Meng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xueyan  Hou</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Huifang  Shan</span>, <span class="hlFld-ContribAuthor ">Lifeng  Zhao</span>, <span class="hlFld-ContribAuthor ">Rui  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 667-686. <a href="https://doi.org/10.1016/j.ejmech.2019.06.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-phenyl-2H-benzo%25255Bb%25255D%25255B1%25252C4%25255Doxazin-3%2525284H%252529-one%252Bderivatives%252Bas%252Bpotent%252Band%252Borally%252Bactive%252BPI3K%25252FmTOR%252Bdual%252Binhibitors%26aulast%3DYan%26aufirst%3DGuoyi%26date%3D2019%26volume%3D178%26spage%3D667%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vaishnavi  Sambandam</span>, <span class="hlFld-ContribAuthor ">Mitchell J.  Frederick</span>, <span class="hlFld-ContribAuthor ">Li  Shen</span>, <span class="hlFld-ContribAuthor ">Pan  Tong</span>, <span class="hlFld-ContribAuthor ">Xiayu  Rao</span>, <span class="hlFld-ContribAuthor ">Shaohua  Peng</span>, <span class="hlFld-ContribAuthor ">Ratnakar  Singh</span>, <span class="hlFld-ContribAuthor ">Tuhina  Mazumdar</span>, <span class="hlFld-ContribAuthor ">Chenfei  Huang</span>, <span class="hlFld-ContribAuthor ">Qiuli  Li</span>, <span class="hlFld-ContribAuthor ">Curtis R.  Pickering</span>, <span class="hlFld-ContribAuthor ">Jeffery N.  Myers</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Faye M.  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">PDK1 Mediates
              NOTCH1
              -Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2019,</strong> <em>25 </em>
                                    (11)
                                     , 3329-3340. <a href="https://doi.org/10.1158/1078-0432.CCR-18-3276" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-18-3276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-18-3276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-18-3276%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DPDK1%252BMediates%252BNOTCH1%252B-Mutated%252BHead%252Band%252BNeck%252BSquamous%252BCarcinoma%252BVulnerability%252Bto%252BTherapeutic%252BPI3K%25252FmTOR%252BInhibition%26aulast%3DSambandam%26aufirst%3DVaishnavi%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D11%26spage%3D3329%26epage%3D3340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Tarantelli</span>, <span class="hlFld-ContribAuthor ">Eugenio  Gaudio</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Filippo  Spriano</span>, <span class="hlFld-ContribAuthor ">Giulio  Sartori</span>, <span class="hlFld-ContribAuthor ">Luca  Aresu</span>, <span class="hlFld-ContribAuthor ">Luciano  Cascione</span>, <span class="hlFld-ContribAuthor ">Denise  Rageot</span>, <span class="hlFld-ContribAuthor ">Ivo  Kwee</span>, <span class="hlFld-ContribAuthor ">Florent  Beaufils</span>, <span class="hlFld-ContribAuthor ">Emanuele  Zucca</span>, <span class="hlFld-ContribAuthor ">Anastasios  Stathis</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Vladimir  Cmiljanovic</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>, <span class="hlFld-ContribAuthor ">Francesco  Bertoni</span>. </span><span class="cited-content_cbyCitation_article-title">The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (6)
                                     , 775. <a href="https://doi.org/10.3390/cancers11060775" title="DOI URL">https://doi.org/10.3390/cancers11060775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11060775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11060775%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DThe%252BNovel%252BTORC1%25252F2%252BKinase%252BInhibitor%252BPQR620%252BHas%252BAnti-Tumor%252BActivity%252Bin%252BLymphomas%252Bas%252Ba%252BSingle%252BAgent%252Band%252Bin%252BCombination%252Bwith%252BVenetoclax%26aulast%3DTarantelli%26aufirst%3DChiara%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D6%26spage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Li  Shen</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Liu</span>, <span class="hlFld-ContribAuthor ">Shuyu  Zhan</span>, <span class="hlFld-ContribAuthor ">Baoyue  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-Acrylamido-Quinoline Derivatives as Potent PI3K/mTOR Dual Inhibitors: The Design, Synthesis, and in vitro and in vivo Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2019,</strong> <em>7 </em><a href="https://doi.org/10.3389/fchem.2019.00236" title="DOI URL">https://doi.org/10.3389/fchem.2019.00236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2019.00236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2019.00236%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DNovel%252B4-Acrylamido-Quinoline%252BDerivatives%252Bas%252BPotent%252BPI3K%25252FmTOR%252BDual%252BInhibitors%25253A%252BThe%252BDesign%25252C%252BSynthesis%25252C%252Band%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252BBiological%252BEvaluation%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2019%26date%3D2019%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Swarna A.  Gamage</span>, <span class="hlFld-ContribAuthor ">Julie A.  Spicer</span>, <span class="hlFld-ContribAuthor ">Kit Y.  Tsang</span>, <span class="hlFld-ContribAuthor ">Patrick D.  O'Connor</span>, <span class="hlFld-ContribAuthor ">Jack U.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Woo‐Jeong  Lee</span>, <span class="hlFld-ContribAuthor ">James M. J.  Dickson</span>, <span class="hlFld-ContribAuthor ">Peter R.  Shepherd</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Gordon W.  Rewcastle</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of Imidazo[1,2‐
              a
              ]pyridine Analogues of the ZSTK474 Class of Phosphatidylinositol 3‐Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – An Asian Journal</span><span> <strong>2019,</strong> <em>14 </em>
                                    (8)
                                     , 1249-1261. <a href="https://doi.org/10.1002/asia.201801762" title="DOI URL">https://doi.org/10.1002/asia.201801762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.201801762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.201801762%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520An%2520Asian%2520Journal%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252BImidazo%25255B1%25252C2%2525E2%252580%252590%252Ba%252B%25255Dpyridine%252BAnalogues%252Bof%252Bthe%252BZSTK474%252BClass%252Bof%252BPhosphatidylinositol%252B3%2525E2%252580%252590Kinase%252BInhibitors%26aulast%3DGamage%26aufirst%3DSwarna%2BA.%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D8%26spage%3D1249%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gangadhara  Gangadhara</span>, <span class="hlFld-ContribAuthor ">Göran  Dahl</span>, <span class="hlFld-ContribAuthor ">Thomas  Bohnacker</span>, <span class="hlFld-ContribAuthor ">Rebecca  Rae</span>, <span class="hlFld-ContribAuthor ">Jenny  Gunnarsson</span>, <span class="hlFld-ContribAuthor ">Stefan  Blaho</span>, <span class="hlFld-ContribAuthor ">Linda  Öster</span>, <span class="hlFld-ContribAuthor ">Helena  Lindmark</span>, <span class="hlFld-ContribAuthor ">Kostas  Karabelas</span>, <span class="hlFld-ContribAuthor ">Nils  Pemberton</span>, <span class="hlFld-ContribAuthor ">Christian  Tyrchan</span>, <span class="hlFld-ContribAuthor ">Mickael  Mogemark</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Roger L.  Williams</span>, <span class="hlFld-ContribAuthor ">Matthew W. D.  Perry</span>, <span class="hlFld-ContribAuthor ">Tineke  Papavoine</span>, <span class="hlFld-ContribAuthor ">Jens  Petersen</span>. </span><span class="cited-content_cbyCitation_article-title">A class of highly selective inhibitors bind to an active state of PI3Kγ. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (4)
                                     , 348-357. <a href="https://doi.org/10.1038/s41589-018-0215-0" title="DOI URL">https://doi.org/10.1038/s41589-018-0215-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41589-018-0215-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41589-018-0215-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DA%252Bclass%252Bof%252Bhighly%252Bselective%252Binhibitors%252Bbind%252Bto%252Ban%252Bactive%252Bstate%252Bof%252BPI3K%2525CE%2525B3%26aulast%3DGangadhara%26aufirst%3DGangadhara%26date%3D2019%26date%3D2019%26volume%3D15%26issue%3D4%26spage%3D348%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deyan Y.  Yosifov</span>, <span class="hlFld-ContribAuthor ">Christine  Wolf</span>, <span class="hlFld-ContribAuthor ">Stephan  Stilgenbauer</span>, <span class="hlFld-ContribAuthor ">Daniel  Mertens</span>. </span><span class="cited-content_cbyCitation_article-title">From Biology to Therapy: The CLL Success Story. </span><span class="cited-content_cbyCitation_journal-name">HemaSphere</span><span> <strong>2019,</strong> <em>3 </em>
                                    (2)
                                     , e175. <a href="https://doi.org/10.1097/HS9.0000000000000175" title="DOI URL">https://doi.org/10.1097/HS9.0000000000000175</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/HS9.0000000000000175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FHS9.0000000000000175%26sid%3Dliteratum%253Aachs%26jtitle%3DHemaSphere%26atitle%3DFrom%252BBiology%252Bto%252BTherapy%25253A%252BThe%252BCLL%252BSuccess%252BStory%26aulast%3DYosifov%26aufirst%3DDeyan%2BY.%26date%3D2019%26volume%3D3%26issue%3D2%26spage%3De175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Singarajanahalli Mundarinti Krishna  Reddy</span>, <span class="hlFld-ContribAuthor ">Jagatheeswaran  Kothandapani</span>, <span class="hlFld-ContribAuthor ">Megarajan  Sengan</span>, <span class="hlFld-ContribAuthor ">Anbazhagan  Veerappan</span>, <span class="hlFld-ContribAuthor ">Subramaniapillai  Selva Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the influence of designer surfactant hydrophobicity in key C C/C N bond forming reactions. </span><span class="cited-content_cbyCitation_journal-name">Molecular Catalysis</span><span> <strong>2019,</strong> <em>465 </em>, 80-86. <a href="https://doi.org/10.1016/j.mcat.2019.01.006" title="DOI URL">https://doi.org/10.1016/j.mcat.2019.01.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mcat.2019.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mcat.2019.01.006%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Catalysis%26atitle%3DExploring%252Bthe%252Binfluence%252Bof%252Bdesigner%252Bsurfactant%252Bhydrophobicity%252Bin%252Bkey%252BC%252BC%25252FC%252BN%252Bbond%252Bforming%252Breactions%26aulast%3DReddy%26aufirst%3DSingarajanahalli%2BMundarinti%2BKrishna%26date%3D2019%26volume%3D465%26spage%3D80%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Boulos  Zacharie</span>, <span class="hlFld-ContribAuthor ">Shaun D.  Abbott</span>, <span class="hlFld-ContribAuthor ">Jean‐Simon  Duceppe</span>, <span class="hlFld-ContribAuthor ">Lyne  Gagnon</span>, <span class="hlFld-ContribAuthor ">Brigitte  Grouix</span>, <span class="hlFld-ContribAuthor ">Lilianne  Geerts</span>, <span class="hlFld-ContribAuthor ">Liette  Gervais</span>, <span class="hlFld-ContribAuthor ">François  Sarra‐Bournet</span>, <span class="hlFld-ContribAuthor ">Valérie  Perron</span>, <span class="hlFld-ContribAuthor ">Nicole  Wilb</span>, <span class="hlFld-ContribAuthor ">Christopher L.  Penney</span>, <span class="hlFld-ContribAuthor ">Pierre  Laurin</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of New 1,3,5‐Trisubstituted Triazines for the Treatment of Cancer and Inflammation. </span><span class="cited-content_cbyCitation_journal-name">ChemistryOpen</span><span> <strong>2018,</strong> <em>7 </em>
                                    (9)
                                     , 737-749. <a href="https://doi.org/10.1002/open.201800136" title="DOI URL">https://doi.org/10.1002/open.201800136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/open.201800136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fopen.201800136%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistryOpen%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNew%252B1%25252C3%25252C5%2525E2%252580%252590Trisubstituted%252BTriazines%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%252Band%252BInflammation%26aulast%3DZacharie%26aufirst%3DBoulos%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D9%26spage%3D737%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John E.  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cell</span><span> <strong>2018,</strong> <em>71 </em>
                                    (5)
                                     , 653-673. <a href="https://doi.org/10.1016/j.molcel.2018.08.005" title="DOI URL">https://doi.org/10.1016/j.molcel.2018.08.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molcel.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molcel.2018.08.005%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cell%26atitle%3DStructural%252BBasis%252Bfor%252BRegulation%252Bof%252BPhosphoinositide%252BKinases%252Band%252BTheir%252BInvolvement%252Bin%252BHuman%252BDisease%26aulast%3DBurke%26aufirst%3DJohn%2BE.%26date%3D2018%26volume%3D71%26issue%3D5%26spage%3D653%26epage%3D673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Brandt</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Andreas  Noack</span>, <span class="hlFld-ContribAuthor ">Kerstin  Römermann</span>, <span class="hlFld-ContribAuthor ">Leon A.  Öhler</span>, <span class="hlFld-ContribAuthor ">Denise  Rageot</span>, <span class="hlFld-ContribAuthor ">Florent  Beaufils</span>, <span class="hlFld-ContribAuthor ">Anna  Melone</span>, <span class="hlFld-ContribAuthor ">Alexander M.  Sele</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Löscher</span>. </span><span class="cited-content_cbyCitation_article-title">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2018,</strong> <em>140 </em>, 107-120. <a href="https://doi.org/10.1016/j.neuropharm.2018.08.002" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2018.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2018.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DThe%252Bnovel%25252C%252Bcatalytic%252BmTORC1%25252F2%252Binhibitor%252BPQR620%252Band%252Bthe%252BPI3K%25252FmTORC1%25252F2%252Binhibitor%252BPQR530%252Beffectively%252Bcross%252Bthe%252Bblood-brain%252Bbarrier%252Band%252Bincrease%252Bseizure%252Bthreshold%252Bin%252Ba%252Bmouse%252Bmodel%252Bof%252Bchronic%252Bepilepsy%26aulast%3DBrandt%26aufirst%3DClaudia%26date%3D2018%26volume%3D140%26spage%3D107%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Wicki</span>, <span class="hlFld-ContribAuthor ">Nicholas  Brown</span>, <span class="hlFld-ContribAuthor ">Alexandros  Xyrafas</span>, <span class="hlFld-ContribAuthor ">Vincent  Bize</span>, <span class="hlFld-ContribAuthor ">Hanne  Hawle</span>, <span class="hlFld-ContribAuthor ">Simona  Berardi</span>, <span class="hlFld-ContribAuthor ">Nataša  Cmiljanović</span>, <span class="hlFld-ContribAuthor ">Vladimir  Cmiljanović</span>, <span class="hlFld-ContribAuthor ">Michael  Stumm</span>, <span class="hlFld-ContribAuthor ">Saša  Dimitrijević</span>, <span class="hlFld-ContribAuthor ">Richard  Herrmann</span>, <span class="hlFld-ContribAuthor ">Vincent  Prêtre</span>, <span class="hlFld-ContribAuthor ">Reto  Ritschard</span>, <span class="hlFld-ContribAuthor ">Alexandar  Tzankov</span>, <span class="hlFld-ContribAuthor ">Viviane  Hess</span>, <span class="hlFld-ContribAuthor ">Alexa  Childs</span>, <span class="hlFld-ContribAuthor ">Cinta  Hierro</span>, <span class="hlFld-ContribAuthor ">Jordi  Rodon</span>, <span class="hlFld-ContribAuthor ">Dagmar  Hess</span>, <span class="hlFld-ContribAuthor ">Markus  Joerger</span>, <span class="hlFld-ContribAuthor ">Roger  von Moos</span>, <span class="hlFld-ContribAuthor ">Cristiana  Sessa</span>, <span class="hlFld-ContribAuthor ">Rebecca  Kristeleit</span>. </span><span class="cited-content_cbyCitation_article-title">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Cancer</span><span> <strong>2018,</strong> <em>96 </em>, 6-16. <a href="https://doi.org/10.1016/j.ejca.2018.03.012" title="DOI URL">https://doi.org/10.1016/j.ejca.2018.03.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejca.2018.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejca.2018.03.012%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Cancer%26atitle%3DFirst-in%252Bhuman%25252C%252Bphase%252B1%25252C%252Bdose-escalation%252Bpharmacokinetic%252Band%252Bpharmacodynamic%252Bstudy%252Bof%252Bthe%252Boral%252Bdual%252BPI3K%252Band%252BmTORC1%25252F2%252Binhibitor%252BPQR309%252Bin%252Bpatients%252Bwith%252Badvanced%252Bsolid%252Btumors%252B%252528SAKK%252B67%25252F13%252529%26aulast%3DWicki%26aufirst%3DAndreas%26date%3D2018%26volume%3D96%26spage%3D6%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Audebert</span>, <span class="hlFld-ContribAuthor ">Clémence  Allain</span>. </span><span class="cited-content_cbyCitation_article-title">Triazines, Tetrazines, and Fused Ring Polyaza Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 399-426. <a href="https://doi.org/10.1016/B978-0-08-102788-2.00014-3" title="DOI URL">https://doi.org/10.1016/B978-0-08-102788-2.00014-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102788-2.00014-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102788-2.00014-3%26sid%3Dliteratum%253Aachs%26atitle%3DTriazines%25252C%252BTetrazines%25252C%252Band%252BFused%252BRing%252BPolyaza%252BSystems%26aulast%3DAudebert%26aufirst%3DPierre%26date%3D2018%26spage%3D399%26epage%3D426%26pub%3DElsevier%26date%3D2018%26volume%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Tarantelli</span>, <span class="hlFld-ContribAuthor ">Eugenio  Gaudio</span>, <span class="hlFld-ContribAuthor ">Alberto J.  Arribas</span>, <span class="hlFld-ContribAuthor ">Ivo  Kwee</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Andrea  Rinaldi</span>, <span class="hlFld-ContribAuthor ">Luciano  Cascione</span>, <span class="hlFld-ContribAuthor ">Filippo  Spriano</span>, <span class="hlFld-ContribAuthor ">Elena  Bernasconi</span>, <span class="hlFld-ContribAuthor ">Francesca  Guidetti</span>, <span class="hlFld-ContribAuthor ">Laura  Carrassa</span>, <span class="hlFld-ContribAuthor ">Roberta Bordone  Pittau</span>, <span class="hlFld-ContribAuthor ">Florent  Beaufils</span>, <span class="hlFld-ContribAuthor ">Reto  Ritschard</span>, <span class="hlFld-ContribAuthor ">Denise  Rageot</span>, <span class="hlFld-ContribAuthor ">Alexander  Sele</span>, <span class="hlFld-ContribAuthor ">Barbara  Dossena</span>, <span class="hlFld-ContribAuthor ">Francesca Maria  Rossi</span>, <span class="hlFld-ContribAuthor ">Antonella  Zucchetto</span>, <span class="hlFld-ContribAuthor ">Monica  Taborelli</span>, <span class="hlFld-ContribAuthor ">Valter  Gattei</span>, <span class="hlFld-ContribAuthor ">Davide  Rossi</span>, <span class="hlFld-ContribAuthor ">Anastasios  Stathis</span>, <span class="hlFld-ContribAuthor ">Georg  Stussi</span>, <span class="hlFld-ContribAuthor ">Massimo  Broggini</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Andreas  Wicki</span>, <span class="hlFld-ContribAuthor ">Emanuele  Zucca</span>, <span class="hlFld-ContribAuthor ">Vladimir  Cmiljanovic</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>, <span class="hlFld-ContribAuthor ">Francesco  Bertoni</span>. </span><span class="cited-content_cbyCitation_article-title">PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (1)
                                     , 120-129. <a href="https://doi.org/10.1158/1078-0432.CCR-17-1041" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-1041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-1041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-1041%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DPQR309%252BIs%252Ba%252BNovel%252BDual%252BPI3K%25252FmTOR%252BInhibitor%252Bwith%252BPreclinical%252BAntitumor%252BActivity%252Bin%252BLymphomas%252Bas%252Ba%252BSingle%252BAgent%252Band%252Bin%252BCombination%252BTherapy%26aulast%3DTarantelli%26aufirst%3DChiara%26date%3D2018%26date%3D2017%26volume%3D24%26issue%3D1%26spage%3D120%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonia  Martínez González</span>, <span class="hlFld-ContribAuthor ">Ana Isabel  Hernández</span>, <span class="hlFld-ContribAuthor ">Rosa María  Álvarez</span>, <span class="hlFld-ContribAuthor ">Antonio  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Francisco  Ramos-Lima</span>, <span class="hlFld-ContribAuthor ">James R.  Bischoff</span>, <span class="hlFld-ContribAuthor ">María Isabel  Albarrán</span>, <span class="hlFld-ContribAuthor ">Antonio  Cebriá</span>, <span class="hlFld-ContribAuthor ">Elena  Hernández-Encinas</span>, <span class="hlFld-ContribAuthor ">Jennifer  García-Arocha</span>, <span class="hlFld-ContribAuthor ">David  Cebrián</span>, <span class="hlFld-ContribAuthor ">Carmen  Blanco-Aparicio</span>, <span class="hlFld-ContribAuthor ">Joaquín  Pastor</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel PI3K inhibitors through a scaffold hopping strategy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (21)
                                     , 4794-4799. <a href="https://doi.org/10.1016/j.bmcl.2017.09.059" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.09.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.09.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.09.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252Bnovel%252BPI3K%252Binhibitors%252Bthrough%252Ba%252Bscaffold%252Bhopping%252Bstrategy%26aulast%3DMart%25C3%25ADnez%2BGonz%25C3%25A1lez%26aufirst%3DSonia%26date%3D2017%26volume%3D27%26issue%3D21%26spage%3D4794%26epage%3D4799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of triazine core PI3K inhibitors <b>1</b>, reference compound <b>2</b>, reported clinical candidate <b>3</b>, and pyrimidine or fused pyrimidine core containing molecules <b>4</b>, <b>5</b>, and <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of C-2-Aryl-Substituted 4,6-Dimorpholino-1,3,5-triazine Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ArBpin, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2–16 h, then HCl (aq), 60 °C, 2–8 h; (ii) ArBpin, Pd(dppf)Cl<sub>2</sub> (cat.), Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane/H<sub>2</sub>O, 90 °C, 16 h; (iii) ArBpin, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2 h; (iv) AcCl, K<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C → rt, 3.5 h; (v) HCl (conc), NaNO<sub>2</sub>, 0 °C → rt, 1 h, then CuCl, rt, 1 h; (vi) isopentyl nitrite, CH<sub>2</sub>Br<sub>2</sub>, rt, 5 min, then (CH<sub>3</sub>)<sub>3</sub>SiBr, rt, 1 h; (vii) CH<sub>3</sub>ONH<sub>2</sub>·HCl, NaHCO<sub>3</sub>, DMSO, 100 °C, 6 h. <sup><i>b</i></sup>Compound <b>1</b> was prepared according to the procedure recently reported.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> ArBpin: boronic acid pinacol ester (the amino group was protected in certain cases).</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Interactions of <b>1</b> with the ATP-binding site of PI3Kγ catalytic subunit p110γ and mTOR kinase. (A) Crystal structure of <b>1</b> in PI3Kγ with a resolution of 2.7 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>; <a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S1</a>). Compound <b>1</b> interacts with the hinge valine V882 in PI3Kγ, and its heteroaryl amine function forms hydrogen bonds with the carboxyl groups of aspartates D836, D841, and D964. (B) Overlay of the compound <b>1</b>/PI3Kγ complex coordinates with the compound <b>4</b>/PI3Kγ data from PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5">3SD5</a>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The pyrimidine core nitrogen atom positions are corrected for the orientation as proposed in ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a> (∗ denotes the position of C–H in compound <b>4</b>); the two molecules are oriented exactly as in (A). (C) The coordinates of a mTOR kinase/PI103 complex resolved to 3.6 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>; docked, yellow) and mTOR at a resolution of 3.2 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a>; relaxed, turquoise) were used to dock <b>1</b> into the ATP-binding site of mTOR kinase. The yellow structure represents the results of a manual predocking process (docked) where PI103 was replaced by <b>1</b> with subsequent energy minimization. The turquoise structure represents the best fit of dynamic docking procedures to <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN">4JSN</a> (relaxed starting conditions). Dotted lines indicate proposed H-bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Action of indicated compounds on cell cycle and PI3K and mTOR signaling. Cell cycle distribution of A2058 (A) and SKOV3 (B) cells after 24 h exposure to 5 μM (A) or 2 μM (B) of indicated drugs (<b>1</b>, green; <b>4</b>, red) or DMSO. After drug exposure cells were collected, fixed, permeabilized and the DNA was stained using propidium iodide. Cell cycle profiles were acquired by fluorescence activated cell sorting. Left panels: Examples of cell cycle histograms. Right panels: Quantification of cells in cell cycle phases G1, S, G2/M, and sub-G1 (as % of total, <i>n</i> = 9, mean ± SD, one way ANOVA test with Dunnett’s multiple comparison test for each cell cycle phase related to DMSO; ns, not significant, (∗∗) <i>p</i> > 0.0021, (∗∗∗∗) <i>p</i> > 0.0001). (C, D) A2058 or SKOV3 cells were exposed to 1 μM drug (rapamycin 100 nM) for 1 h, subsequently lysed, and the denatured lysates subjected to SDS–PAGE, Western blotting, and immune detection. (C) Detection of total and phosphorylated (pT308 and pS473) PKB/Akt, and α-tubulin (left, A2058; right, SKOV3). Top: Quantification of phospho-PKB/Akt levels related to DMSO control (blue, pT308; red, pS473; <i>n</i> = 3, mean ± SEM). (D) Detection of total and phosphorylated (pS235/236) ribosomal protein S6 and of total and phosphorylated (S6K T389) S6 kinase (left, A2058; right, SKOV3). Top: Quantification of phospho-protein levels, related to DMSO control (blue, phospho S6; red, phospho S6K; <i>n</i> = 3, mean ± SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cell proliferation in response to <b>1</b> represented as a waterfall blot. Concentrations of half-maximal growth inhibition (GI<sub>50</sub>) for <b>1</b> were obtained from dose–response growth curves derived from 4 different tumor cell line panels (a total of 135 cell lines; if a cell line was contained in several panels, its GI<sub>50</sub> was averaged). Individual GI<sub>50</sub> of a cell line was related to the mean GI<sub>50</sub> of all cells lines, and cell lines were sorted by lowest to highest sensitivity for <b>1</b> from left to right. Individual cell lines and values for the four cell panels are given in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf" class="ext-link">Table S3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK/PD assessment of <b>1</b> in mice, rats, and dogs: time course of <b>1</b> abundance in vivo. Compound <b>1</b> was administered in all species as single dose either per os (po, 10 mg/kg) or via intravenous injection (iv, 5 mg/kg). At indicated time-points <b>1</b> was extracted from tissue and its abundance determined using HPLC/MS–MS. (A) Levels of <b>1</b> in CD1-mice tissue. Right graph: Zoomed view on early time points, indicated in left graph by dashed square (<i>n</i> = 3, mean ± SD). (B) Concentrations of <b>1</b> in tissues from Sprague-Dawly rats. Right graph: Zoomed view on early time points, indicated in left graph by dashed square (<i>n</i> = 3, mean ± SD). (C) Plasma levels of <b>1</b> in male Beagle dogs. Panels on the right: zoomed in to dotted line boxes to visualize early time points (<i>n</i> = 3, mean ± SD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/medium/jm-2017-00930r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Efficacy model for antitumor activity of <b>1</b> in PC3 xenografts in nude rats. (A) Tumor volume: Indicated amounts of <b>1</b> (po, daily) or vinorelbine (iv, weekly) were given from day 17 to day 44 and from day 51 to day 58 after tumor inoculation (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>; <i>n</i> = 4–8, mean ± SEM). (B) Body weight changes in nude rats (treated as in (A), <i>n</i> = 4–8, mean ± SEM). (C) Time course of <b>1</b> abundance in nude rats. Compound <b>1</b> was administered as single dose per os (po, 15 mg/kg). At indicated time points <b>1</b> was extracted from tissue and its abundance determined using HPLC/MS–MS (<i>n</i> = 3, mean ± SD). (D) Time course of blood glucose and insulin levels tumor bearing rats after a single dose of <b>1</b> (15 mg/kg po; <i>n</i> = 3, mean ± SEM; except for time points with values above detection limit). (E) Plasma insulin and (F) plasma glucose concentrations on day 57 of the efficacy model, 4 h after the last administration of <b>1</b> at indicated doses (<i>n</i> = 6–7, mean ± SEM; for insulin levels below detection level, values were set constant to 0.04 [lowest measured value]; for glucose levels above quantification limit, levels were set 20 [upper quantification limit of kit]). (G) Time course of phosphorylation of Ser473 in PKB/Akt in PC3 tumor xenograft lysates after a single dose of <b>1</b> (15  mg/kg po or 10 mg/kg iv). Lysates were subjected to SDS–PAGE and Western blotting. Phosphorylated Ser473 levels were corrected for total PKB/Akt levels and compared to vehicle-treated xenografts (<i>n</i> = 3, mean ± SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00930/20170908/images/large/jm-2017-00930r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00930&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneiter, R.</span><span> </span><span class="NLM_article-title">Lipid signalling in disease</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span><span class="refDoi"> DOI: 10.1038/nrm2335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrm2335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=18216772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=162-176&author=M.+P.+Wymannauthor=R.+Schneiter&title=Lipid+signalling+in+disease&doi=10.1038%2Fnrm2335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid signalling in disease</span></div><div class="casAuthors">Wymann, Matthias P.; Schneiter, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-176</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling lipids such as eicosanoids, phosphoinositides, sphingolipids and fatty acids control important cellular processes, including cell proliferation, apoptosis, metab. and migration.  Extracellular signals from cytokines, growth factors and nutrients control the activity of a key set of lipid-modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase.  These enzymes and their downstream targets constitute a complex lipid signaling network with multiple nodes of interaction and cross-regulation.  Imbalances in this network contribute to the pathogenesis of human disease.  Although the function of a particular signaling lipid is traditionally studied in isolation, this review attempts a more integrated overview of the key role of these signaling lipids in inflammation, cancer and metabolic disease, and discusses emerging strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYZ1NX2T9QbVg90H21EOLACvtfcHk0lj0X0CuLCMHSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D&md5=c96aabfdfa8e93c9e98386f1a407de85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2335%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DSchneiter%26aufirst%3DR.%26atitle%3DLipid%2520signalling%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D162%26epage%3D176%26doi%3D10.1038%2Fnrm2335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Thorpe, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuzugullu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1038/nrc3860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc3860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=25533673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=7-24&author=L.+M.+Thorpeauthor=H.+Yuzugulluauthor=J.+J.+Zhao&title=PI3K+in+cancer%3A+divergent+roles+of+isoforms%2C+modes+of+activation+and+therapeutic+targeting&doi=10.1038%2Fnrc3860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting</span></div><div class="casAuthors">Thorpe, Lauren M.; Yuzugullu, Haluk; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-24</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli.  Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers.  In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxh6fOPe86x7Vg90H21EOLACvtfcHk0lj0X0CuLCMHSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N&md5=0b609a62c2ec9fcc6efae437d2ed7a24</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc3860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3860%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DL.%2BM.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DPI3K%2520in%2520cancer%253A%2520divergent%2520roles%2520of%2520isoforms%252C%2520modes%2520of%2520activation%2520and%2520therapeutic%2520targeting%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D7%26epage%3D24%26doi%3D10.1038%2Fnrc3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Targeting PI3K signalling in cancer: opportunities, challenges and limitations</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nrc2664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc2664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19629070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFylsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=550-562&author=J.+A.+Engelman&title=Targeting+PI3K+signalling+in+cancer%3A+opportunities%2C+challenges+and+limitations&doi=10.1038%2Fnrc2664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K signalling in cancer: opportunities, challenges and limitations</span></div><div class="casAuthors">Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">550-562</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There are ample genetic and lab. studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells.  Inhibitors targeting this pathway are entering the clinic at a rapid pace.  In this Review, the therapeutic potential of drugs targeting PI3K-Akt signaling for the treatment of cancer is discussed.  I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCwdUnGEC20LVg90H21EOLACvtfcHk0lhFl0bup31dqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFylsrg%253D&md5=f0d4cc1fabf879e95f8b76e48cc9c1ad</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2664%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520PI3K%2520signalling%2520in%2520cancer%253A%2520opportunities%252C%2520challenges%2520and%2520limitations%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D550%26epage%3D562%26doi%3D10.1038%2Fnrc2664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Wymann, M.</span><span> </span><span class="NLM_article-title">PI3Ks-Drug targets in inflammation and cancer</span> <span class="citation_source-journal">Subcell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1007/978-94-007-3012-0_5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1007%2F978-94-007-3012-0_5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=22403076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCqsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=111-181&author=M.+Wymann&title=PI3Ks-Drug+targets+in+inflammation+and+cancer&doi=10.1007%2F978-94-007-3012-0_5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Ks - drug targets in inflammation and cancer</span></div><div class="casAuthors">Wymann, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Subcellular Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">Phosphoinositides I: Enzymes of Synthesis and Degradation</span>),
    <span class="NLM_cas:pages">111-181</span>CODEN:
                <span class="NLM_cas:coden">SBCBAG</span>;
        ISSN:<span class="NLM_cas:issn">0306-0225</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3Ks) control cell growth, proliferation, cell survival, metabolic activity, vesicular trafficking, degranulation, and migration.  Through these processes, PI3Ks modulate vital physiol.  When over-activated in disease, PI3K promotes tumor growth, angiogenesis, metastasis or excessive immune cell activation in inflammation, allergy and autoimmunity.  This chapter will introduce mol. activation and signaling of PI3Ks, and connections to target of rapamycin (TOR) and PI3K-related protein kinases (PIKKs).  The focus will be on class I PI3Ks, and extend into current developments to exploit mechanistic knowledge for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyaS7PZJpOk7Vg90H21EOLACvtfcHk0li35UgD0et5BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCqsLzM&md5=9145cabbb88503a95ad462617cf708ab</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2F978-94-007-3012-0_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-94-007-3012-0_5%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%26atitle%3DPI3Ks-Drug%2520targets%2520in%2520inflammation%2520and%2520cancer%26jtitle%3DSubcell.%2520Biochem.%26date%3D2012%26volume%3D58%26spage%3D111%26epage%3D181%26doi%3D10.1007%2F978-94-007-3012-0_5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puglisi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span> </span><span class="NLM_article-title">Treatment of HER2-positive breast cancer: current status and future perspectives</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2011.177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrclinonc.2011.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1CqtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=16-32&author=C.+L.+Arteagaauthor=M.+X.+Sliwkowskiauthor=C.+K.+Osborneauthor=E.+A.+Perezauthor=F.+Puglisiauthor=L.+Gianni&title=Treatment+of+HER2-positive+breast+cancer%3A+current+status+and+future+perspectives&doi=10.1038%2Fnrclinonc.2011.177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of HER2-positive breast cancer: current status and future perspectives</span></div><div class="casAuthors">Arteaga, Carlos L.; Sliwkowski, Mark X.; Osborne, C. Kent; Perez, Edith A.; Puglisi, Fabio; Gianni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-32</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the advent of HER2-directed therapies, many patients with HER2-pos. early stage breast cancer relapse and die of this disease.  Trials to define, refine and optimize the use of the approved HER2-targeted agents are ongoing.  New approaches are being developed and a series of large trials in the adjuvant and neoadjuvant settings are planned or in progress.  In this Review, Arteaga et al. describe the current treatment for HER2-pos. breast cancer and provide an update on ongoing clin. trials and translational research.  The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-pos. early stage breast cancer.  However, a significant proportion of these patients still relapse and die of breast cancer.  Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-pos. early stage breast cancer are ongoing.  In addn., promising new approaches are being developed including monoclonal antibodies and small-mol. tyrosine kinase inhibitors targeting HER2 or other HER family members, antibodies linked to cytotoxic moieties or modified to improve their immunol. function, immunostimulatory peptides, and targeting the PI3K and IGF-1R pathways.  Improved understanding of the HER2 signaling pathway, its relationship with other signaling pathways and mechanisms of resistance has also led to the development of rational combination therapies and to a greater insight into treatment response in patients with HER2-pos. breast cancer.  Based on promising results with new agents in HER2-pos. advanced-stage disease, a series of large trials in the adjuvant and neoadjuvant settings are planned or ongoing.  This Review focuses on current treatment for patients with HER2-pos. breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clin. trials and translational research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxxTh8iuH1BLVg90H21EOLACvtfcHk0li35UgD0et5BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1CqtbbI&md5=5d0f876567faecaf49327eb3f1b4b7f1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.177%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DPuglisi%26aufirst%3DF.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DTreatment%2520of%2520HER2-positive%2520breast%2520cancer%253A%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D16%26epage%3D32%26doi%3D10.1038%2Fnrclinonc.2011.177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Sun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aceto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meerbrey, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, D. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlova, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardi, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dephoure, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilsenbeck, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzny, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentires-Alj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elledge, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, T. F.</span><span> </span><span class="NLM_article-title">Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">703</span><span class="NLM_x">–</span> <span class="NLM_lpage">718</span><span class="refDoi"> DOI: 10.1016/j.cell.2011.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.cell.2011.02.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=703-718&author=T.+Sunauthor=N.+Acetoauthor=K.+L.+Meerbreyauthor=J.+D.+Kesslerauthor=C.+Zhouauthor=I.+Migliaccioauthor=D.+X.+Nguyenauthor=N.+N.+Pavlovaauthor=M.+Boteroauthor=J.+Huangauthor=R.+J.+Bernardiauthor=E.+Schmittauthor=G.+Huauthor=M.+Z.+Liauthor=N.+Dephoureauthor=S.+P.+Gygiauthor=M.+Raoauthor=C.+J.+Creightonauthor=S.+G.+Hilsenbeckauthor=C.+A.+Shawauthor=D.+Muznyauthor=R.+A.+Gibbsauthor=D.+A.+Wheelerauthor=C.+K.+Osborneauthor=R.+Schiffauthor=M.+Bentires-Aljauthor=S.+J.+Elledgeauthor=T.+F.+Westbrook&title=Activation+of+multiple+proto-oncogenic+tyrosine+kinases+in+breast+cancer+via+loss+of+the+PTPN12+phosphatase&doi=10.1016%2Fj.cell.2011.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DT.%26aulast%3DAceto%26aufirst%3DN.%26aulast%3DMeerbrey%26aufirst%3DK.%2BL.%26aulast%3DKessler%26aufirst%3DJ.%2BD.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DMigliaccio%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DD.%2BX.%26aulast%3DPavlova%26aufirst%3DN.%2BN.%26aulast%3DBotero%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DBernardi%26aufirst%3DR.%2BJ.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DM.%2BZ.%26aulast%3DDephoure%26aufirst%3DN.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DShaw%26aufirst%3DC.%2BA.%26aulast%3DMuzny%26aufirst%3DD.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DWheeler%26aufirst%3DD.%2BA.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DBentires-Alj%26aufirst%3DM.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26atitle%3DActivation%2520of%2520multiple%2520proto-oncogenic%2520tyrosine%2520kinases%2520in%2520breast%2520cancer%2520via%2520loss%2520of%2520the%2520PTPN12%2520phosphatase%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D703%26epage%3D718%26doi%3D10.1016%2Fj.cell.2011.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Samuels, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ericson, K.</span><span> </span><span class="NLM_article-title">Oncogenic PI3K and its role in cancer</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1097/01.cco.0000198021.99347.b9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1097%2F01.cco.0000198021.99347.b9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16357568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlahu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2006&pages=77-82&author=Y.+Samuelsauthor=K.+Ericson&title=Oncogenic+PI3K+and+its+role+in+cancer&doi=10.1097%2F01.cco.0000198021.99347.b9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic PI3K and its role in cancer</span></div><div class="casAuthors">Samuels, Yardena; Ericson, Kajsa</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-82</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The purpose of this review is to examine the contribution of the PI3K signaling pathway to the development of human tumors and to propose further studies to elucidate how to develop therapeutics for patients with mutations in this pathway.  Recent findings: More than 30% of various solid tumor types were recently found to contain mutations in PIK3CA, the catalytic subunit of PI3K.  Further anal. of key genes in this pathway identified an addnl. eight genes altered in tumors.  These were generally found to be mutated in a mutually exclusive manner, thus increasing the mutation frequency of the pathway to 40% in colorectal cancers and emphasizing the importance of the PI3K pathway in tumorigenesis.  Functional analyses of PIK3CA mutations revealed that they increase its enzymic activity, stimulate AKT signaling, allow growth factor-independent growth as well as increasing cell invasion and metastasis.  Summary: The PI3K signaling pathway is dysregulated by a variety of mechanisms in a large fraction of human tumors.  Both mutational and functional analyses have shown that PIK3CA is an oncogene that plays an important role in tumor progression.  Mutant members of the PI3K pathway, including PIK3CA, are good targets for therapeutic intervention because most of them are kinases, making them attractive for drug development.  Gaining further insights into PIK3CA oncogenic mechanisms may produce new biomarkers and help the development of targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5GUGZgvUSVrVg90H21EOLACvtfcHk0lgBBuGbYNjcrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlahu73P&md5=6a4504dd3201451956dc862b105e610e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2F01.cco.0000198021.99347.b9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cco.0000198021.99347.b9%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DEricson%26aufirst%3DK.%26atitle%3DOncogenic%2520PI3K%2520and%2520its%2520role%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2006%26volume%3D18%26spage%3D77%26epage%3D82%26doi%3D10.1097%2F01.cco.0000198021.99347.b9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hollander, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, P. A.</span><span> </span><span class="NLM_article-title">PTEN loss in the continuum of common cancers, rare syndromes and mouse models</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1038/nrc3037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc3037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=21430697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1CqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=289-301&author=M.+C.+Hollanderauthor=G.+M.+Blumenthalauthor=P.+A.+Dennis&title=PTEN+loss+in+the+continuum+of+common+cancers%2C+rare+syndromes+and+mouse+models&doi=10.1038%2Fnrc3037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN loss in the continuum of common cancers, rare syndromes and mouse models</span></div><div class="casAuthors">Hollander, M. Christine; Blumenthal, Gideon M.; Dennis, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-301</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PTEN is among the most frequently inactivated tumor suppressor genes in sporadic cancer.  PTEN has dual protein and lipid phosphatase activity, and its tumor suppressor activity is dependent on its lipid phosphatase activity, which neg. regulates the PI3K-AKT-mTOR pathway.  Germline mutations in PTEN have been described in a variety of rare syndromes that are collectively known as the PTEN hamartoma tumor syndromes (PHTS).  Cowden syndrome is the best-described syndrome within PHTS, with approx. 80% of patients having germline PTEN mutations.  Patients with Cowden syndrome have an increased incidence of cancers of the breast, thyroid and endometrium, which correspond to sporadic tumor types that commonly exhibit somatic PTEN inactivation.  Pten deletion in mice leads to Cowden syndrome-like phenotypes, and tissue-specific Pten deletion has provided clues to the role of PTEN mutation and loss in specific tumor types.  Studying PTEN in the continuum of rare syndromes, common cancers and mouse models provides insight into the role of PTEN in tumorigenesis and will inform targeted drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn2C-Gc5BQ_bVg90H21EOLACvtfcHk0lgBBuGbYNjcrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1CqsLc%253D&md5=328ccdcbc50d15d2772ae8fb0d6580a4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc3037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3037%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DM.%2BC.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DDennis%26aufirst%3DP.%2BA.%26atitle%3DPTEN%2520loss%2520in%2520the%2520continuum%2520of%2520common%2520cancers%252C%2520rare%2520syndromes%2520and%2520mouse%2520models%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D289%26epage%3D301%26doi%3D10.1038%2Fnrc3037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gewinner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teruya-Feldstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etemadmoghadam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowtell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rameh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmena, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1016/j.ccr.2009.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.ccr.2009.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19647222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCjsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=115-125&author=C.+Gewinnerauthor=Z.+C.+Wangauthor=A.+Richardsonauthor=J.+Teruya-Feldsteinauthor=D.+Etemadmoghadamauthor=D.+Bowtellauthor=J.+Barretinaauthor=W.+M.+Linauthor=L.+Ramehauthor=L.+Salmenaauthor=P.+P.+Pandolfiauthor=L.+C.+Cantley&title=Evidence+that+inositol+polyphosphate+4-phosphatase+type+II+is+a+tumor+suppressor+that+inhibits+PI3K+signaling&doi=10.1016%2Fj.ccr.2009.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</span></div><div class="casAuthors">Gewinner, Christina; Wang, Zhigang C.; Richardson, Andrea; Teruya-Feldstein, Julie; Etemadmoghadam, Dariush; Bowtell, David; Barretina, Jordi; Lin, William M.; Rameh, Lucia; Salmena, Leonardo; Pandolfi, Pier Paolo; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that knocking down the expression of inositol polyphosphate 4-phosphatase type II (INPP4B) in human epithelial cells, like knockdown of PTEN, resulted in enhanced Akt activation and anchorage-independent growth and enhanced overall motility.  In xenograft expts., overexpression of INPP4B resulted in reduced tumor growth.  INPP4B preferentially hydrolyzes phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) with no effect on phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3), suggesting that PI(3,4)P2 and PI(3,4,5)P3 may cooperate in Akt activation and cell transformation.  Dual knockdown of INPP4B and PTEN resulted in cellular senescence.  Finally, we found loss of heterozygosity (LOH) at the INPP4B locus in a majority of basal-like breast cancers, as well as in a significant fraction of ovarian cancers, which correlated with lower overall patient survival, suggesting that INPP4B is a tumor suppressor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOv8VFGY_XorVg90H21EOLACvtfcHk0lgBBuGbYNjcrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCjsrfL&md5=c7c4d81e03f1f8b515a7a6cb3c6864f9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DGewinner%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%2BC.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DEtemadmoghadam%26aufirst%3DD.%26aulast%3DBowtell%26aufirst%3DD.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DW.%2BM.%26aulast%3DRameh%26aufirst%3DL.%26aulast%3DSalmena%26aufirst%3DL.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DEvidence%2520that%2520inositol%2520polyphosphate%25204-phosphatase%2520type%2520II%2520is%2520a%2520tumor%2520suppressor%2520that%2520inhibits%2520PI3K%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D115%26epage%3D125%26doi%3D10.1016%2Fj.ccr.2009.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span><span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0li79zFqKyQ7aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">Inhibition of the PI3K/AKT/mTOR pathway in solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3803</span><span class="NLM_x">–</span> <span class="NLM_lpage">3815</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.0018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1200%2FJCO.2014.59.0018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=3803-3815&author=P.+M.+LoRusso&title=Inhibition+of+the+PI3K%2FAKT%2FmTOR+pathway+in+solid+tumors&doi=10.1200%2FJCO.2014.59.0018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.0018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.0018%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DInhibition%2520of%2520the%2520PI3K%252FAKT%252FmTOR%2520pathway%2520in%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D3803%26epage%3D3815%26doi%3D10.1200%2FJCO.2014.59.0018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Bohnacker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaufils, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglis, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rageot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sele, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhmanova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">14683</span><span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+D%C3%ADazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eZNGKeBz-CZKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yaguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koshimizu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span> </span><span class="NLM_article-title">Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span><span class="refDoi"> DOI: 10.1093/jnci/djj133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1093%2Fjnci%2Fdjj133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16622124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XjslOjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=545-556&author=S.+Yaguchiauthor=Y.+Fukuiauthor=I.+Koshimizuauthor=H.+Yoshimiauthor=T.+Matsunoauthor=H.+Goudaauthor=S.+Hironoauthor=K.+Yamazakiauthor=T.+Yamori&title=Antitumor+activity+of+ZSTK474%2C+a+new+phosphatidylinositol+3-kinase+inhibitor&doi=10.1093%2Fjnci%2Fdjj133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor</span></div><div class="casAuthors">Yaguchi, Shin-ichi; Fukui, Yasuhisa; Koshimizu, Ichiro; Yoshimi, Hisashi; Matsuno, Toshiyuki; Gouda, Hiroaki; Hirono, Shuichi; Yamazaki, Kanami; Yamori, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: We previously synthesized a novel s-triazine deriv., ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], that strongly inhibited the growth of tumor cells.  We identified its mol. target, investigated its effects on cellular signaling pathways, and examd. its antitumor efficacy and toxicity in vivo.  Methods: We used COMPARE anal. of chemosensitivity measurements from 39 human cancer cell lines and identified phosphatidylinositol 3-kinase (PI3K) as a mol. target for ZSTK474.  PI3K was immunopptd. from A549 cell lysates, and its activity was measured by assessing the incorporation of 32P into phosphatidylinositol.  We used the crystal structure of the PI3K-LY294002 complex to model the binding of ZSTK474 to PI3K (where LY294002 is a known PI3K inhibitor).  PI3K downstream activity was analyzed by immunoblotting.  Antitumor activity of ZSTK474 was examd. against A549, PC-3, and WiDr xenografts in nude mice.  Phosphorylation of Akt, a serine/threonine protein kinase and a major signaling component downstream of PI3K, was assessed in vivo by immunohistochem.  Results: PI3K was identified as a mol. target for ZSTK474 by COMPARE anal.  We confirmed that ZSTK474 directly inhibited PI3K activity more efficiently than the PI3K inhibitor LY294002.  At concns. of 1 μM, ZSTK474 and LY2194002 reduced PI3K activity to 4.7% (95% confidence interval [CI] = 3.2% to 6.1%) and 44.6% (95% CI = 38.9% to 50.3%), resp., of the untreated control level.  Mol. modeling of the PI3K-ZSTK474 complex indicated that ZSTK474 could bind to the ATP-binding pocket of PI3K.  ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3β, and mediated a decrease in cyclin D1 levels.  ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in crit. organs.  Akt phosphorylation was reduced in xenograft tumors after oral administration of ZSTK474.  Conclusion: ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in crit. organs.  ZSTK474 merits further investigation as an anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0v8LFKdruLVg90H21EOLACvtfcHk0lgm0EIe57Rwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjslOjsLw%253D&md5=a2593024975536089ab2ee7e53234ebc</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjj133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjj133%26sid%3Dliteratum%253Aachs%26aulast%3DYaguchi%26aufirst%3DS.%26aulast%3DFukui%26aufirst%3DY.%26aulast%3DKoshimizu%26aufirst%3DI.%26aulast%3DYoshimi%26aufirst%3DH.%26aulast%3DMatsuno%26aufirst%3DT.%26aulast%3DGouda%26aufirst%3DH.%26aulast%3DHirono%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DYamori%26aufirst%3DT.%26atitle%3DAntitumor%2520activity%2520of%2520ZSTK474%252C%2520a%2520new%2520phosphatidylinositol%25203-kinase%2520inhibitor%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2006%26volume%3D98%26spage%3D545%26epage%3D556%26doi%3D10.1093%2Fjnci%2Fdjj133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamage, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baguley, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kestell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lill, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, P. R.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7105</span><span class="NLM_x">–</span> <span class="NLM_lpage">7126</span><span class="refDoi"> DOI: 10.1021/jm200688y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200688y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7105-7126&author=G.+W.+Rewcastleauthor=S.+A.+Gamageauthor=J.+U.+Flanaganauthor=R.+Frederickauthor=W.+A.+Dennyauthor=B.+C.+Baguleyauthor=P.+Kestellauthor=R.+Singhauthor=J.+D.+Kendallauthor=E.+S.+Marshallauthor=C.+L.+Lillauthor=W.+J.+Leeauthor=S.+Kolekarauthor=C.+M.+Buchananauthor=S.+M.+Jamiesonauthor=P.+R.+Shepherd&title=Synthesis+and+biological+evaluation+of+novel+analogues+of+the+pan+class+I+phosphatidylinositol+3-kinase+%28PI3K%29+inhibitor+2-%28difluoromethyl%29-1-%5B4%2C6-di%284-morpholinyl%29-1%2C3%2C5-triazin-2-yl%5D-1H-benzimidazole+%28ZSTK474%29&doi=10.1021%2Fjm200688y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-Kinase (PI3K) inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)</span></div><div class="casAuthors">Rewcastle, Gordon W.; Gamage, Swarna A.; Flanagan, Jack U.; Frederick, Raphael; Denny, William A.; Baguley, Bruce C.; Kestell, Philip; Singh, Ripudaman; Kendall, Jackie D.; Marshall, Elaine S.; Lill, Claire L.; Lee, Woo-Jeong; Kolekar, Sharada; Buchanan, Christina M.; Jamieson, Stephen M. F.; Shepherd, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7105-7126</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-activity relationship (SAR) study of the pan class I PI 3-kinase inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474) I identified substitution at the 4 and 6 positions of the benzimidazole ring as having significant effects on the potency of substituted derivs.  The 6-amino-4-methoxy analog II displayed a greater than 1000-fold potency enhancement over the corresponding 6-aza-4-methoxy III analog against all three class Ia PI 3-kinase enzymes (p110α, p110β, and p110δ) and also displayed significant potency against two mutant forms of the p110α isoform (H1047R and E545K).  This compd. was also evaluated in vivo against a U87MG human glioblastoma tumor xenograft model in Rag1-/- mice, and at a dose of 50 mg/kg given by i.p. injection at a qd × 10 dosing schedule it dramatically reduced cancer growth by 81% compared to untreated controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqirsalawdjHrVg90H21EOLACvtfcHk0lgm0EIe57Rwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7rJ&md5=250fb3eeb02505e2a5b24fd511ec94f3</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1021%2Fjm200688y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200688y%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DGamage%26aufirst%3DS.%2BA.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DFrederick%26aufirst%3DR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DKestell%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DMarshall%26aufirst%3DE.%2BS.%26aulast%3DLill%26aufirst%3DC.%2BL.%26aulast%3DLee%26aufirst%3DW.%2BJ.%26aulast%3DKolekar%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DC.%2BM.%26aulast%3DJamieson%26aufirst%3DS.%2BM.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520analogues%2520of%2520the%2520pan%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%2520inhibitor%25202-%2528difluoromethyl%2529-1-%255B4%252C6-di%25284-morpholinyl%2529-1%252C3%252C5-triazin-2-yl%255D-1H-benzimidazole%2520%2528ZSTK474%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7105%26epage%3D7126%26doi%3D10.1021%2Fjm200688y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Brachmann, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleylein-Sohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaulis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blommers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazic-Legueux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laborde, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattenberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaxelaire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guthy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruemmendorf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span> </span><span class="NLM_article-title">Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1747</span><span class="NLM_x">–</span> <span class="NLM_lpage">1757</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-1021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1158%2F1535-7163.MCT-11-1021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=22653967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1747-1757&author=S.+M.+Brachmannauthor=J.+Kleylein-Sohnauthor=S.+Gaulisauthor=A.+Kauffmannauthor=M.+J.+Blommersauthor=M.+Kazic-Legueuxauthor=L.+Labordeauthor=M.+Hattenbergerauthor=F.+Staufferauthor=J.+Vaxelaireauthor=V.+Romanetauthor=C.+Henryauthor=M.+Murakamiauthor=D.+Guthyauthor=D.+Sterkerauthor=S.+Berglingauthor=C.+Wilsonauthor=T.+Bruemmendorfauthor=C.+Fritschauthor=C.+Garcia-Echeverriaauthor=W.+R.+Sellersauthor=F.+Hofmannauthor=S.+M.+Maira&title=Characterization+of+the+mechanism+of+action+of+the+pan+class+I+PI3K+inhibitor+NVP-BKM120+across+a+broad+range+of+concentrations&doi=10.1158%2F1535-7163.MCT-11-1021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations</span></div><div class="casAuthors">Brachmann, Saskia M.; Kleylein-Sohn, Julia; Gaulis, Swann; Kauffmann, Audrey; Blommers, Marcel J. J.; Kazic-Legueux, Malika; Laborde, Laurent; Hattenberger, Marc; Stauffer, Fabian; Vaxelaire, Juliane; Romanet, Vincent; Henry, Chrystele; Murakami, Masato; Guthy, Daniel Alexander; Sterker, Dario; Bergling, Sebastian; Wilson, Christopher; Bruemmendorf, Thomas; Fritsch, Christine; Garcia-Echeverria, Carlos; Sellers, William R.; Hofmann, Francesco; Maira, Sauveur-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1747-1757</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The pan-phosphoinositide 3-kinase (PI3K) inhibitor BKM120 was found, at high concns., to cause cell death in various cellular systems, irresp. of their level of PI3K addiction.  Transcriptional and biochem. profiling studies were used to identify the origin of these unexpected and apparently PI3K-independent effects.  At 5- to 10-fold, the concn. needed to half-maximally inhibit PI3K signaling.  BKM120 treatment caused changes in expression of mitotic genes and the induction of a robust G2-M arrest.  Tubulin polymn. assays and NMR-binding studies revealed that BKM120 inhibited microtubule dynamics upon direct binding to tubulin.  To assess the contribution of this off-target activity vis-a-vis the antitumor activity of BKM120 in PI3K-dependent tumors, we used a mechanistic PI3K-α-dependent model.  We obsd. that, in vivo, daily treatment of mice with doses of BKM120 up to 40 mg/kg led to tumor regressions with no increase in the mitotic index.  Thus, strong antitumor activity can be achieved in PI3K-dependent models at exposures that are below those necessary to engage the off-target activity.  In comparison, the clin. data indicate that it is unlikely that BKM120 will achieve exposures sufficient to significantly engage the off-target activity at tolerated doses and schedules.  However, in preclin. settings, the consequences of the off-target activity start to manifest themselves at concns. above 1 μmol/L in vitro and doses above 50 mg/kg in efficacy studies using s.c. tumor-bearing mice.  Hence, careful concn. and dose range selection is required to ensure that any observation can be correctly attributed to BKM120 inhibition of PI3K.  Mol Cancer Ther; 11(8); 1747-57. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKHhs5m02qfrVg90H21EOLACvtfcHk0lhHhmkma4d1mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrM&md5=26f5cd3377b49f9e61a092191d86194b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1021%26sid%3Dliteratum%253Aachs%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DKleylein-Sohn%26aufirst%3DJ.%26aulast%3DGaulis%26aufirst%3DS.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DBlommers%26aufirst%3DM.%2BJ.%26aulast%3DKazic-Legueux%26aufirst%3DM.%26aulast%3DLaborde%26aufirst%3DL.%26aulast%3DHattenberger%26aufirst%3DM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DVaxelaire%26aufirst%3DJ.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DBergling%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBruemmendorf%26aufirst%3DT.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26atitle%3DCharacterization%2520of%2520the%2520mechanism%2520of%2520action%2520of%2520the%2520pan%2520class%2520I%2520PI3K%2520inhibitor%2520NVP-BKM120%2520across%2520a%2520broad%2520range%2520of%2520concentrations%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1747%26epage%3D1757%26doi%3D10.1158%2F1535-7163.MCT-11-1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Elkabets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juric, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muranen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrik-Outmezguine, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">196ra99</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3005747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1126%2Fscitranslmed.3005747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=23903756" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=196ra99&author=M.+Elkabetsauthor=S.+Voraauthor=D.+Juricauthor=N.+Morseauthor=M.+Mino-Kenudsonauthor=T.+Muranenauthor=J.+Taoauthor=A.+B.+Camposauthor=J.+Rodonauthor=Y.+H.+Ibrahimauthor=V.+Serraauthor=V.+Rodrik-Outmezguineauthor=S.+Hazraauthor=S.+Singhauthor=P.+Kimauthor=C.+Quadtauthor=M.+Liuauthor=A.+Huangauthor=N.+Rosenauthor=J.+A.+Engelmanauthor=M.+Scaltritiauthor=J.+Baselga&title=mTORC1+inhibition+is+required+for+sensitivity+to+PI3K+p110alpha+inhibitors+in+PIK3CA-mutant+breast+cancer&doi=10.1126%2Fscitranslmed.3005747"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005747%26sid%3Dliteratum%253Aachs%26aulast%3DElkabets%26aufirst%3DM.%26aulast%3DVora%26aufirst%3DS.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DMorse%26aufirst%3DN.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DMuranen%26aufirst%3DT.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DCampos%26aufirst%3DA.%2BB.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DY.%2BH.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DRodrik-Outmezguine%26aufirst%3DV.%26aulast%3DHazra%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DmTORC1%2520inhibition%2520is%2520required%2520for%2520sensitivity%2520to%2520PI3K%2520p110alpha%2520inhibitors%2520in%2520PIK3CA-mutant%2520breast%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26spage%3D196ra99%26doi%3D10.1126%2Fscitranslmed.3005747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Zoncu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efeyan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">mTOR: from growth signal integration to cancer, diabetes and ageing</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1038/nrm3025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrm3025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=21157483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGqsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=21-35&author=R.+Zoncuauthor=A.+Efeyanauthor=D.+M.+Sabatini&title=mTOR%3A+from+growth+signal+integration+to+cancer%2C+diabetes+and+ageing&doi=10.1038%2Fnrm3025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR: from growth signal integration to cancer, diabetes and ageing</span></div><div class="casAuthors">Zoncu, Roberto; Efeyan, Alejo; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-35</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In all eukaryotes, the target of rapamycin (TOR) signalling pathway couples energy and nutrient abundance to the execution of cell growth and division, owing to the ability of TOR protein kinase to simultaneously sense energy, nutrients and stress and, in metazoans, growth factors.  Mammalian TOR complex 1 (mTORC1) and mTORC2 exert their actions by regulating other important kinases, such as S6 kinase (S6K) and Akt.  In the past few years, a significant advance in our understanding of the regulation and functions of mTOR has revealed the crucial involvement of this signalling pathway in the onset and progression of diabetes, cancer and aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfHzFJues0NLVg90H21EOLACvtfcHk0liOJe3aelFeEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGqsbnK&md5=3631307dc34df2ecc2eb79900c10b74c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrm3025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3025%26sid%3Dliteratum%253Aachs%26aulast%3DZoncu%26aufirst%3DR.%26aulast%3DEfeyan%26aufirst%3DA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%253A%2520from%2520growth%2520signal%2520integration%2520to%2520cancer%252C%2520diabetes%2520and%2520ageing%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D21%26epage%3D35%26doi%3D10.1038%2Fnrm3025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Marone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Targeting phosphoinositide 3-kinase: moving towards therapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1784</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2007.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.bbapap.2007.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=17997386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1784&publication_year=2008&pages=159-185&author=R.+Maroneauthor=V.+Cmiljanovicauthor=B.+Gieseauthor=M.+P.+Wymann&title=Targeting+phosphoinositide+3-kinase%3A+moving+towards+therapy&doi=10.1016%2Fj.bbapap.2007.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase-Moving towards therapy</span></div><div class="casAuthors">Marone, Romina; Cmiljanovic, Vladimir; Giese, Bernd; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1784</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">159-185</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3K) orchestrate cell responses including mitogenic signaling, cell survival and growth, metabolic control, vesicular trafficking, degranulation, cytoskeletal rearrangement and migration.  Deregulation of the PI3K pathway occurs by activating mutations in growth factor receptors or the PIK3CA locus coding for PI3Kα, by loss of function of the lipid phosphatase and tensin homolog deleted in chromosome ten (PTEN/MMAC/TEP1), by the up-regulation of protein kinase B (PKB/Akt), or the impairment of the tuberous sclerosis complex (TSC1/2).  All these events are linked to growth and proliferation, and have thus prompted a significant interest in the pharmaceutical targeting of the PI3K pathway in cancer.  Genetic targeting of PI3Kγ (p110γ) and PI3Kδ (p110δ) in mice has underlined a central role of these PI3K isoforms in inflammation and allergy, as they modulate chemotaxis of leukocytes and degranulation in mast cells.  Proof-of-concept mols. selective for PI3Kγ have already successfully alleviated disease progress in murine models of rheumatoid arthritis and lupus erythematosus.  As targeting PI3K moves forward to therapy of chronic, non-fatal disease, safety concerns for PI3K inhibitors increase.  Many of the present inhibitor series interfere with target of rapamycin (TOR), DNA-dependent protein kinase (DNA-PKcs) and activity of the ataxia telangiectasia mutated gene product (ATM).  Here we review the current disease-relevant knowledge for isoform-specific PI3K function in the above mentioned diseases, and review the progress of > 400 recent patents covering pharmaceutical targeting of PI3K.  Currently, several drugs targeting the PI3K pathway have entered clin. trials (phase I) for solid tumors and suppression of tissue damage after myocardial infarction (phases I,II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwrI_aSA632bVg90H21EOLACvtfcHk0liOJe3aelFeEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D&md5=bf9f259b3da61067631823656658e0f7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2007.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2007.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520phosphoinositide%25203-kinase%253A%2520moving%2520towards%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2008%26volume%3D1784%26spage%3D159%26epage%3D185%26doi%3D10.1016%2Fj.bbapap.2007.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Marone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erhart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertz, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohnacker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">613</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1158%2F1541-7786.MCR-08-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19372588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1anur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=601-613&author=R.+Maroneauthor=D.+Erhartauthor=A.+C.+Mertzauthor=T.+Bohnackerauthor=C.+Schnellauthor=V.+Cmiljanovicauthor=F.+Staufferauthor=C.+Garcia-Echeverriaauthor=B.+Gieseauthor=S.+M.+Mairaauthor=M.+P.+Wymann&title=Targeting+melanoma+with+dual+phosphoinositide+3-kinase%2Fmammalian+target+of+rapamycin+inhibitors&doi=10.1158%2F1541-7786.MCR-08-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors</span></div><div class="casAuthors">Marone, Romina; Erhart, Dominik; Mertz, Ann C.; Bohnacker, Thomas; Schnell, Christian; Cmiljanovic, Vladimir; Stauffer, Frederic; Garcia-Echeverria, Carlos; Giese, Bernd; Maira, Sauveur-Michel; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-613</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K)/protein kinase B/Akt and Ras/mitogen-activated protein kinase pathways are often constitutively activated in melanoma and have thus been considered as promising drug targets.  Exposure of melanoma cells to NVP-BAG956, NVP-BBD130, and NVP-BEZ235, a series of novel, potent, and stable dual PI3K/mammalian target of rapamycin (mTOR) inhibitors, resulted in complete G1 growth arrest, redn. of cyclin D1, and increased levels of p27KIP1, but negligible apoptosis.  In contrast, treatment of melanoma with the pan-class I PI3K inhibitor ZSTK474 or the mTORC1 inhibitor rapamycin resulted only in minor redn. of cell proliferation.  In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity.  Metastatic melanoma in inhibitor-treated mice displayed reduced nos. of proliferating and significantly smaller tumor cells.  In addn., neovascularization was blocked and tumoral necrosis increased when compared with vehicle-treated mice.  In conclusion, compds. targeting PI3K and mTOR simultaneously were advantageous to attenuate melanoma growth and they develop their potential by targeting tumor growth directly, and indirectly via their interference with angiogenesis.  Based on the above results, NVP-BEZ235, which has entered phase I/II clin. trials in patients with advanced solid tumors, has a potential in metastatic melanoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo75H1e5k7uxrVg90H21EOLACvtfcHk0liOJe3aelFeEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1anur8%253D&md5=1098c3d2f8e0c169550adb0409fff1e2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0366%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DErhart%26aufirst%3DD.%26aulast%3DMertz%26aufirst%3DA.%2BC.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520melanoma%2520with%2520dual%2520phosphoinositide%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2009%26volume%3D7%26spage%3D601%26epage%3D613%26doi%3D10.1158%2F1541-7786.MCR-08-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Corcoran, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faber, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazarian, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winokur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">196ra98</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3005753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1126%2Fscitranslmed.3005753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=23903755" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=196ra98&author=R.+B.+Corcoranauthor=S.+M.+Rothenbergauthor=A.+N.+Hataauthor=A.+C.+Faberauthor=A.+Pirisauthor=R.+M.+Nazarianauthor=R.+D.+Brownauthor=J.+T.+Godfreyauthor=D.+Winokurauthor=J.+Walshauthor=M.+Mino-Kenudsonauthor=S.+Maheswaranauthor=J.+Settlemanauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=D.+A.+Haberauthor=J.+A.+Engelman&title=TORC1+suppression+predicts+responsiveness+to+RAF+and+MEK+inhibition+in+BRAF-mutant+melanoma&doi=10.1126%2Fscitranslmed.3005753"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005753%26sid%3Dliteratum%253Aachs%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DFaber%26aufirst%3DA.%2BC.%26aulast%3DPiris%26aufirst%3DA.%26aulast%3DNazarian%26aufirst%3DR.%2BM.%26aulast%3DBrown%26aufirst%3DR.%2BD.%26aulast%3DGodfrey%26aufirst%3DJ.%2BT.%26aulast%3DWinokur%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DTORC1%2520suppression%2520predicts%2520responsiveness%2520to%2520RAF%2520and%2520MEK%2520inhibition%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26spage%3D196ra98%26doi%3D10.1126%2Fscitranslmed.3005753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Burger, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atallah, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartulis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhagen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwanowicz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussiere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaror, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voliva, C. F.</span><span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">774</span><span class="NLM_x">–</span> <span class="NLM_lpage">779</span><span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.+J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.+M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0lg1Z8lJx9ZMYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.%2BJ.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7579</span><span class="NLM_x">–</span> <span class="NLM_lpage">7587</span><span class="refDoi"> DOI: 10.1021/jm2009327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.+Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+class+I+phosphatidylinositol+3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+kinase+inhibitor+%28GDC-0980%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm2009327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lg1Z8lJx9ZMYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.%2BY.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587%26doi%3D10.1021%2Fjm2009327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Dehnhardt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delos-Santos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span> </span><span class="NLM_article-title">Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4773</span><span class="NLM_x">–</span> <span class="NLM_lpage">4778</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.06.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.bmcl.2011.06.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4773-4778&author=C.+M.+Dehnhardtauthor=A.+M.+Venkatesanauthor=Z.+Chenauthor=E.+Delos-Santosauthor=S.+Ayral-Kaloustianauthor=N.+Brooijmansauthor=K.+Yuauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=R.+Mallon&title=Identification+of+2-oxatriazines+as+highly+potent+pan-PI3K%2FmTOR+dual+inhibitors&doi=10.1016%2Fj.bmcl.2011.06.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.06.063%26sid%3Dliteratum%253Aachs%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDelos-Santos%26aufirst%3DE.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DMallon%26aufirst%3DR.%26atitle%3DIdentification%2520of%25202-oxatriazines%2520as%2520highly%2520potent%2520pan-PI3K%252FmTOR%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4773%26epage%3D4778%26doi%3D10.1016%2Fj.bmcl.2011.06.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span><span class="refDoi"> DOI: 10.1021/jm800295d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer&doi=10.1021%2Fjm800295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0ljvTBdkWyZobg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532%26doi%3D10.1021%2Fjm800295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Arcaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1042/bj2960297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1042%2Fbj2960297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=8257416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADyaK3sXms1yqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=1993&pages=297-301&author=A.+Arcaroauthor=M.+P.+Wymann&title=Wortmannin+is+a+potent+phosphatidylinositol+3-kinase+inhibitor%3A+the+role+of+phosphatidylinositol+3%2C4%2C5-trisphosphate+in+neutrophil+responses&doi=10.1042%2Fbj2960297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-triphosphate in neutrophil responses</span></div><div class="casAuthors">Arcaro, Alexandre; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">297-301</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">Phosphatidylinositol 3,4,5-trisphosphate (PtdInsP3) is rapidly produced upon exposure of neutrophils to the chemoattractant N-formylmethionyl-leucyl-phenylalanine (fMLP), and has been proposed to act as a second messenger mediating actin polymn. and respiratory burst activity.  Here the authors present evidence that wortmannin, a known inhibitor of respiratory burst activity, acts on PtdIns 3-kinase, the enzyme producing PtdInsP3 from PtdIns(4,5)P2.  Pretreatment of 32P-labeled human neutrophils with 100 nM wortmannin totally abolished fMLP-mediated PtdInsp3 prodn., raised PtdInsP2 levels, and did not affect cellular PtdInsP and PtdIns contents.  The inhibitory effect of PtdInsP3 formation in intact cells was dose-dependent, with an IC50 of ∼5 nM.  Similar results were obtained with PtdIns 3-kinase immunopptd. by antibodies against the p85 regulatory subunit: wortmannin totally inhibited PtdIns3P prodn. in immunoppts. at concns. of 10-100 nM (IC50 ∼ 1 nM).  These results illustrate the direct and specific inhibition of PtdIns 3-kinase by wortmannin.  Since agonist-mediated respiratory burst activation is most sensitive to wortmannin (IC50 = 12 nM), this suggests that agonist-mediated PtdInsP3 formation is indispensable for this cell response.  Neutrophils pretreated with wortmannin develop oscillatory changes in F-actin content, but actin polymn. in response to fMLP is not inhibited.  This, and the absence of PtdInsP3 under these conditions, are in agreement with a modulatory role for PtdInsP3 in cytoskeletal rearrangements, but imply that PtdInsP3 prodn. is not a primary event triggering elongation of actin filaments in neutrophils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_hGL9IT_4XLVg90H21EOLACvtfcHk0lhtAADCbMu0ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXms1yqur4%253D&md5=f04ac034fa98e73237690ff27c163cd8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1042%2Fbj2960297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2960297%26sid%3Dliteratum%253Aachs%26aulast%3DArcaro%26aufirst%3DA.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DWortmannin%2520is%2520a%2520potent%2520phosphatidylinositol%25203-kinase%2520inhibitor%253A%2520the%2520role%2520of%2520phosphatidylinositol%25203%252C4%252C5-trisphosphate%2520in%2520neutrophil%2520responses%26jtitle%3DBiochem.%2520J.%26date%3D1993%26volume%3D296%26spage%3D297%26epage%3D301%26doi%3D10.1042%2Fbj2960297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulgarelli-Leva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panayotou, G.</span><span> </span><span class="NLM_article-title">Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1722</span><span class="NLM_x">–</span> <span class="NLM_lpage">1733</span><span class="refDoi"> DOI: 10.1128/MCB.16.4.1722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1128%2FMCB.16.4.1722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=8657148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADyaK28XhvVags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=1722-1733&author=M.+P.+Wymannauthor=G.+Bulgarelli-Levaauthor=M.+J.+Zvelebilauthor=L.+Pirolaauthor=B.+Vanhaesebroeckauthor=M.+D.+Waterfieldauthor=G.+Panayotou&title=Wortmannin+inactivates+phosphoinositide+3-kinase+by+covalent+modification+of+Lys-802%2C+a+residue+involved+in+the+phosphate+transfer+reaction&doi=10.1128%2FMCB.16.4.1722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</span></div><div class="casAuthors">Wymann, Matthias P.; Bulgarelli-Leva, Ginette; Zvelebil, Marketa J.; Pirola, Luciano; Vanhaesebroeck, Bart; Waterfield, Michael D.; Panayotou, George</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1722-33</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Wortmannin at nanomolar concns. is a potent and specific inhibitor of phosphoinositide (PI) 3-kinase and has been used extensively to demonstrate the role of this enzyme in diverse signal transduction processes.  At higher concns., wortmannin inhibits the ataxia telangiectasia gene (ATM)-related DNA dependent protein kinase (DNA-PKcs).  The authors report here the identification of the site of interaction of wortmannin in the catalytic subunit of PI3-kinase, p110α.  At physiol. pH (6.5 to 8) wortmannin reacted specifically with p110α.  Phosphatidylinositol-4,5-diphosphate, ATP, and ATP analogs [adenine and 5'-(4-fluorosulfonylbenzoyl)adenine] competed effectively with wortmannin, while substances contg. nucleophilic amino acid side chain functions had no effect at the same concns.  This suggests that the wortmannin target site is localized in proximity to the substrate-binding site and that residues involved in wortmannin binding have an increased nucleophilicity because of their protein environment.  Proteolytic fragments of wortmannin-treated, recombinant P110α were mapped with anti-wortmannin and anti-p110α peptide antibodies, thus limiting the target site within a 10-kDa fragment, colocalizing with the ATP-binding site.  Site-directed mutagenesis of all candidate residues within this region showed that only the conservative Lys-802-59-Arg mutation abolished wortmannin binding.  Inhibition of PI 3-kinase occurs, therefore, by the formation of an enamine following the attack of Lys-802 on the furan ring (at C-20) of wortmannin.  The Lys-802-t9-Arg mutant was also unable to bind FSBA and was catalytically inactive in lipid and protein kinase assays, indicating a crucial role for Lys-802 in the phosphotransfer reaction.  In contrast, an Arg-916-to-Pro mutation abolished the catalytic activity whereas covalent wortmannin binding remained intact.  The results provide the basis for the design of novel and specific inhibitors of an enzyme family, including PI kinases and ATM-related genes, that play a central role in many physiol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoobMQ6HMdUcbVg90H21EOLACvtfcHk0lhtAADCbMu0ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVags7s%253D&md5=54ebe365b4ad8260555c8b962e03d28b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FMCB.16.4.1722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.16.4.1722%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DBulgarelli-Leva%26aufirst%3DG.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DPirola%26aufirst%3DL.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DPanayotou%26aufirst%3DG.%26atitle%3DWortmannin%2520inactivates%2520phosphoinositide%25203-kinase%2520by%2520covalent%2520modification%2520of%2520Lys-802%252C%2520a%2520residue%2520involved%2520in%2520the%2520phosphate%2520transfer%2520reaction%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D1722%26epage%3D1733%26doi%3D10.1128%2FMCB.16.4.1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Venkatesan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehnhardt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delos Santos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dos Santos, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khafizova, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2636</span><span class="NLM_x">–</span> <span class="NLM_lpage">2645</span><span class="refDoi"> DOI: 10.1021/jm901830p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901830p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2636-2645&author=A.+M.+Venkatesanauthor=C.+M.+Dehnhardtauthor=E.+Delos+Santosauthor=Z.+Chenauthor=O.+Dos+Santosauthor=S.+Ayral-Kaloustianauthor=G.+Khafizovaauthor=N.+Brooijmansauthor=R.+Mallonauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=K.+Yuauthor=J.+Gibbonsauthor=R.+T.+Abrahamauthor=I.+Chaudharyauthor=T.+S.+Mansour&title=Bis%28morpholino-1%2C3%2C5-triazine%29+derivatives%3A+potent+adenosine+5%E2%80%B2-triphosphate+competitive+phosphatidylinositol-3-kinase%2Fmammalian+target+of+rapamycin+inhibitors%3A+discovery+of+compound+26+%28PKI-587%29%2C+a+highly+efficacious+dual+inhibitor&doi=10.1021%2Fjm901830p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm901830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901830p%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDelos%2BSantos%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDos%2BSantos%26aufirst%3DO.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DKhafizova%26aufirst%3DG.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DBis%2528morpholino-1%252C3%252C5-triazine%2529%2520derivatives%253A%2520potent%2520adenosine%25205%25E2%2580%25B2-triphosphate%2520competitive%2520phosphatidylinositol-3-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitors%253A%2520discovery%2520of%2520compound%252026%2520%2528PKI-587%2529%252C%2520a%2520highly%2520efficacious%2520dual%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2636%26epage%3D2645%26doi%3D10.1021%2Fjm901830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lg5-YaDroqOHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svenson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5013</span><span class="NLM_x">–</span> <span class="NLM_lpage">5016</span><span class="refDoi"> DOI: 10.1021/jm900851f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900851f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5013-5016&author=A.+Zaskauthor=J.+C.+Verheijenauthor=K.+Curranauthor=J.+Kaplanauthor=D.+J.+Richardauthor=P.+Nowakauthor=D.+J.+Malwitzauthor=N.+Brooijmansauthor=J.+Bardauthor=K.+Svensonauthor=J.+Lucasauthor=L.+Toral-Barzaauthor=W.+G.+Zhangauthor=I.+Hollanderauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=S.+Ayral-Kaloustianauthor=T.+S.+Mansourauthor=K.+Yu&title=ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin%3A+design+and+synthesis+of+highly+potent+and+selective+pyrazolopyrimidines&doi=10.1021%2Fjm900851f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm900851f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900851f%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DSvenson%26aufirst%3DK.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%2BG.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%253A%2520design%2520and%2520synthesis%2520of%2520highly%2520potent%2520and%2520selective%2520pyrazolopyrimidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5013%26epage%3D5016%26doi%3D10.1021%2Fjm900851f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Walker, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span><span class="refDoi"> DOI: 10.1016/S1097-2765(05)00089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+determinants+of+phosphoinositide+3-kinase+inhibition+by+wortmannin%2C+LY294002%2C+quercetin%2C+myricetin%2C+and+staurosporine&doi=10.1016%2FS1097-2765%2805%2900089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0lg5-YaDroqOHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520determinants%2520of%2520phosphoinositide%25203-kinase%2520inhibition%2520by%2520wortmannin%252C%2520LY294002%252C%2520quercetin%252C%2520myricetin%252C%2520and%2520staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919%26doi%3D10.1016%2FS1097-2765%2805%2900089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">O’Reilly, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1500</span><span class="NLM_x">–</span> <span class="NLM_lpage">1508</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0lhb09DK-rqElA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhb09DK-rqElA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Shoemaker, R. H.</span><span> </span><span class="NLM_article-title">The NCI60 human tumour cell line anticancer drug screen</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">823</span><span class="refDoi"> DOI: 10.1038/nrc1951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc1951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16990858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVCmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=813-823&author=R.+H.+Shoemaker&title=The+NCI60+human+tumour+cell+line+anticancer+drug+screen&doi=10.1038%2Fnrc1951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The NCI60 human tumour cell line anticancer drug screen</span></div><div class="casAuthors">Shoemaker, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">813-823</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The US National Cancer Institute (NCI) 60 human tumor cell line anticancer drug screen (NCI60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumors in anticancer drug screening.  This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumor-cell kill.  Recently, its role has changed to that of a service screen supporting the cancer research community.  The author reviews the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0ysyTSc1-p7Vg90H21EOLACvtfcHk0lhb09DK-rqElA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVCmu7c%253D&md5=c6c1a074b9dc7e138f45734499769284</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrc1951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1951%26sid%3Dliteratum%253Aachs%26aulast%3DShoemaker%26aufirst%3DR.%2BH.%26atitle%3DThe%2520NCI60%2520human%2520tumour%2520cell%2520line%2520anticancer%2520drug%2520screen%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D813%26epage%3D823%26doi%3D10.1038%2Fnrc1951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">The insulin and insulin-like growth factor receptor family in neoplasia: an update</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1038/nrc3215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1038%2Fnrc3215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=22337149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit12jsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=159-169&author=M.+Pollak&title=The+insulin+and+insulin-like+growth+factor+receptor+family+in+neoplasia%3A+an+update&doi=10.1038%2Fnrc3215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin and insulin-like growth factor receptor family in neoplasia: an update</span></div><div class="casAuthors">Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">159-169</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Although several early phase clin. trials raised enthusiasm for the use of insulin-like growth factor I receptor (IGF1R)-specific antibodies for cancer treatment, initial Phase III results in unselected patients have been disappointing.  Further clin. studies may benefit from the use of predictive biomarkers to identify probable responders, the use of rational combination therapies and the consideration of alternative targeting strategies, such as ligand-specific antibodies and receptor-specific tyrosine kinase inhibitors.  Targeting insulin and IGF signalling also needs to be considered in the broader context of the pathophysiol. that relates obesity and diabetes to neoplasia, and the effects of anti-diabetic drugs, including metformin, on cancer risk and prognosis.  The insulin and IGFI receptor family is also relevant to the development of PI3K-AKT pathway inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNoGWXuldjobVg90H21EOLACvtfcHk0lj87xdst9DP0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit12jsrs%253D&md5=23f0966929a8fecbcc183fc22541980f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrc3215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3215%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DThe%2520insulin%2520and%2520insulin-like%2520growth%2520factor%2520receptor%2520family%2520in%2520neoplasia%253A%2520an%2520update%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D159%26epage%3D169%26doi%3D10.1038%2Fnrc3215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Sugino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hisaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tohnai, N.</span><span> </span><span class="NLM_article-title">Amphiphilic inclusion spaces for various guests and regulation of fluorescence intensity of 1,8-bis(4-aminophenyl)anthracene crystals</span> <span class="citation_source-journal">Chem.—Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3069</span><span class="NLM_x">–</span> <span class="NLM_lpage">3076</span><span class="refDoi"> DOI: 10.1002/chem.201304541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1002%2Fchem.201304541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=24677343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=3069-3076&author=M.+Suginoauthor=K.+Hatanakaauthor=Y.+Arakiauthor=I.+Hisakiauthor=M.+Miyataauthor=N.+Tohnai&title=Amphiphilic+inclusion+spaces+for+various+guests+and+regulation+of+fluorescence+intensity+of+1%2C8-bis%284-aminophenyl%29anthracene+crystals&doi=10.1002%2Fchem.201304541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Amphiphilic Inclusion Spaces for Various Guests and Regulation of Fluorescence Intensity of 1,8-Bis(4-aminophenyl)anthracene Crystals</span></div><div class="casAuthors">Sugino, Misa; Hatanaka, Keisuke; Araki, Yusuke; Hisaki, Ichiro; Miyata, Mikiji; Tohnai, Norimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3069-3076</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A host framework for inclusion of various guest mols. was studied by prepn. of inclusion crystals of 1,8-bis(4-aminophenyl)anthracene (1,8-BAPA) with org. solvents.  X-ray crystallog. anal. revealed construction of the same inclusion space incorporating 1,8-BAPA and eight guest mols. including both nonpolar (benzene) and polar guests (DMF, DMF).  Fluorescence efficiencies varied depending on guest mol. polarity; DMF inclusion crystals exhibited the highest fluorescence intensity (ΦF = 0.40), four times as high as that of a benzene inclusion crystal (ΦF = 0.10).  According to systematic studies of inclusion phenomena, strong host-guest interactions and filling of the inclusion space led to a high fluorescence intensity.  Temp.-dependent fluorescence spectral measurements revealed these factors effectively immobilized the host framework.  Although hydrogen bonding commonly decreases fluorescence intensity, the present study demonstrated that such strong interactions provide excellent conditions for fluorescence enhancement.  Thus, this remarkable behavior has potential application toward sensing of highly polar mols., such as biogenic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSpyD5EYkKkLVg90H21EOLACvtfcHk0lj87xdst9DP0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGgsbw%253D&md5=10ddc95c12a41e881e481e5711bfd356</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fchem.201304541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201304541%26sid%3Dliteratum%253Aachs%26aulast%3DSugino%26aufirst%3DM.%26aulast%3DHatanaka%26aufirst%3DK.%26aulast%3DAraki%26aufirst%3DY.%26aulast%3DHisaki%26aufirst%3DI.%26aulast%3DMiyata%26aufirst%3DM.%26aulast%3DTohnai%26aufirst%3DN.%26atitle%3DAmphiphilic%2520inclusion%2520spaces%2520for%2520various%2520guests%2520and%2520regulation%2520of%2520fluorescence%2520intensity%2520of%25201%252C8-bis%25284-aminophenyl%2529anthracene%2520crystals%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2014%26volume%3D20%26spage%3D3069%26epage%3D3076%26doi%3D10.1002%2Fchem.201304541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span> </span><span class="NLM_article-title">1,3,5-Triazine inhibitors of histone deacetylases: synthesis and biological activity</span> <span class="citation_source-journal">Med. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5188</span><span class="NLM_x">–</span> <span class="NLM_lpage">5196</span><span class="refDoi"> DOI: 10.1007/s00044-014-1084-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1007%2Fs00044-014-1084-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKlsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=5188-5196&author=X.+Zhaoauthor=Q.+Tanauthor=Z.+Zhangauthor=Y.+Zhao&title=1%2C3%2C5-Triazine+inhibitors+of+histone+deacetylases%3A+synthesis+and+biological+activity&doi=10.1007%2Fs00044-014-1084-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">1,3,5-Triazine inhibitors of histone deacetylases: synthesis and biological activity</span></div><div class="casAuthors">Zhao, Xiaodong; Tan, Qiu; Zhang, Zhitao; Zhao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5188-5196</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">A series of 1,3,5-triazine-based hydroxamic acids 6a-6i were designed and synthesized, and they were potent inhibitors of human histone deacetylases.  These compds. were evaluated for their antiproliferative activity by MTT assay, and most of them exhibited significant antiproliferative effect on HCT-116, MCF-7, and HeLa cancer cell lines.  DNA flow cytometric anal. revealed that compd. 6i induced apoptosis and cell cycle arrest at G2/M phase in HCT-116 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBjYH-wBNYebVg90H21EOLACvtfcHk0lj87xdst9DP0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKlsrbF&md5=bbd419ce273ad50c07c4f45e3e37828a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs00044-014-1084-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-014-1084-z%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3D1%252C3%252C5-Triazine%2520inhibitors%2520of%2520histone%2520deacetylases%253A%2520synthesis%2520and%2520biological%2520activity%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2014%26volume%3D23%26spage%3D5188%26epage%3D5196%26doi%3D10.1007%2Fs00044-014-1084-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+pharmacological+map+of+the+PI3-K+family+defines+a+role+for+p110alpha+in+insulin+signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0liP7dKu4FF5gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520pharmacological%2520map%2520of%2520the%2520PI3-K%2520family%2520defines%2520a%2520role%2520for%2520p110alpha%2520in%2520insulin%2520signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span> </span><span class="NLM_article-title">Mosflm—a programme for processing X-ray diffraction data</span>.  <span class="citation_source-book">Joint CCP4/ESF-EACBM Newsletter on Protein Crystallography</span>; <span class="NLM_publisher-name">Daresbury Laboratory</span>: <span class="NLM_publisher-loc">Warrington, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">1992</span><span class="NLM_x">; </span>No. <span class="NLM_issue">26</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=A.+G.+W.+Leslie&title=Joint+CCP4%2FESF-EACBM+Newsletter+on+Protein+Crystallography"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26atitle%3DMosflm%25E2%2580%2594a%2520programme%2520for%2520processing%2520X-ray%2520diffraction%2520data%26btitle%3DJoint%2520CCP4%252FESF-EACBM%2520Newsletter%2520on%2520Protein%2520Crystallography%26pub%3DDaresbury%2520Laboratory%26date%3D1992%26issue%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1107/S0021889893005588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0021889893005588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADyaK2cXptFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=795-800&author=W.+Kabsch&title=Automatic+processing+of+rotation+diffraction+data+from+crystals+of+initially+unknown+symmetry+and+cell+constants&doi=10.1107%2FS0021889893005588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">795-800</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">An algorithm was developed for the automatic interpretation of a given set of obsd. reciprocal-lattice points.  It exts. a reduced cell and assigns indexes to each reflection by a graph-theor. implementation of the local indexing method.  All possible symmetries of the obsd. lattice compatible with the metric of the reduced cell are recognized and reported, together with the unit-cell consts. and the linear index transformation relating the conventional to the reduced cell.  This algorithm was incorporated into the program XDS (K., 1988), which is now able to process single-crystal area-detector data without prior knowledge of the symmetry and the unit-cell consts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1lV8_7cDv7Vg90H21EOLACvtfcHk0liP7dKu4FF5gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXptFeltw%253D%253D&md5=2b703225206ce99af0d7e38acf6d75b3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1107%2FS0021889893005588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889893005588%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DAutomatic%2520processing%2520of%2520rotation%2520diffraction%2520data%2520from%2520crystals%2520of%2520initially%2520unknown%2520symmetry%2520and%2520cell%2520constants%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1993%26volume%3D26%26spage%3D795%26epage%3D800%26doi%3D10.1107%2FS0021889893005588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography</span>.  <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span>, DOI: <span class="refDoi"> DOI: 10.1107/S0907444994003112</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=15299374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A280%3ADC%252BD2czpsV2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+CCP4+suite%3A+programs+for+protein+crystallography.+Acta+Crystallogr.%2C+Sect.+D%3A+Biol.+Crystallogr.+1994%2C+50%2C+760%E2%80%93763%2C+DOI%3A+10.1107%2FS0907444994003112."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The CCP4 suite: programs for protein crystallography</span></div><div class="casAuthors">Anonymous</div><div class="citationInfo"><span class="NLM_cas:title">Acta crystallographica. Section D, Biological crystallography</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">Pt 5</span>),
    <span class="NLM_cas:pages">760-3</span>
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    </div><div class="casAbstract">The CCP4 (Collaborative Computational Project, number 4) program suite is a collection of programs and associated data and subroutine libraries which can be used for macromolecular structure determination by X-ray crystallography.  The suite is designed to be flexible, allowing users a number of methods of achieving their aims and so there may be more than one program to cover each function.  The programs are written mainly in standard Fortran77.  They are from a wide variety of sources but are connected by standard data file formats.  The package has been ported to all the major platforms under both Unix and VMS.  The suite is distributed by anonymous ftp from Daresbury Laboratory and is widely used throughout the world.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1Q-skJYIZ2IYPsCkJIw00fW6udTcc2ebH9-xKHaVaxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czpsV2gug%253D%253D&md5=92b759927d6071ea3f20c08b78ad1eb2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span> </span><span class="NLM_article-title">Solving structures of protein complexes by molecular replacement with Phaser</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1107/S0907444906045975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444906045975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=17164524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlSqu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=32-41&author=A.+J.+McCoy&title=Solving+structures+of+protein+complexes+by+molecular+replacement+with+Phaser&doi=10.1107%2FS0907444906045975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Solving structures of protein complexes by molecular replacement with Phaser</span></div><div class="casAuthors">McCoy, Airlie J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-41</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Mol. replacement (MR) generally becomes more difficult as the no. of components in the asym. unit requiring sep. MR models (i.e. the dimensionality of the search) increases.  When the proportion of the total scattering contributed by each search component is small, the signal in the search for each component in isolation is weak or non-existent.  Maximum-likelihood MR functions enable complex asym. units to be built up from individual components with a 'tree search with pruning' approach.  This method, as implemented in the automated search procedure of the program Phaser, has been very successful in solving many previously intractable MR problems.  However, there are a no. of cases in which the automated search procedure of Phaser is suboptimal or encounters difficulties.  These include cases where there are a large no. of copies of the same component in the asym. unit or where the components of the asym. unit have greatly varying B factors.  Two case studies are presented to illustrate how Phaser can be used to best advantage in the std. 'automated MR' mode and two case studies are used to show how to modify the automated search strategy for problematic cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAvs9W8hQ3l7Vg90H21EOLACvtfcHk0liP7dKu4FF5gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlSqu77F&md5=323a5297bdf622ebaf398a87c39dc794</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444906045975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444906045975%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26atitle%3DSolving%2520structures%2520of%2520protein%2520complexes%2520by%2520molecular%2520replacement%2520with%2520Phaser%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2007%26volume%3D63%26spage%3D32%26epage%3D41%26doi%3D10.1107%2FS0907444906045975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0li5s8evylp0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span> </span><span class="NLM_article-title">Electronic ligand builder and optimization workbench (eLBOW): a tool for ligand coordinate and restraint generation</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1074</span><span class="NLM_x">–</span> <span class="NLM_lpage">1080</span><span class="refDoi"> DOI: 10.1107/S0907444909029436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444909029436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=19770504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKnsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=1074-1080&author=N.+W.+Moriartyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adams&title=Electronic+ligand+builder+and+optimization+workbench+%28eLBOW%29%3A+a+tool+for+ligand+coordinate+and+restraint+generation&doi=10.1107%2FS0907444909029436"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation</span></div><div class="casAuthors">Moriarty, Nigel W.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1074-1080</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The electronic Ligand Builder and Optimization Workbench (eLBOW) is a program module of the PHENIX suite of computational crystallog. software.  It is designed to be a flexible procedure that uses simple and fast quantum-chem. techniques to provide chem. accurate information for novel and known ligands alike.  A variety of input formats and options allow the attainment of a no. of diverse goals including geometry optimization and generation of restraints.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojnN4AVY_DwrVg90H21EOLACvtfcHk0li5s8evylp0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKnsLnN&md5=3f9a9c6c31c9a4b014a9f151fb6aa8d9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444909029436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909029436%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26atitle%3DElectronic%2520ligand%2520builder%2520and%2520optimization%2520workbench%2520%2528eLBOW%2529%253A%2520a%2520tool%2520for%2520ligand%2520coordinate%2520and%2520restraint%2520generation%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2009%26volume%3D65%26spage%3D1074%26epage%3D1080%26doi%3D10.1107%2FS0907444909029436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0li5s8evylp0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IBE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IBE','PDB','3IBE'); return false;">PDB: 3IBE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4','PDB','5OQ4'); return false;">PDB: 5OQ4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5','PDB','3SD5'); return false;">PDB: 3SD5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6','PDB','4JT6'); return false;">PDB: 4JT6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JSN','PDB','4JSN'); return false;">PDB: 4JSN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JHB','PDB','5JHB'); return false;">PDB: 5JHB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E8Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1E8Y','PDB','1E8Y'); return false;">PDB: 1E8Y</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-4"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00930">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_37021"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00930">10.1021/acs.jmedchem.7b00930</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_001.csv">CSV</a>)</p></li><li><p class="inline">X-ray crystallography parameters and refinement values for <b>1</b> (Table S1); a TREEspot representation (Figure S1) and its raw data (Table S2); the antiproliferative action of compound <b>1</b> in four cell line panels (Table S3); extended Tables S4 and S5 with in vitro pharmacology data; the safety profile of <b>1</b> (Table S6); comparative solubility of <b>1</b> (Table S7); efficacy of compound <b>1</b> intermittent dosing in tumor bearing rats (Figure S2); <sup>1</sup>H NMR spectra; <sup>19</sup>F{<sup>1</sup>H} NMR spectra; <sup>13</sup>C{<sup>1</sup>} NMR spectra; ESI-HRMS spectra; MALDI-MS spectra; HPLC chromatograms; and appendix of chemical formula of compounds synthesized here (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_001.csv">jm7b00930_si_001.csv (1.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00930/suppl_file/jm7b00930_si_002.pdf">jm7b00930_si_002.pdf (8.59 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of compound <b>1</b> in PI3Kγ have been deposited with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a> at <a href="http://wwpdb.org" class="extLink">wwpdb.org</a> and <a href="http://rcsb.org" class="extLink">rcsb.org</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00930%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-17%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00930" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679960771a0c3c0a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
